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ABSTRACT 
The objective was to prepare new solid phases, i.e. co-crystal forms, of two sulfa antibiotic 
drugs (sulfamethoxazole and sulfasalazine) with trimethoprim and fourteen potential co-
formers with GRAS status. Trimethoprim was chosen for its synergistic effects with both 
sulfa drugs and the other co-formers were selected in an attempt to improve the 
physicochemical properties of the antibiotics.   
A variety of co-crystallization techniques, including solvent assisted grinding, slow 
evaporation, slurry method and solidification of the melt were used to obtain these results. 
From these methods, three new solid phases were successfully isolated for the 
sulfamethoxazole antibiotic, viz. sulfamethoxazole-benzoic anhydride (SMZ-BAN) co-crystal 
by the slurry method, amorphous sulfamethoxazole-trimethoprim (SMZ-TMP) form by 
solidification of the melt and amorphous sulfamethoxazole-oxalic acid (SMZ-OA) by slow 
evaporation. For the sulfasalazine antibiotic, co-crystallization experimentation produced, 
sulfasalazine-trimethoprim salt (SSZ-TMPs) by slow evaporation, sulfasalazine-trimethoprim 
co-crystal (SSZ-TMP) by solvent assisted grinding and sulfasalazine-nicotinamide co-crystal 
(SSZ-NC) by solidification of the melt. 
Of these six compounds subjected to single crystal X-ray analysis, only one of their structures 
was elucidated i.e. the salt, SSZ-TMPs.  
Different techniques that were used to assess the thermal behaviour of the products included 
hot stage microscopy, differential scanning calorimetry and thermogravimetric analysis. FTIR 
provided information on the purity of the compounds and the suggested host-guest interaction 
sites. X-ray powder diffraction supported the determination of the new phase comparative to 
the parent compounds. Finally dissolution testing was carried out for successful candidates 
with encouraging recommendations for future work. 
Key words: Co-crystals, co-crystal formers, sulfamethoxazole, sulfasalazine, trimethoprim, 
antibiotics, dissolution. 
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1. INTRODUCTION 
 
Drug molecules with poor aqueous solubility have become increasingly more recurring in 
pharmaceutical research and development. These types of molecules can offer a number of 
challenges and may potentially lead to slow dissolution, unpredictable systemic exposure and 
subsequently sub-optimal efficacy in patients, particularly when delivered by the oral route of 
administration. Crystal engineering suggests a number of ways to improve solubility, 
dissolution rate and other physicochemical properties, which can be implemented through an 
in-depth knowledge of the crystallisation processes and the molecular properties of active 
pharmaceutical ingredients.1 The ability to deliver the drug to the patient in an efficient, safe, 
and cost-effective manner depends largely on the physicochemical properties of the active 
pharmaceutical ingredient (API) in the solid state.2 
The concept of crystal engineering was introduced by Pepinky3 in 1955 and was first applied 
by Schmidt4 in 1971 in the context of covalent bond formation in the solid state. Crystal 
engineering is defined as, "the understanding of intermolecular interactions in the context of 
crystal packing and the utilization of such understanding in the design of new solids with 
desired physical and chemical properties."5 Molecular self-assembly is at the core of crystal 
engineering, and it involves an interaction between complementary hydrogen-bonding faces 
or a metal and a ligand.6  
Hence, crystal engineering includes many aspects of solid state supramolecular  chemistry 
which is the chemistry of molecular aggregates assembled via non-covalent interaction.  
1.1 Supramolecular chemistry 
Supramolecular chemistry examines the weaker and reversible non-covalent interactions 
between molecules. There are a number of such interactions that can be utilized. They 
include: hydrogen bonding, metal coordination, hydrophobic or solvatophobic effects, Van 
der Waals forces, electrostatic effects and π-π stacking interactions.7 
An understanding of intermolecular forces is essential in the study of supramolecular 
chemistry. When molecules interact, both repulsive and attractive forces operate. As two 
molecules are brought close together, the opposite charges in the two molecules are closer 
together than the like charges and cause the molecules to attract one another. When the 
molecules are brought so close that the outer charge clouds touch, the molecules repel each 
other like rigid elastic bodies. Thus, attractive forces are necessary in order that molecules 
cohere and repulsive forces are necessary in order that molecules do not interpenetrate and 
annihilate one another.8 
2 
 
 
 
 
 
1.1.1 Hydrogen-bonding 
Hydrogen-bonding interactions, being reasonably strong and highly directional, are widely 
used as structure-directing tools in supramolecular assembly to generate novel topological 
structures.9 It includes the interaction between molecules containing a hydrogen atom and a 
strongly electronegative atom such as fluorine, oxygen or nitrogen. Because of the small size 
of a hydrogen atom and its large electrostatic field, it can move close to the electronegative 
atom and form an electrostatic type of union known as a hydrogen bond or hydrogen bridge. 
Hydrogen bonds are relatively weak, having a bond energy of about 2 to 8 Kcal/mol 
compared with a value of about 50 to 100 Kcal/mol for a covalent bond and well over 100 
Kcal/mol for the ionic bond.8 Several classes of interactions, known as Van der Waals forces 
and other interactions are classed according to their bond energy in table 1.1.8 
 
Table 1.1 Intermolecular forces and Valence Bonds 
Bond type                                                                                               Bond energy 
(Kcal/mol) 
                             Van der Waals Forces and Other Intermolecular interaction 
 
Dipole-dipole interaction 
Dipole-induce dipole interaction                   1-10 
Induce dipole-induce dipole interaction 
Ion- dipole interaction 
 
Hydrogen bonds 
Hydrogen bonds   O−H…O                                                                        6 
                            C−H…O                                                                       2-3         
                            O−H…N                                                                       4-7 
                            N−H…O                                                                       2-3 
                            F−H…F                                                                         7 
                                                            Primary Valence Bond 
 
Covalent bond                                                                                         50-150 
 
Electrovalent, ionic, heteropolar bond                                                      100-200                                                                           
 
 
An example of a hydrogen bonding interaction between molecules is nevirapine (NV) and 
tartaric acid (TA) shown in figure 1.1. One NV molecule is linked to a TA molecule by 
hydrogen bonding (O−H…O, N−H…O).10 
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 Figure 1.1 Hydrogen bond interactions between nevirapine and rac-tartaric acid. 
1.1.2 Van der Waals forces  
When any two atoms approach each other closely, they create a weak, nonspecific attractive 
force that produces a Van der Waals interaction. These nonspecific interactions result from 
the momentary random fluctuations in the distribution of the electrons of any atom, which 
give rise to a transient unequal distribution of electrons that is a transient electric dipole. If 
two non-covalently bonded atoms are close enough together, the transient dipole in one atom 
will perturb the electron cloud of the other. This perturbation generates a transient dipole in 
the second atom, and the two dipoles will attract each other weakly. Similarly, a polar 
covalent bond in one molecule will attract an oppositely oriented dipole in another.11 
A dipole molecule is a molecule that has a slight charge on one end and an opposite charge of 
the same magnitude at the other end (Figure 1.2). Dipolar molecules frequently tend to align 
themselves with their neighbours, so that the negative pole of one molecule points toward the 
positive pole of the next.  
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 Figure 1.2 A dipole molecule with a positive charge on one end opposite a negative charge on 
the other end of equal magnitude.  
 
The types of Van der Waals forces are:8 
•  Dipole-dipole (Keesom forces): In which the molecules may be associated through weak 
attractions. 
• Dipole-induced dipole (Debay, interactions): Permanent dipoles are capable of inducing an 
electric dipole in non-polar molecules (which is easily polarizable) in order to produce dipole-
induced dipole. 
• Induced dipole-induced dipole (London attractions): Non-polar molecules can induce polarity 
in one another. These several interactions are necessary for drug solubility, certain biological 
processes and drug actions. 
These types of interactions are present in all types of solids but is often swamped by the other 
stronger interactions 
1.1.3 π-π stacking interactions  
π–π stacking  refers to attractive, non-covalent interactions between aromatic rings (when 
unsaturated organic groups are involved in non-covalent interactions) regularly in situations 
where one is relatively e--deficient and another is e--rich. Two general types of π-π stacking 
exist: edge-to-face and face-to-face (Figure 1.3). Edge-to-face π-π stacking interactions may 
be regarded as weak forms of H-bonds between the slightly e--deficient hydrogen atoms of 
one aromatic ring and the electron rich π-cloud of another.12,13 Face-to-face configuration is 
not nearly as stable an interaction as the edge-to-face due to the high electrostatic repulsion of 
the electrons in the π orbitals.14 
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Figure 1.3 π-π stacking interaction 
An example of π-π stacking interaction between molecules nevirapine and maleic acid is 
shown in figure 1.4. These cyclic motifs engage in stacking along [100] mediated by a 
second, stronger π-π stacking interaction, with a centroid-to-centroid distance of only 3.671 
Å. This distance is indicated by the dashed line in figure 1.4.15 
 
 
 
Figure 1.4 π-π stacking interaction between nevirapine and maleic acid. The short π-π 
stacking interaction is represented by the red dashed line. 
1.1.4 Hydrophobic effects 
Hydrophobic effects generally relate to the exclusion from polar solvent, mainly water, 
otherwise it is the desire for non-polar molecules to aggregate in an aqueous solution in order 
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to separate from water. This phenomenon leads to minimum exposed surface area of non-
polar molecules to the polar water molecules (typically spherical droplets).12,16 
1.2 Solid forms of APIs 
Active pharmaceutical ingredients (APIs) are commonly delivered to the patient in the solid-
state as part of an approved dosage form (e.g. tablets, capsules). Solids provide a convenient, 
compact and generally stable format to store an API or a drug product. Understanding and 
controlling the solid-state chemistry of APIs, both as a pure drug substance and in formulated 
products, is therefore an important aspect of the drug development process. Pharmaceutical 
solids can be classified into two major categories based on the order of molecular packing: 
amorphous and crystalline. The crystalline form may be a single component [polymorphism] 
or multiple components [hydrate, solvate, salts and co-crystals] (Figure 1.5).17 
These solid crystalline forms are generally non-covalently bonded. Each form displays unique 
physicochemical properties that can profoundly influence the bioavailability, 
manufacturability, purification, stability and other performance characteristics of the drug.14,15 
 
 
Figure 1.5 A schematic representation of solid forms of APIs. 
 
Solid form discovery and design depends on the nature of the molecules and type of physical 
property challenges faced in its development. The preferred solid form is generally the 
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thermodynamically most stable crystalline form of the compound.18,19 However, the stable 
crystal form of the parent compound may exhibit inadequate solubility or dissolution rate 
resulting in poor oral absorption, particularly for water-insoluble compounds. In this case, 
alternative solid forms may be investigated.18,20 
1.2.1 Amorphous solids 
An amorphous solid has no long-range order of molecular packing or well-defined molecular 
conformation. It consists of disordered arrangements of molecules and do not possess a 
distinguishable crystal lattice. Amorphous solids exist in many industrially important 
products, such as polymers, ceramics, metals, optical materials (e.g. glass and fibres), foods 
and pharmaceuticals. In the case of pharmaceutical materials, the importance of amorphous 
solids stems from: 21-24 
1. Useful properties: Generally amorphous solids have higher solubility, higher dissolution 
rate, and sometimes better compression characteristics than corresponding crystals. 
2. Instability: Amorphous solids are generally less stable physically and chemically than 
corresponding crystals. 
3. Common occurrence: Amorphous solids can be produced by standard pharmaceutical 
processes and are the common form of certain materials (e.g., proteins, peptides, some sugars 
and polymers). 
The three-dimensional long-range order that normally exists in a crystalline material does not 
exist in the amorphous state, and the position of molecules relative to one another is more 
random than in the liquid state. Typically amorphous solids exhibit short-range order over a 
few molecular dimensions and have physical properties quite different from those of their 
corresponding crystalline states22 (Figure1.6). Whether or not a drug is amorphous or 
crystalline has been shown to affect its therapeutic activity. Thus, the crystalline form of the 
antibiotic novobiocin acid is poorly absorbed and has no activity, whereas the amorphous 
form is readily absorbed and therapeutically active.24 
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 Figure 1.6 Form structure for a solid polymer showing crystalline and amorphous regions 
 
Characterization of amorphous solids 
The system for characterizing amorphous solids and crystalline solids are different. 
Molecular-level structural interpretation is possible for crystalline solids by diffraction and 
spectroscopic methods but is less applicable to amorphous solids and greater emphasis is 
placed on structural mobility and changes. It is expected to characterize an amorphous 
material both below and above the glass transition temperature, i.e. both as the frozen solid 
and as the supercooled viscous liquid. The physical characterization of amorphous solids 
utilizes a wide range of techniques (Table 1.2) and offers several types of information:25 
1. Structure: Amorphous solids are not random at the molecular level, but may possess short-
range order, residual crystallinity, polymorphic states, and regions of different density. 
2. Thermodynamics: Amorphous solids have higher energy, entropy and free energy than the 
corresponding crystals. The excess properties are parameters in some theoretical models of 
crystallization and structural relaxation. 
3. Changes: Amorphous solids can crystallize or undergo structural relaxation owing to its 
instability with respect to the corresponding crystals and “equilibrium” glasses. 
4. Multi-component systems: Many pharmaceutical formulations are multi-component, with 
water being a ubiquitous ingredient. It is desirable to predict properties of multi-component 
systems from those of individual components. 
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Table 1.2 Physical techniques for characterizing amorphous solids 
Technique Information 
X-ray Diffraction (XRD) DOC, CK 
Molecular Spectroscopy SR (e.g., Raman and NMR), microheterogeneity 
Differential Scanning Calorimetry 
(DSC) 
DOC, microcrystalline or truly amorphous, CK, SR 
Isothermal Calorimetry SR, CK, DOC 
Modulated DSC (MDSC) Reversing vs. non-reversing heat flow, Cp, SR (0.1–
0.01 Hz) 
Solution Calorimetry Excess enthalpy, DOC 
Adiabatic Calorimetry Excess enthalpy, entropy and free energy 
Dielectric Analysis (DEA) SR, primary vs. secondary processes 
Dynamic Mechanical Analysis 
(DMA) 
SR 
Viscometry SR 
Dilatometry Tg, liquid/glass expansion coefficients 
Solubility Excess free energy 
Density Density difference from crystalline solids 
Therm. Stimul. Cur. (TSC) SR, DOC, microheterogeneity 
Water absorption (gravimetric) Hygroscopicity, DOC, CK 
Key: SR=structural relaxation (Tg, fragility); DOC=degree of crystallinity; CK=crystallization 
kinetics; Tg = glass transition temperature. 
 
Amorphous forms have a characteristic temperature at which there is a major change in 
properties. This is called the glass transition temperature (Tg). If the sample is stored below 
the Tg, the amorphous form will be brittle, described as being in the glassy state. If the sample 
is above its Tg, it becomes rubbery. The Tg, although not well understood, is a point at which 
the molecules in the glass state exhibit a major change in mobility. The lack of mobility when 
the sample is glassy allows the amorphous form to exist for a longer time, whereas when Tg is 
below the storage temperature, the increased molecular mobility allows rapid conversion to 
the crystalline form. 
Most amorphous materials are able to absorb large quantities of water vapour. Absorption is a 
process whereby one molecule passes into the bulk of another material and should not be 
confused with adsorption, which is where something concentrates at the surface of another 
material.26 
1.2.2   Crystalline solids 
1.2.2.1   Solvates and hydrates 
Solvates are crystalline solid adducts containing either stoichiometric or nonstoichiometric 
amounts of a solvent incorporated within the crystal structure. If the incorporated solvent is 
water, the solvates are also commonly known as hydrates. 18 
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They may have different physicochemical properties (such as solubility, dissolution rate, 
mechanical behaviour, stability and bioavailability) from their unsolvated counterparts.27                                                                                                                          
Crystal solvates exhibit a wide range of behaviour depending on the interaction between the 
solvent and the crystal structure. With some solvates the solvent plays a key role in holding 
the crystal together. For example, it may be part of a hydrogen-bonded network within the 
crystal structure. These solvates may be very stable and difficult to desolvate. When these 
crystals lose their solvent they collapse and recrystallize in a new crystal form.28  
Approximately, one-third of active pharmaceutical substances are capable of forming 
crystalline hydrates.29 The water molecule, because of its small size, can often fill structural 
cavities and, because of its ability to participate in multidirectional hydrogen bonding, is also 
capable of settling in most drug molecules to form new crystal structures.  
The ordinary presence of water in a system is not sufficient for hydrate formation. The 
molecular (and crystal) structure, the activity of water in the crystallization medium and the 
temperature determine whether a given hydrate structure will form.30 Solvates impart toxicity 
so their use in the development of API crystals is rare. Most solvates are biologically toxic in 
nature.31 
An example of the hydrate form is the antibiotic, ampicillin. The faster dissolving anhydrous 
form of ampicillin is absorbed to a greater extent from both hard gelatine capsules and an 
aqueous suspension than is the slower dissolving trihydrate form (ampicillin anhydrous is 
more soluble in water than the trihydrate, 13 mg/ml and 6 mg/ml at 20°C respectively). 
(Figure1.7).32 
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 Figure 1.7 Ampicillin trihydrate 
1.2.2.2 Pharmaceutical salts 
A salt can be defined as a multi-component system where protons are transferred from an acid 
to base in the ionic state.33 For ionisable drugs (anionic, cationic and zwitterionic) salt 
formation is the simplest, most cost-effective plan to address poor aqueous solubility and it 
enhances bioavailability.20,34,35   
The selection of pharmaceutical salts provides a means to improve solubility, dissolution rate, 
drug absorption and the bioavailability of drugs compared to the parent form of the drug 
molecule without changing the pharmacologically active moiety.36 In addition to the positive 
impact on solubility, salts can usefully affect the purity of the active pharmaceutical 
ingredient (API), isolation of the API, stability (both chemical and physical), 
manufacturability (particularly flow) and can influence irritancy/toxicity of the dosage form. 
This is typically achieved through influencing the solid-state properties of the API; such as 
intrinsic solubility, dissolution rate, crystallinity, hygroscopicity, melting point, bulk physical 
properties (habit, particle size, flow properties) and polymorphism/solvation.20,35 The salt 
formation of 9-aminoacridine (aminacrine) with sulfa drug (sulfadimidine) by salt linkages 
was found to have a synergistic antimicrobial activity (Figure 1.8).37 
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 Figure 1.8 Salt formation between sulfadimidine- and aminacrine+ 
 
1.2.2.3 Polymorphism  
Polymorphism is often characterized as the ability of a drug substance to exist as two or more 
crystalline phases that have different arrangements and/or conformations of the molecules in 
the crystal lattice.38 Polymorphic forms of a drug substance can have different chemical and 
physical properties, including melting point, apparent solubility, dissolution rate, optical and 
mechanical properties, vapour pressure and density.39 These properties can have a direct effect 
on the ability to process and/or manufacture the drug substance and the drug product, as well 
as on drug product stability, dissolution and bioavailability. Thus, polymorphism can affect 
the quality, safety and efficacy of the drug product. Since polymorphic forms differ in their 
internal solid-state structure, a drug substance that exists in various polymorphic forms can 
have different aqueous solubilities and dissolution rates.40 When there are differences in the 
apparent solubilities of the various polymorphic forms, it is better to focus on the potential 
effect.  Such differences can have an effect on drug product bioavailability (BA) and 
bioequivalence (BE).8 Polymorphs can have different physical and chemical reactivity 
properties. These differences arise based upon differences in thermodynamic stability and also 
upon differences in molecular mobility. For this reason, the most thermodynamically stable 
polymorphic form of a drug substance is often chosen during development based on the 
minimal potential for conversion to another polymorphic form and on its greater chemical 
stability. However, a metastable form can be chosen for various reasons, including 
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bioavailability enhancement. It is noted though, that the unstable form is more soluble and has 
a high bioavailability.25 For example, probucol has two polymorphic forms existing as either 
white crystals Form I (m.p. 124.5- 126 ◦C) or yellow crystals Form II (m.p. 125.5-126.5 ◦C), 
these two polymorphic forms are different in their packing arrangement and cell data. Form II 
eventually transforms into Form I upon standing and the conversion had also been observed 
upon grinding. The structures of Form I and Form II are reported below (Figure 1.9).41  
 
 
Figure 1.9 Molecular conformation of probucol in its two polymorphic forms 
There are two types of polymorphs, enantiotropes [reversible transition] and monotropes 
[irreversible transition]. If one polymorph is stable [have lower free energy and solubility over 
a certain temperature range and pressure] while another polymorph is stable as well [has a 
lower free energy and solubility over a different temperature range and pressure], the two 
polymorphs are said to be enantiotropes, and the system of the two solid phases is said to be 
enantiotropic. The reversible transition can be observed at a definite transition temperature at 
which the free energy curves cross before the melting point is reached (Fig. 1.10 a). An 
example showing such behaviour include acetazolamide.42,43,44 If only one polymorph is stable 
at all temperatures below the melting point with all other polymorphs being unstable these 
polymorphs are said to be monotropes, and the system of the two solid phases is said to be 
monotropic. In the monotropic system the free energy curves do not cross, so no reversible 
transition can be observed below the melting point (Figure 1.10 b). An example of this type of 
system includes chloramphenicol palmitate.42-44 
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                               a                                                                     b                  
  
Figure 1.10 Plot of Gibbs free energy G and the enthalpy H at constant pressure against the 
absolute temperature T for (a) an enantiotropic and (b) a monotropic system 
         
1.2.2.4 Co-crystallization 
Compared to other solid-state modification techniques employed by the pharmaceutical 
industry, co-crystal formation appears to be an advantageous alternative for drug discovery, 
drug delivery (solubility, bioavailability) and chiral resolution.45,46                                        
A pharmaceutical co-crystal can be designed by crystal engineering with the intention to 
improve the solid-state properties of an API without affecting its intrinsic structure or non-
covalent interactions. Crystal engineering affords a model for rapid development of 
pharmaceutical co-crystals. It can be defined as an application of the concepts of 
supramolecular chemistry to the solid state with particular emphasis upon the idea that 
crystalline solids are actual manifestations of self-assembly.47 
Co-crystals may be defined as materials which contain two or more discrete molecular entities 
in the crystal lattice.48 In pharmaceutical terms co-crystals are the formation of a molecular 
complex of an active pharmaceutical ingredient and a second molecule typically requiring 
complementary hydrogen bonding between the two components.49 Co-crystals incorporate an 
API with a pharmaceutically acceptable guest molecule into a crystal lattice. Physicochemical 
properties of pharmaceuticals can be improved by obtaining co-crystals using co-
crystallization.50,51 With pharmaceutically acceptable compounds, co-crystallization does not 
affect pharmacological activity of the API but can improve its physical properties, such as 
solubility, hygroscopicity and compaction behavior.52 
The components in a co-crystal exist in a definite stoichiometric ratio and assemble via non-
covalent interactions.53 Generally, co-crystals in their pure state are solids at room 
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temperature. They can have different properties compared to the crystals of the individual 
components. Furthermore, co-crystals  have different  crystal  structures  compared to  the  
pure  components, contain different  intermolecular packing patterns, and as  such  they often 
exhibit widely different  physical  properties to the  pure  components.54,55An example of a co-
crystal is sulfadimidine and acetylsalicylic acid (aspirin)  ( Figure 1.11).55 One molecule of 
sulfadimidine is connected to one molecule of aspirin by hydrogen bond type O−H…N and 
N−H…O.                                 
                                  
 
Figure 1.11 Sulfadimidine-acetylsalicylic acid co-crystal, the dashed lines indicate  
hydrogen bonding 
The packing of drug molecules is known to affect its stability, ease of manufacture and 
biopharmaceutical performance of the drug. Typical drug molecules have complex chemical 
structures with multifunctional groups and conformations. They are prone to form different 
packing arrangements with small local free energy minima differences either by themselves 
(polymorphs), or with other molecular components (co-crystals or solvates) or counter ions 
(salts), producing materials with different physical, chemical, mechanical and 
biopharmaceutical properties.56 Co-crystallization is as a result of competing molecular 
associations between similar molecules or homomers, and different molecules or heteromers. 
Hydrogen bonds are the basis of molecular recognition phenomena in pharmaceutical systems 
and are responsible for the generation of families of molecular networks with the same 
molecular components, i.e. single component crystals and their polymorphs or with different 
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molecular components, i.e. multiple component crystals or co-crystals in the crystalline 
state.57;2 
Co-crystals and salts may sometimes be confused. The understanding of the difference 
between salt formation and a co-crystal is very important to both pre-formulation activities 
and chemical or pharmaceutical development aspects. Indeed, salts and co-crystals can be 
considered as opposite ends of multi-component structures.58-60                                                                                                                                                                                               
Salts are often chosen instead of the free acid or base as these can improve crystallinity, 
solubility and stability of a pharmaceutical compound.  Co-crystals are an alternative to salts 
when these do not have the appropriate solid state properties or cannot be formed due to the 
absence of ionizable sites in the API. Salt formation is an acid–base reaction between the API 
and an acidic or basic substance. The widespread use of salt formation is evidenced by the 
large number of marketed crystalline salts of APIs.61,62                                                                                                                                                                                                                                                                                                        
For non-ionisable drugs, or compounds with pKa values in a range where possible salt 
formation is very limited, co-crystal formation is an attractive alternative. For many 
crystalline compounds, the only difference between a salt and a co-crystal (composed of a 
base and an acid), is whether the proton is located on the acid or the base. The number of 
publications in the field of co-crystals has increased significantly over the last 20 years, and 
their possible use in pharmaceutics as an optimisation strategy for the physico-chemical 
properties of an API have been discussed extensively.63 
Formation of a co-crystal often offers scope to transform an amorphous or hard-to-crystallize 
API into a readily handled, stable crystalline solid.64,65 A pharmaceutical co-crystal can be 
designed by crystal engineering with the intention to improve the solid-state properties of an 
API without affecting its intrinsic structure. Co-crystals are constructed by crystal engineering 
which involves the non-covalent intermolecular interactions such as van der Waals contact 
forces, π⋯π stacking interactions and hydrogen bonding.54,67,68 
 
Crystal Engineering of pharmaceutical co-crystals 
Supramolecular synthons are spatial arrangements of intermolecular interactions and the 
overall goal of crystal engineering is therefore to recognise and design synthons that are 
robust enough to be interchanged between network structures. This ensures generality 
ultimately leading to the predictability of one-, two- and three-dimensional patterns formed by 
intermolecular interactions. 1 
Representative examples of pharmaceutically acceptable co-crystal formers that are able to 
co-crystallise with APIs include carboxylic acids, amides, carbohydrates, alcohols, and amino 
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acids. The most common supramolecular synthons utilised in pharmaceutical co-crystals are 
shown in figure 1.12.69 
 
 
          Figure 1.12 Typical hydrogen bonds utilised in crystal engineering. 
 
Existing widely in drugs, the carboxylic acid functional group has been extensively studied in 
the pharmaceutical co-crystal research area. With self-complementary hydrogen bond donor 
and acceptor, the formation of carboxylic acid homosynthon in figure 1.12 (1) through 
C=O⋯H–O hydrogen bond is very common.70 Another widely studied homosynthon is the 
amide homodimer in figure 1.12 (3), forming a co-crystal through C=O⋯H–N hydrogen 
bond. Apart from homosynthons, some favorable heterosynthons (stronger than 
homosynthons) are also shown in figure 1.12 such as carboxylic acid-pyridine in figure 1.12 
(2), carboxylic–amide in figure 1.12 (4), and alcohol-ether in figure 1.12 (5). 
Physicochemical properties of the supramolecular derivatized solid forms 
Physical and chemical properties of crystals are critical to the improvement of APIs. The 
overall motivation for investigating pharmaceutical supramolecular derivatized solid forms as 
an alternative approach during drug development is the adjustment of the physiochemical 
properties to improve the overall stability and efficacy of a dosage form.71 
Physicochemical properties such as melting point, stability, solubility, dissolution and 
bioavailability will be discussed in detail below. 
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A- Melting Point 
Melting point is the temperature at which the solid phase is at equilibrium with the liquid 
phase. It is a fundamental physical property and an important consideration during solid drug 
development. It is normal to determine the melting point of a compound as a means of 
characterization or purity identification. However, the melting point is also very valuable due 
to its associations to aqueous solubility and vapour pressure.72 The melting point, in fact, has 
been directly correlated with the logarithm of solubility.73 Thus, being able to determine the 
melting point of a particular API before it was synthesized would be very beneficial in order 
to tailor its aqueous solubility toward a particular function. Unfortunately, correlations 
relating to chemical structure directly to melting point data remain elusive.74,75 
The impact of crystal packing on the melting points of co-crystals were investigated by 
Fleischman et al. (2003),76 in which four co-crystals with the same fundamental heteromeric 
O–H⋯N hydrogen bond but different overall packing arrangements had different melting 
points. In addition, it was also shown that there were some correlations between a compound's 
melting point and its solubility, which was that high melting points may contribute to poor 
solubility of co-crystals.76  
B- Stability 
Stability is an important parameter for drug development, it is key to evaluating properties of 
a pharmaceutical drug. Different types of stability data need to be considered depending on 
the structure and characteristics of the molecule. Chemical and physical stability data are 
commonly obtained at accelerated stability conditions to determine development and shelf 
life.18 
Water uptake is included from a handling and packaging point of view. The amount of water 
present can also lead to form changes, degradation, and worse if the effect of the water uptake 
is not investigated early in the process.77 Thermal stress studies are also incorporated, and 
extra work may be warranted for hydrates or thermally labile materials. In the case of co-
crystals and salts, solution stability may be a factor due to the dissociation of the material 
resulting in the precipitation of the less soluble parent compound or a less soluble form such 
as a hydrate in aqueous media.78 
Solid form discovery and design depends on the nature of the molecule of interest and type of 
physical property challenges faced in its development. The preferred solid form is generally 
the thermodynamically most stable crystalline form of the compound. 18 
However, the stable crystal form of the parent compound may exhibit inadequate solubility or 
dissolution rate resulting in poor oral absorption, particularly for water-insoluble compounds. 
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In this case, alternative solid forms may be investigated. For ionizable compounds, 
preparation of salt forms using pharmaceutically acceptable acids and bases is a common 
strategy to improve bioavailability.18,20,34 Like the parent compound, pharmaceutical salts may 
exist in several polymorphic, solvated and/or hydrated forms. Usually, the stability testing of 
a newly developed drug or crystal includes four aspects: relative humidity stress, thermal 
stress, chemical stability and solution stability. 
 
Relative Humidity Stress 
The relative humidity stress test is used to identify the best storage conditions for the product 
because the amount of water present in the drug or crystal can lead to quality deterioration. It 
was found that better performance of the crystals was displayed during water 
sorption/desorption experiments.77,79 
Mechanized moisture sorption/desorption studies are commonly performed to determine 
problem areas and to provide direction for more detailed studies when the need arises. X-ray 
powder diffraction (XRPD) data collected on the solid at the end of the moisture balance 
experiment provides information on the final form, but not necessarily on any form 
conversions that may have occurred during the experiment. Significant moisture uptake 
during the course of the experiment may warrant longer exposure at a specific relative 
humidity using a relative humidity chamber and subsequent analysis of the sample after 
equilibration. For example, Co-crystals of glutaric acid and 2-[4-(4-chloro-2-
fluorphenoxy)phenyl]pyrimidine-4-carboxamide sorbed less than 0.08% water, up to 95% 
relative humidity over repeated sorption/desorption cycles.80 Results showed that these co-
crystals are stable with respect to moisture under normal processing and storage conditions. 
Relative humidity is not a major concern for these co-crystals. 
 
Thermal Stress 
Thermal data studies provide valuable information that should be explored in relation to other 
processes, such as drying and accelerated stability. Very few reports show that thermal stress 
studies can provide valuable information about physicochemical stability.81,82 
High temperature stress is a common condition used to determine chemical and physical 
stability based on accelerated stability conditions. For the co-crystal of a monophosphate salt 
with phosphoric acid, an 8-week exposure at 60 °C resulted in no detectable degradation or 
form change.83  
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Chemical Stability 
Chemical stability is essential for the development of a new compound and to minimize any 
chemical degradation that may occur.  
Samples of a glutaric acid co-crystal of 2-[4-(4-chloro-2-fluorphenoxy)phenyl]pyrimidine-4-
carboxamide were placed at the same conditions for 2 months, and HPLC impurity analysis 
did not show any significant increases in known degradants.80 
A 1:1 carbamazepine/saccharin co-crystal was compared to carbamazepine (Form III) in a 
chemical stability study using temperature (5, 40 and 60 °C at ambient humidity) and elevated 
RH conditions (25 °C/60% RH and 40 °C/75% RH) over 2 months.84 
Degradation was not observed for either material at the elevated temperatures; however, both 
materials showed similar degradation patterns under the second set of conditions. In this case, 
a significant improvement in chemical stability was not needed, and the co-crystal proved to 
be as stable as the marketed carbamazepine form under these conditions. 
 
Solution Stability 
Solution stability is the ability of the crystal components to stay in solution and not readily 
crystallize and it’s an important parameter during drug development. Water, simulated gastric 
fluid (SGF), simulated intestinal fluid (SIF), formulation vehicles, and buffered solutions can 
be used as vehicles. The reason for solution stability is because dissociation of a crystal can 
occur. For example, an aqueous solution of a 1:1 carbamazepine/saccharin co-crystal was 
slurried with equal parts carbamazepine dihydrate and saccharin in solution in order to 
determine the form present in aqueous solution.84 After 24 h, only the co-crystal was evident 
based on XRPD data and the carbamazepine dihydrate was not detected. This is likely based 
on the concentration of the co-former present, which had been investigated for a number of 
systems.85 
C- Solubility 
Drugs with limited aqueous solubility are becoming the main reason to investigate new 
crystals for solubility improvement. Traditional methods for improving solubility of poorly 
water-soluble drugs include salt formation, solid dispersion (emulsification), and particle size 
reduction (micronisation). However, there are practical limitations with this techniques.1 
Pharmaceutical co-crystallisation as a novel way to improve the physicochemical properties 
of a drug such as solubility, which has attracted great interests from researchers1,64,80,86 tried to 
improve the solubilities of two APIs, exemestane (EX) and megestrol acetate(MA), in which 
two novel co-crystals, exemestane/maleic acis (EX/MAL) and megestrol acetate/saccharin 
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(MA/SA), were prepared from organic solutions with different particle sizes. Co-
crystallisations of the EX and MA improved initial dissolution rates compared to the 
respective original crystals. Co-crystal MA/SA showed supersaturation with fine particles.  
The supersaturated concentration of MA from MA/SA co-crystal at 15 minute was about six 
times greater than the saturated concentration of fine MA and was two times greater within 
4 h.87 
D- Intrinsic Dissolution 
Intrinsic dissolution measures the rate of dissolution of a pure drug substance from a constant 
surface area without the effect of particle size. The sample used in the intrinsic dissolution test 
is pressed into a disk or pellet,63 which should have no form change upon pressing and the 
disk needs to remain intact during the experiment. Thus, the intrinsic dissolution rate is a 
good indicator for in vivo performance of APIs. Various factors need to be considered and 
extra experiments may be needed to obtain and interpret intrinsic dissolution data on crystals 
correctly.63 
One co-crystal example, a low solubility API, 2-[4-(4-chloro-2-
fluorophenoxy)phenyl]pyrimidine-4-carboxamide, was co-crystallised with glutaric acid to 
achieve 18 times higher intrinsic dissolution rate.80 
E- Bioavailability 
Bioavailability is a measurement of the rate and extent of the active drug that reaches 
systemic circulation.88 The bioavailability of the animal is an important parameter to consider 
when preparing new forms of a compound. These studies are usually performed during early 
development and can be small studies (4−6 animals) to determine pharmacokinetic data 
quickly on a new form. Usually the same animals are used for all forms/formulations with a 
washout period, typically, a week in length, between the doses. This gives a direct comparison 
within the same animals for all the materials in the study.63 Studies can be set up in a number 
of different ways to obtain specific information for development. A study with both the parent 
material and the derivatized crystal will give a direct assessment of bioavailability 
improvements of the new form. In a relative or comparative bioavailability study, the amount 
of drug in the blood is measured after oral administration of the original form and then the 
new form. Blood samples are taken after dosing to investigate blood levels over time. It is 
important to note that the materials used in the study need to be formulated in the same way if 
a direct comparison is desired. 
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For dog studies of a 1:1 2-[4-(4-chloro-2-fluorphenoxy)phenyl]pyrimidine-4-
carboxamide/glutaric acid co-crystal, a simple powder in capsule formulation was used at two 
dose levels (5 and 50 mg/kg).80 The co-crystal was compared directly to the crystalline API 
(2-[4-(4-chloro-2-fluorphenoxy)phenyl]pyrimidine-4-carboxamide). Six dogs were used and 
samples were collected for 36 h post dose. The mean Cmax values for the 5 mg dose were 89 
and 25 ng/mL for the co-crystal and parent compound, respectively. For the 50 mg dose, the 
Cmax values were 278 and 89 ng/mL for the co-crystal and parent compound, respectively. 
The co-crystal was found to be over three times more bioavailable than the parent material 
using only powder in a capsule as a formulation. 
1.2 Characterization of crystal forms 
Crystal form characterisation is an essential component within crystal engineering research. 
The basic physicochemical properties of crystals can usually be characterised by powder X-
ray diffraction (PXRD), single crystal X-ray diffraction (SXRD), infrared spectroscopy (IR), 
Raman spectroscopy, differential scanning calorimetry (DSC), hot stage microscopy, 
thermogravimetric analysis and solid state nuclear magnetic resonance spectroscopy 
(SSNMR). 
X-ray powder diffraction (XRPD) is the most convenient way to determine crystal forms, 
since different crystal forms produce different diffraction patterns. Although a relatively large 
amount of API is usually required for detailed investigation and the sample is also reusable. 
Theoretically, a slight difference in diffraction pattern should indicate different crystal forms; 
however, slight differences are frequently observed for identical crystal forms of actual 
candidates due to many reasons including difference in crystallinity, difference in particle size 
and habit, and contamination of the small amount of the different crystal form. A typical 
example is that shown by Tian et al,89 in which identical crystal forms of carbamazepine 
exhibited slightly different XRPD patterns due to differences in the crystal habit. Other 
spectroscopic methods, including infrared, Raman, and near-infrared spectroscopy, may also 
differentiate crystal forms.90 - 93. 
SXRD is a basic characterisation technique for the determination of the solid-state structure of 
crystals at an atomic level. However, the problem is that a single pharmaceutical crystal 
which qualifies for SXRD testing cannot always be produced. Therefore, PXRD is utilised 
more frequently to verify the formation of different forms. While, PXRD cannot distinguish 
solvates, hydrates or polymorphs from co-crystals, pharmaceutical co-crystals are prone to 
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forming isostructural phases.54 Solid-state fluorescence spectra can also work for 
discrimination of polymorphs in some cases.94 
Solid-state NMR is a very powerful method for investigating crystal forms, since it can 
provide information including studying structure and conformation, analyzing molecular 
motions (relaxation and exchange spectroscopy),  assigning resonances (spectral editing and 
two-dimensional correlation spectroscopy) and measuring intermolecular distances.95     
IR is a very common spectroscopic technique in determining the chemical conformation of 
compounds. It can be a very powerful tool in distinguishing co-crystals from salts when a 
carboxylic acid is involved in hydrogen bond formation.96 A neutral carboxylic group (–
COOH) has a strong carbonyl (C=O) stretching peak around 1700 cm-1 and a weak C–O 
stretch around 1200 cm−1; however, if deprotonating has occurred, a carboxylate anion (–
COO−) has only a single C–O stretch in the fingerprint region of 1000–1400 cm-1. 
Thermal analysis is a very sensitive method for evaluating crystal forms and can directly 
provide thermodynamic information.97 DSC is the most widely used technique for the thermal 
property testing of crystals. DSC is the preferred technique for obtaining comprehensive 
melting point data and additional thermal data, such as the enthalpy of melting which can also 
be obtained simultaneously. In addition to being a characterisation technique, DSC has 
recently been used as a screening tool for rapid co-crystal screening.98 
 
1.3 Crystal structure determination 
Crystal systems consist of minimal building blocks, each of which contains all the structural 
features and symmetry elements, and which is repeated regularly in a three-dimensional 
space. The minimal building block is termed the unit cell (Figure 1.13)99,100 and contains at 
least one molecule. Symmetry considerations show 230 unique arrangements of points in 
space, termed space groups. These 230 space groups describe all the possible ways in which 
identical objects can be arranged in an infinite lattice.101 
The dimensions of the unit cell are characterized by six quantities; three axial lengths (a, b, c) 
and three interaxial angles (α,β,γ). Each unit cell contains at least one molecule and can be 
classified by one of the seven three-dimensional coordinate systems (Table 1.3),100 which are 
the seven primitive crystal systems. Each of these crystal systems has one or more symmetry 
elements that describe the internal symmetry of the unit cell. The different symmetry elements 
comprise rotation, mirror, screw, glide, and rotation-inversion operations. 
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Table 1.3 Crystal systems and lattice parameters 
 
 
 
 
System Relationship between 
 lattice parameters 
Cubic 
 
Tetragonal 
 
Orthorhombic 
 
Rhombohedral 
(or trigonal) 
Hexagonal 
 
Monoclinic 
 
Triclinic 
a = b = c 
α = β = γ = 90◦ 
a = b ≠ c 
α = β = γ = 90◦ 
a ≠ b ≠ c 
α = β = γ = 90◦ 
a = b = c 
α = β = 90◦ γ ≠ 90◦ 
a = b ≠ c 
α = β = 90◦, γ = 120◦ 
a ≠ b ≠ c 
α = γ = 90◦, β ≠ 90◦ 
a ≠ b ≠ c 
α ≠ β ≠ γ ≠ 90◦ 
 
There are 32 possible unique combinations of the different crystallographic symmetry 
elements, each defined by a point group. Bravais discovered that some crystal lattices are 
more complex but still conform to the seven crystal systems.100,101 In these so-called 
nonprimitive lattices, each lattice point and every symmetry element in the primitive lattice 
are reproduced with a corresponding offset. In total, there are 14 Bravais lattices consisting of 
seven primitive and seven nonprimitive lattices.102 The combination of 32 point groups with 
14 Bravais lattices leads to 230 unique arrangements of points in space, termed space groups 
(Figure 1.13). 
A space group determined in this way describes the spatial symmetry of the crystal. By 
definition, a crystallographic space group is the set of geometrical symmetry operation that 
take a three-dimensional periodic crystal into itself.100 
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                        A                                                                            B                                                                                                                                                                               
   
Figure 1.13 Fundamentals of crystal structure: A. The unit cells and the six quantities 
characterized by three dimensions of the unit cells, three axial lengths (a, b, c) and three 
interaxial angles (α,β,γ). B. The features and symmetry elements of space group P21/c (in 
which pharmaceuticals often crystallize) is exemplified with the unit cell of 4-
methylacetanilide (CSD Refcode ACTOLD01).103  
 
The arrangement of the molecules in a crystal determines its physical properties and in certain 
cases its chemical properties.104 The physicochemical properties of the solid drug can affect its 
performance. The shape and particle size of the solid drug can influence pharmaceutical 
operations, such as filtration, washing, drying, milling, mixing, tableting, dissolution, 
recrystallization of a suspension and lyophilisation.18,105,106             
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1.4 The selected APIs and co-formers 
Sulfonamides 
 
The sulfonamide drugs were the first effective chemotherapeutic agents to be employed 
systemically for the prevention and cure of bacterial infections.107-109 The chemical structure 
of sulfonamides is characterized by a benzene ring in combination with a sulfanilamide group 
(Figure 1.14).110 Sulfonamides antimicrobial activity is caused by the para position of the 
substitutes. Derivatives differ in the substitutes bound to the nitrogen in the sulfonamide 
group and hence, show differences in metabolism, solubility, protein binding and 
excretion.111,112 
 
 
Figure 1.14 Sulfanilamide structure 
Sulfonamides are susceptible to radical and light catalysed oxidation. Radical oxidation of 
sulfonamide with potassium ferricyanide or hydrogen peroxide gives rise to the corresponding 
azobenzene 4,4-disulfonamide and azoxibenzene-4,4-disulfonamide. Light-catalysed 
oxidation gives an analogous product. Medicinal sulfonamides must in consequence be stored 
in well-closed containers and be protected from light.113 
Effects of sulfonamides on microbial agents 
Sulfonamides have a wide range of antimicrobial activity against both gram-positive and 
gram-negative microorganisms. In general, the sulfonamides exert only a bacteriostatic effect 
in the body with both cellular and humoral defense mechanisms of the host being essential for 
the final eradication of the infection. The microorganisms highly susceptible in vitro to 
sulfonamides are streptococcus pyogenes, streptococcus Pneumonia, some strains of bacillus 
anthracis, corynebacterium diphtheria, haemophilus influenza, haemophilus ducreyi, 
brucella, vibrio cholera, yersinia pestis, nocardia, actinomyces, calymmatobacterium 
granulomatis, and chlamydia trachomatis. Most strains of escherichia coli isolated from 
patients with urinary tract infections that have not previously been treated are susceptible to 
sulfonamides.114  
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Mechanism of action of sulfonamides 
Sulfonamides are structural analogs and competitive antagonists of para-aminobenzoic acid 
(PABA), and thus prevent normal bacterial utilization of PABA for the synthesis of folic acid. 
Sulfonamides are competitive inhibitors of the bacterial enzyme responsible for the 
incorporation of PABA into dihydropteroic acid, the immediate precursor of folic acid (Figure 
1.15).115,116 
Synergists and antagonists of sulfonamides 
Trimethoprim is one of the most active agents that exerts a synergistic effect when used with 
sulfonamides.117 This compound is a potent and selective inhibitor of microbial dihydrofolate 
reductase, the enzyme that reduces dihydrofolate to tetrahydrofolate (Figure 1.15). The 
simultaneous administration of a sulfonamide and trimethoprim thus introduces sequential 
blocks in the pathway by which microorganisms synthesize tetrahydrofolate from precursor 
molecules. 
 
Figure 1.15 Tetrahydrofolate synthesis pathways 
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Metabolism of sulfonamides 
The metabolic modification of sulfonamide is known to occur to different extents in tissues, 
especially in the liver. The major metabolic derivative is the N4-acetylated sulfonamide. Each 
sulfonamide is acetylated differently. Furthermore, the acetylated forms of some of the older 
sulfonamides are less soluble and hence contribute to crystalluria and renal complication.114 
Excretion of sulfonamides 
Sulfonamides are excreted primarily as mixtures of unmetabolized drugs, N4- acetate, and 
glucuronides. The N4-acetate, and glucuronides are inactive. Sulfisoxazole, for example is 
excreted about 80% unchanged and sulfamethoxazole 20% unchanged. The correlation 
between structure and route of metabolism has not yet been delineated.  
The largest fraction is excreted in the urine, and the half-life of sulfonamides in the body is 
thus dependent on the body’s renal function. Small amounts are eliminated in the feces, bile, 
milk, and other secretions.114 
Protein binding 
The sulphonamides vary widely in plasma protein binding, for example, sulfisoxazole 76%, 
sulfamethoxazole 60%, sulfamethoxypyridazine 77%, sulfadiazine 38%.118 
The fraction that is protein bound is not active as an antibacterial, but because the binding is 
reversible, free, and therefore active, sulphonamide eventually becomes available. 
Surprisingly, the N4–acetylated metabolites, although more strongly protein-bound, are 
excreted more rapidly than the starting drugs. 
Currently, the relationship between plasma protein binding and the biological half-life is not 
clear. Many competing factors within the body’s physiology are involved, as reflected in 
sulfadiazine, with a serum half-life of 17 hrs, which is much less protein-bound compared to 
sulfamethoxazole, with a serum half-life of 11 hrs.118 
Sulfa drugs may be classified into four groups on the basis of rapidity with which they are 
absorbed and excreted:114 
1- Rapidly absorbed and rapidly eliminated sulfonamides: 
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Sulfisoxazole is a rapidly absorbed and rapidly excreted sulphonamide with excellent 
antibacterial activity, equal to that of sulfadiazine. Sulfisoxazole is appreciably more soluble 
than the older sulphonamides. 
Sulfamethoxazole is a close congener of sulfisoxazole, but its rate of enteric absorption and 
urinary excretion is slower. Other examples include: sulfadiazine, sulfacytine, 
sulfamethiazole. 
2- Rapidly absorbed and slowly excreted sulfonamides: 
Sulfamethoxypyridazine and sulfameter offer the potential advantage of maintenance of 
effective plasma concentrations when administered only once or twice a day because these 
agents are rapidly absorbed and slowly excreted.  
3- Poorly absorbed sulfonamides: 
Sulfasalazine and phthalylsulfathiazole are very poorly absorbed from the gastrointestinal 
tract. 
4- Sulfonamides for topical use: 
Examples include: sulfacetamide, silver sulfadiazine, mafenid. 
The active pharmaceutical ingredients in this study are sulfamethoxazole, sulfasalazine and 
trimethoprim (Table 1.4). 
Table 1.4 Physical properties of selected APIs 
API Solubility at pH 7 at 24 ºC Melting point (°C)         pKa                      
Sulfamethoxazole Slightly soluble in water  
(0.5 g/L)      
  167-170                      5.7 
Trimethoprim Slightly soluble in water  
(1 g/L)  
  199-203                      7.04 
Sulfasalazine Practically insoluble in water     255 followed              2.7 
   immediately by 
  decomposition      
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Sulfamethoxazole (SMZ) 
Mechanism of action of sulfamethoxazole  
Sulfamethoxazole (SMZ) is an intermediate-acting sulfonamide drug that inhibits bacterial 
synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding 
to dihydropteroate synthetase (dihydrofolate synthetase). Sulfamethoxazole is bacteriostatic in 
nature. Inhibition of dihydrofolic acid synthesis decreases the synthesis of bacterial 
nucleotides and DNA.  
SMZ resembles sulfisoxazole in chemical structure and antibacterial activity, but is absorbed 
and excreted more slowly; it has a greater tendency to cause crystalluria. This drug has a high 
potency, and it has been used for many years. It is useful for urinary tract infections and may 
be particularly valuable for the treatment of pyelonephritis, since it is cleared relatively slowly 
(half-life 11 hrs).119,120 
Description of sulfamethoxazole 
Sulfamethoxazole (SMZ) (N1-(5-methyl-3-isoxazolyl)sulfanilamide) is a  
common sulfonamide, the molecular formula is C10H11N3O3S, it is slightly soluble in water 
(0.5 g/L at pH=7 and  25 °C) and has a melting point of 167-170 °C (Table1.4). 
Sulfamethoxazole is a white to off-white powder, practically odourless and tasteless. It has a 
plasma half-life of 11 hrs as a crystalline powder with a molecular weight of 253.28 g/mol 
and with the following structural formula (Figure 1.16).110,120 
 
 
Figure 1.16 Sulfamethoxazole chemical structure 
Solubility of sulfamethoxazole in different solvent systems 
Sulfamethoxazole is soluble in specific solvent systems as shown in table 1.5. Based on the 
table sulfamethoxazole is more soluble in polar solvents. 
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Table 1.5 Solubility of sulfamethoxazole in different solvent systems at 25 °C.120 
Solvent  Solubility (g/L) 
Ethanol 30.6 
Benzene 0.5 
Chloroform  2.3 
95% ethanol 37.8 
Ethyl ether 2.7 
Isopropanol  8.8 
Methanol 90.3 
Petroleum ether   0.2 
0.1 N NaOH 16.0 
 
Sulfasalazine (SSZ) 
Mechanism of action of sulfasalazine 
Sulfasalazine (SSZ) also known as salazopyrine or salazosulfapyridine within the class of 
sulfa drugs. It is a conjugate of 5-aminosalicylic acid, an anti-inflammatory drug and 
sulfapyridine an antibacterial drug. Sulfapyridine inhibits growth of bacteria by competitive 
inhibition of para-aminobenzoic acid (PABA), a substrate of the enzyme, dihydropteroate 
synthetase. This inhibition reaction is necessary in bacteria for the synthesis of folic 
acid.121,122 Sulfasalazine possess antimicrobial properties, and is used as a drug for treating 
inflammatory bowel disorders,123,124 and rheumatoid arthritis.125  
Description of sulfasalazine 
Sulfasalazine (SSZ) is 5-{4-[(2-pyridylamino) sulfonyl]phenyldiazenyl}salicylic acid with the 
following chemical formula, C18H14N4O5S (Fig 1.10). It is slightly soluble in water and has a 
melting point of 255 °C followed by immediate decomposition (Table1.4). The compound has 
a bright yellow to brownish-yellow colour, it is odorless and it is a fine powder with a 
molecular weight of 398.4 g/mol.121 There are two tautomeric isomers of sulfasalazine, the 
triclinic (amide tautomer)126 and the monoclinic (imide tautomer)127 (Figure 1.17) Tautomers 
are organic compounds that are interconvertable by a chemical reaction called 
tautomerization. This reaction results in the formal migration of a hydrogen atom or proton, 
accompanied by a switch of a single bond and adjacent double bond. Both the C5-N2 shown 
by blue the arrow in figure 1.17 as [1.348 (4) Å] and the S1-N2 shown by red arrow as [1.586 
(3) Å] bond lengths on the monoclinic form are much shorter than those observed in the 
triclinic amide form [1.425 (2) and 1.6539 (16) Å, respectively], indicating conjugation 
between the pyridine ring and the side chain. 
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Figure 1.17 Sulfasalazine chemical structure of the triclinic and monoclinic form 
 
Solubility of sulfasalazine 
The solubility of sulfasalazine is as follows: Practically insoluble in water, ether, chloroform 
and benzene, very slightly soluble in alcohol, soluble in aqueous solutions of alkali 
hydroxides.121 
Trimethoprim (TMP) 
Mechanism of action of trimethoprim 
Trimethoprim (TMP) blocks the production of tetrahydrofolic acid from dihydrofolic acid by 
binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase.128 The 
combination of SMZ and TMP blocks two consecutive steps in the biosynthesis of nucleic 
acids and proteins essential to many bacteria (Figure 1.15). 
Description of trimethoprim 
Trimethoprim (TMP) is 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine, the molecular 
formula is C14H18N4O3, it is slightly soluble in water (<1 g/L at pH=7, 25 °C), and has a 
melting point of 199-203 °C (table1.4). It is a white or cream-colored crystal or crystalline 
powder with a molecular weight of 290.3 g/mol, with the following structural formula (Figure 
1.18): 129,130 
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 Figure 1.18 Trimethoprim chemical structure 
Solubility of trimethoprim 
The solubility data for trimethoprim in different solvents at 25 °C are shown in table 1.6.  
Table 1.6 Solubility of trimethoprim in different solvents at 25 °C.129  
Solvent Solubility ( g/100ml ) 
Water  0.04 
95% ethanol 0.81 
Methanol  1.21 
Isopropanol 0.12 
Chloroform 1.82 
Ethyl ether   0.003 
Acetone  0.35 
Benzene  0.002 
Synergistic combination of sulfamethoxazole with trimethoprim 
Sulfamethoxazole is normally given in combination with trimethoprim, a dihydrofolate 
reductase inhibitor, which inhibits the reduction of dihydrofolic acid to tetrahydrofolic acid 
(Figure 1.15). 
Sulfamethoxazole is most often used as part of a synergistic combination with trimethoprim 
in  a 5:1 molar ratio as a mixture in the preparation called co-trimoxazole branded as 
Bactrim.®131 
In vitro studies have shown that bacterial resistance develops more slowly with both 
sulfamethoxazole and trimethoprim in combination than with either sulfamethoxazole or 
trimethoprim alone.132 In vitro serial dilution tests have shown that the spectrum of 
antibacterial activity of sulfamethoxazole and trimethoprim includes the common urinary tract 
pathogens with the exception of Pseudomonas aeruginosa. The following organisms are 
usually susceptible: Escherichia coli, Klebsiella species, Enterobacter species, Morganella 
morganii, Proteus mirabilis and Indole-positive proteus species including Proteus vulgaris. 
The usual spectrum of antimicrobial activity of sulfamethoxazole and trimethoprim includes 
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the following bacterial pathogens isolated from middle ear exudate and from bronchial 
secretions: Haemophilus influenzae, including ampicillin-resistant strains, and Streptococcus 
pneumonia, Shigella flexneri and Shigella sonnei are also usually susceptible. The usual 
spectrum also includes Enterotoxigenic strains of Escherichia Coli (ETEC) causing bacterial 
gastroenteritis.132 
There is no combination of sulfasalazine and trimethoprim bounded covalently or non- 
covalently currently on the market. This study will attempt to make a non-covalent 
combination of the two compounds to improve possibly its antimicrobial activity and 
dissolution profile.                                  
Due to the low solubility and low antimicrobial activity of sulphonamides alone, this study 
will attempt co-crystallization studies with drug molecules in other classes such as 
trimethoprim or with selected compounds with good co-forming properties. Ultimately, the 
aim is to improve the solubility, antimicrobial activity and/or other physicochemical 
properties of SMZ and SSZ. 
Molecules in the sulphonamide class typically contain multiple hydrogen bond donor and 
acceptor functions, which provide good opportunities to make co-crystal.  
Based on the Cambridge Structural Database103 and a thorough literature search: Co-crystasl 
of SMZ and TMP, were prepared by the slurry method.133 The SMZ-TMP co-crystal from the 
slurry method was prepared and produced as small (fibrous) crystal for data collection; 
however no crystal structure had been solved as yet due to the poor quality of the crystal.   
On the other hand a salt of SMZ and TMP was prepared by Nakai et al.134 Proton transfer 
from the sulfamethoxazole to a pyrimidine nitrogen atom of trimethoprim accompanies the 
reaction, leading to the formation of an eight membered hydrogen-bonded ring (Figure 1.19). 
This compound TMP+. SMZ- is a salt and does not correlate to the modern definition of a co-
crystal.  
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 Figure 1.19 Salt formation between SMZ- and trimethoprim TMP+ 
Furthermore, there is a co-crystal of TMP and a less acidic sulfa drug sulfadimidine (pKa 
=7.4) made from a methanolic solution (figure 1.20).135 
 
Figure 1.20 Methanol solvate of trimethoprim sulfadimidine co-crystal 
Trimethoprim (TMP) and sulfamethoxypyridazine (SMPD) resulted in a co-crystal when the 
crystallization medium was methanol but as a hydrated salt when crystallization was from 
water (Figure 1.21).136  
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 Figure 1.21 A: TMP-SMPD co-crystal B: TMP+SMPD- salt 
Sulfamethoxazole has five polymorphs and a hemihydrate form (Table 1.7) different in 
structure parameters. The melting point for polymorphs I, II and IV are 170 °C, polymorph III 
this polymorph transforms to form II upon heating between 145 °C and 150 °C, form II then 
transform to form I around 166 °C, which subsequently melts at 170 °C. 
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Table 1.7 Sulfamethoxazole polymorphic structure data 
SMZ structure A B C   α  
 
β       ϒ 
 Polymorph  I 137 
 
 
 
16.062(2) 
 
 
5.479(1) 
 
 
25.757(3) 
 
 
90.00 
 
 
96.12(2) 
 
 
    90.00 
Polymorph  II 137 
 
 
 
25.095(4) 
 
 
7.226(1) 
 
 
14.848(2) 
 
 
90.00 
 
 
117.99(1) 
 
 
90.00 
Polymorph III 138   
 
 
 
11.640(3) 
 
 
6.819(1) 
 
 
15.419(4) 
 
 
90.00 
 
 
107.11(<1) 
 
 
      90.00 
Polymorph  IV 138  
              
 
 
5.490(<1) 
 
 
16.761(3) 
 
 
12.422(2) 
 
 
90.00 
 
 
97.08(<1) 
 
 
     90.00 
Polymorph   V 139 
 
5.440(10) 8.550(20) 32.210(90) 124.90(60) 112.10(10) 103.10(50) 
Hemihydrate 140 9.726(<1) 15.122(<1) 8.363(<1) 90.00 101.68(<1)     90.00 
Objectives of the study 
* To prepare co-crystal forms of sulfamethoxazole, sulfasalazine and trimethoprim, in an 
attempt to improve their physicochemical properties by adding selected co-formers. The 
selection of co-formers depends on the functional groups that interact with each API.  
* To explore a new direction to deal with the solubility and dissolution problem of selected 
APIs.  
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* To prepare a good quality crystal based on the work of Zaini et al133 to elucidate a single 
crystal structure by single X-ray diffraction.        
* To examine the physicochemical properties and structures of newly derivatized forms by  
DSC, HSM, TGA, FTIR and X-ray diffraction. DSC, TGA curves and HSM provided 
information on the thermal stabilities and thermal decompositions of these compounds. FTIR 
provided information on the purity of the compounds and the suggested host-guest interaction 
sites. X-ray powder diffraction supported the determination of the new phase and single 
crystal X-ray diffraction elucidated the structure of isolated crystals comparative to the parent 
compounds.                      
* To investigate a new interaction between API and API in the selected classes of drugs for 
possible synergistic effects. 
The methodology of this study now follows in chapter 2.  
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Chapter 2 offers an overview of materials and methods used to prepare co-crystals and the 
instruments e mp lo ye d  to  i de n t i f y  a n d  an a l ys e  t h e s e  compounds. 
  
2.1 Materials 
 
The active pharmaceutical ingredients in this study were sulfamethoxazole, sulfasalazine 
(monoclinic form) and trimethoprim obtained from Sigma-Aldrich, India. 
Fourteen well known co-formers were included in this study for the co-crystallization 
experimentation. These were saccharin, nicotinamide, salicylic acid, L-tartaric acid, D-tartaric 
acid, L-aspartic acid, maleic acid, benzoic anhydride, oxalic acid dihydrate, L-glutamic acid, 
succinic acid, benzoic acid, 4-hydroxybenzoic acid and citric  acid (as the monohydrate) 
which were supplied by Sigma-Aldrich, India. The different  solvents used in the experiments 
included methanol, ethanol 96%, propan-2-ol, benzyl alcohol, 1,4-dioxane, diethyl ether, 
chloroform, acetone, ethyl acetate, tetrahydrofuran (THF), butanol, butanone and dimethyl 
sulfoxide (DMSO) which were obtained from the same source mentioned above. 
 
2.2 Compound identification 
 
All chemical substances used in this research were supplied with a certificate of analysis 
(CFA) report, which were identified and characterized with different analytical techniques 
upon comparison of the two. Melting point determination of each compound was the first 
identification procedure. For this purpose, thermal analysis utilizing differential scanning 
calorimetry (DSC) was conducted. Fourier transform infrared spectroscopy (FTIR) was 
another useful technique utilized for characterization and identification of compounds. From 
the FTIR spectra, information about the molecular structure was obtained. All identification 
data will be discussed and illustrated in appendix A (see CD-Rom). 
 
2.3    Experimental methods 
    Methods to prepare co-crystals 
 
Synthesis of co-crystals can be accomplished via a number of methods, including slow 
solvent evaporation (crystallization from solution), solvent-free grinding, solvent drop 
grinding, sublimation, slow cooling (flask method), vapour diffusion, slurry technique and 
crystallization from melt.1-7. 
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 Solvent evaporation method (crystallization from solution) 
Crystallization from solution was employed by preparing a solution containing a 
stoichiometric amount of a co-crystal former and an API using one solvent or a mixture of 
solvents. By using a hot plate and a magnetic stirrer, each component was dissolved 
separately into the solvent until complete dissolution occurred. All temperatures were kept 
below the melting point of the lowest melting component and 10 °C below the estimated 
boiling point of the solvent system. The two components ideally should have a similar 
solubility in the system otherwise the least soluble component will precipitate out exclusively. 
However, similar solubility alone will not guarantee a successful co-crystal formation. The 
two solutions are then added, mixed together, stirred once more and filtered through a 0.45 
µm micro filter into a clean vial. The vial was closed with parafilm® and perforated to allow 
the solvent to evaporate. In this method the sample was allowed to evaporate at different 
temperatures (room temperature 25 °C, refrigerator temperature 4 °C – 6 °C and high 
temperature 35 °C - 45 °C), because the temperature at which crystals will grow could not be 
predicted. The solubility of the compounds played a very important role in the preparation of 
the co-crystals from the solution.8 
 
Dry grinding 
When preparing co-crystals, the product obtained from grinding is generally consistent with 
that obtained from solution. This may indicate that hydrogen-bond connectivity patterns are 
not idiosyncratic or determined by non-specific and unmanageable solvent effects or 
crystallization conditions. However there are exceptions. Whilst many co-crystal materials 
can be prepared from both solution growth and solid-state grinding, some can only be 
obtained by solid-state grinding. An example is that in the co-crystallisation of 2,4,6-
trinitrobenzoic acid and indole-3-acetic acid, different crystal forms were obtained from 
solution compared with grinding. Failure to form co-crystals by grinding may be due to an 
inability to generate suitable co-crystal arrangements rather than due to the stability of the 
initial phases. When co-crystal formation has been successful from solution, but not from 
grinding, solvent inclusion in stabilizing the supramolecular structure may be a factor. 
Pharmaceutical co-crystals can be formed by neat (dry) grinding, in which the active 
pharmaceutical ingredient and co-crystal formers were mixed and ground together manually 
using a small porcelain mortar and pestle. The grinding was carried out for a specific period 
of time.8-10. 
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A few co-crystal materials can only be prepared by neat or dry grinding, whereas a large 
number of these materials can be prepared by both solution growth and solvent drop 
grinding.9, 11. 
 
Solvent drop grinding 
Solvent assisted grinding is another technique to prepare co-crystals. Here the addition of a 
small amount of the appropriate solvent to the mixture of an API and the co-crystal former 
was prepared. The mixture is then manually or mechanically ground to reduce the excessive 
use of the crystallization solvent.12 The adding of small amounts of solvent during the 
grinding process has been shown to enhance the kinetics and facilitate co-crystal formation. 
This kinetic enhancement was rationalised by the additional degree of orientational and 
conformational freedom open to the molecules at the various interfaces with increased 
opportunities for molecular collisions.8, 13. 
Furthermore, this method has an advantage of cost-effectiveness and reliability. It accounts as 
a green method for exploring new co-crystals and also for the preparation of obtainable co-
crystals.14 Trask et al.15 reported that grinding of cyclohexane-1,3-cis-5-cis-tricarboxylic acid 
and 4,4′-bipyridine in the dry state does not afford a co-crystal whereas grinding the two 
components with a few drops of methanol facilitates complete conversion within minutes. 
 
Sublimation 
The term sublimation refers only to the phase change from solid to vapor without the 
intervention of the liquid phase and back to solid again. In this method a small quantity of the 
respective co-formers in stoichiometric amounts was placed in a petri dish that was covered 
with a watch glass. The petri dish was heated gently on a hot plate and the watch glass was 
observed to determine if co-crystals were growing on it.16   
 
Slow cooling (Flask method) 
Slow cooling of saturated solutions often gives results when the liquid diffusion method is 
inapplicable or when the compound is soluble in most liquids. The flask and solvent to be 
used should be dust-free. The flask of warm solution is allowed to cool in warm water over a 
period of several days. 17 
Vapour diffusion 
This method is normally the most successful method of obtaining single crystals (Figure 2.1). 
A small amount of solution (the compound to be crystallized is in the good solvent) is placed 
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in an open tube that was stored in a desiccator containing a small amount of the solvent. The 
desiccator was then tightly closed. This second solvent should be less dense than, and 
miscible with, the first solvent. As solvent equilibrium was reached, the non-solvent diffused 
through the vapor phase into the solution, and saturation or supersaturation was achieved. The 
solubility of the compound in a precipitant used in a two-solvent crystallisation method such 
as vapour diffusion should be as low as possible (much less than 1 mg/ml), and the precipitant 
(the solvent in which the compound is poorly soluble) should be miscible with the solvent and 
the saturated solution. If no crystal had formed in 24 hours, try again with a stronger solution. 
Commonly used solvent/precipitant pairs are water/acetone or chloroform; methylene 
chloride/petroleum ether or cyclohexane. This method is also suitable when only a small 
quantity of material is available since about 0.1 ml of solution is quite adequate. 17 
 
 
Figure 2.1 The vapour diffusion method. (i) Solution of compound to be crystallised. (ii) 
Introduce precipitant and stopper firmly. (iii) Crystals form after some days. 
 
Advantages of this method are that several tubes may be set up in the same container where a 
sealed desiccator is often used and that very small quantities may be used on a spot plate. 
Crystal formation is somewhat slower and may take several days. 17   
Slurry technique 
Slurry induced formation of the co-crystalline phase among two or more active solid materials 
or between the active solid materials and the excipients. Equimolar amounts are dissolved in a 
small amount of solvent at ambient temperature, the slurry were stirred for a long time (24 hr 
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or more) at constant temperature, the solution then filtered, and slowly evaporated at room 
temperature during a period of time to promote co-crystallization.18 
 
Crystallization from the melt 
Co-crystal formation by simply melting two co-crystal formers is achieved, followed by 
cooling. In case of no co-crystal formation from a melt, a seed from a melt may be employed 
in a crystallization solution in order to afford a co-crystal.19 
 
2.4 Identification of a quality crystal 
The quality of the crystals cannot be immediately recognised, the microscope is necessary for 
crystal examination. Some of the crystals are removed from their mother liquor and placed on 
a slide. Careful attention is given not to remove all of the crystals, even if the compound is 
known to be air stable, because crystals often decompose by loss of solvent of crystallization 
once out of contact with the mother liquor. 
A good single crystal will normally have well-formed, clear faces. A crazed or fibrous 
appearance is an indication of poor quality. If crystals have grown in clumps, single crystals 
may often be separated with a needle or cut off with a scalpel or razor blade. To prevent 
crystals from flying off and becoming lost they can be fixed to the slide with a drop of 
silicone grease. If a microscope with a polarising attachment is available, the identification of 
good crystals is made much easier. When a good single crystal is viewed between crossed 
polars (black back-ground) it will probably show up brightly. 17 
 
2.5 Analytical methods 
Hot stage microscopy, differential scanning calorimetry, thermogravimetric analysis, fourier 
transform infrared spectroscopy, elemental analysis, powder X-ray diffraction, single X-ray 
diffraction, dissolution and ultra-violet spectrophotometry were all employed to characterize 
and analyze the different forms of the API. 
 
Hot stage microscopy (HSM) 
Hot stage microscopy was used to determine the melting point, decomposition, and shape of 
the sample. A small amount of the sample was used. The samples were treated with silicon oil 
under the microscope which is important for solvent detection in the sample.  In this study a 
Linkam TH MS600 Temperature control stage connected to a T95 Linkpad System Controller 
was used. Heating of the products was controlled at a fixed rate of 10 °C per minute. An 
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Olympus SZX7 stereoscopic microscope connected to Olympus UC30 color video camera 
was used to capture a picture for the determination of visual observation and characterization. 
The images were recorded and saved by Stream Essential software.® 
 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetry is a thermal analysis technique used to determine the 
melting point and decomposition of the sample. It is an important technique which confirms 
the hot stage microscopy results. The samples were analysed using a PerkinElmer differential 
scanning calorimeter DSC7 connected with a Perkin Elmer thermal analysis controller 
TAC7/DX and Perkin Elmer thermal analysis gas station. The samples were scanned at a 
fixed heating rate (10 °C/min)  under  a N2 gas with a flow rate of 20 ml/min. Samples were 
removed from the mother liquor, dried on filter paper, weighed (the mass range was 1-2 mg) 
and crushed to an appropriate particle size and sealed in a crimped, vented aluminium pan. 
The reference used was a sealed empty pan. The calibrations of the DSC were performed by 
the melting point determination of indium which is 165 °C. The samples were heated over the 
range of 30-400 °C to see the decomposition. The data were collected and analysed using 
Pyris software.® Endothermic and exothermic peaks appearing in the DSC traces were 
analysed in terms of their onset temperatures, temperature range of the peak determined from 
the first derivative of the trace and the enthalpy of the peak measured in J/g. The various 
endothermic and exothermic peaks observed in the DSC trace were interpreted in conjunction 
with HSM and TGA to be associated with solvent loss, phase changes in the sample and 
decomposition. 
 
Thermogravimetric analysis (TGA) 
Thermogravimetry is a thermal analysis in which changes in physical and chemical properties 
of materials are measured as a function of increasing temperature (with constant heating rate). 
TGA is commonly used to determine small and large weight changes of a sample. It is used to 
establish the stoichiometry of inclusion compounds and to study the decomposition of 
desolvated materials. 
TGA analyses for all compounds were performed on a PerkinElmer TGA 4000 instrument 
under N2 gas purging at a flow rate of 20 mL/min. The PerkinElmer TGA instrument was 
calibrated using alumel (mp = 156.6 ºC ), perkalloy (mp = 596.0 ºC) and iron (mp = 780.0 ºC)  
in an automated process in which temperature calibration, thereafter furance calibration was 
done. The cystals were rapidly dried on a filter paper to remove surface solvent. The weighed 
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samples were placed in an open porcelain pan. The programmed TG analyses were carried out 
over a temperature range 30 ºC to 400 ºC at the predetermined linear heating rate of 10 K/min. 
This technique was primarily used to determine the stoichiometry of the compounds from the 
percentage weight loss. The samples were continuously purged by a stream of dry nitrogen 
gas at a flow rate of 20 mL/min. 
 
Infrared spectroscopy (FTIR) 
Fourier Transform Infrared (FTIR) was used for compound identification. All spectra were 
collected using a Perkin Elmer Spectrum 400 FT-IR Spectrometer. The analysis of the spectra 
conducted used Spectrum software version 6.3.5. The IR spectra of the new compounds were 
compared to the parent compounds spectra, where each molecule has a specific infra-red 
absorption pattern.20 
 
Elemental Analysis 
Elemental analysis is an experiment that determines the amount of an element in a compound 
(typically a weight percent). The most common type of elemental analysis is for carbon, 
hydrogen, and nitrogen (CHN analysis). This type of analysis is especially useful for organic 
compounds. 
Elemental analysis was performed on a Fisons EA1108 CHNS-O Elemental Analyser. It was 
used to determine the percentage of carbon, hydrogen, sulfa and nitrogen present in the 
sample. 
 
UV spectrophotometry 
UV spectra were recorded on a Cintra® 2.2 GBC Scientific Equipment Pty. Ltd. UV/visible 
spectrophotometer over a wavelength range of 190– 450 nm at a scanning rate of 1200 
nm/min was applied. The samples were placed in 2 mm quartz cuvettes and the concentrations 
were suitably adjusted such that all absorbance readings were measurable between zero and 
one absorbance unit. Calibration curves for the various drugs were constructed using readings 
taken at the   λmax value of the appropriate drug. The aborbance of a solution with an 
accurately known concentration was determined.  
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Crystal structure determination 
Powder X-ray diffraction (PXRD) 
X-ray powder diffraction (PXRD) is an instrumental analytical technique, which has been 
used to identify crystalline materials for almost a century. The technique was originally used 
to examine the nature of crystal lattices by the diffraction of X-rays through the closely 
spaced lattice of atoms.21 
X-ray crystallography techniques are concerned only with the structure analysis. This 
technique is especially useful in the absence of good quality crystals for single crystal 
structure determination, it uniquely identifies materials thus allowing for the identification of 
new compounds. 
Powder patterns of ground samples were recorded on a Philips PW1050/25 vertical 
goniometer with Ni-filtered CuKα radiation (λ = 1.5418 Å) produced at 48 kV and 25 mA. 
Samples were applied to a MYLAR® polyester film (Thin-film that supports sample, West 
Chester, Pennsylvania, USA) with a thin layer of paratone N oil, The MYLAR® was 
suspended on a flat sample holder. Step scans of 0.1º 2θ, with 2 s counting times, in the range 
5-40º 2θ were employed.  
 
Single crystal X-ray diffraction (SXRD) 
Single X-ray diffraction is the most preferred technique for structure determination. It 
provides an in depth structure of the crystal.  
 
Crystal Structure Determination  
In each case single crystals, typically between 0.2  and 0.5 mm in all dimensions, of good 
quality were selected for their ability to extinguish plane-polarised light uniformly.  Crystals 
were mounted on a nylon loop and coated with paratone® N oil to prevent the loss of 
included solvent and to provide a rigid mount during low temperature data-collection.  The 
nylon loop was mounted on a goniometer head.   
Two single crystal X-ray diffractometers were employed in this study: a Nonius Kappa CCD 
(Charge Coupled Device) single crystal X-ray diffractometer and a Bruker KAPPA APEX II 
DUO diffractometer.      
Data-collection 
Crystal intensity data were collected on a Nonius Kappa CCD (Charge Coupled Device) 
single crystal X-ray diffractometer, using graphite-monochromated MoKα radiation (λ = 
0.71069 Å) generated by a Nonius FR590 generator operated at 50 kV and 30 mA.  Unit cell 
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determinations were carried out both at ambient temperature (294 ± 2 K) as well as low 
temperature (113 ± 2  K). This check was performed to ensure there were no significant 
changes in the unit cell dimensions that might indicate phase transformations induced by 
cooling. All full intensity data-sets were measured at 113 ± 2 K.  The low temperatures were 
maintained by cooling the crystals with a constant stream of N2 gas at a flow rate of 20 
ml/min with the aid of a Cryostream cooler (Oxford Cryosystems, UK).  Data were corrected 
for Lorentz-polarisation effects; unit cell refinement and data-reduction were performed using 
the programs DENZO and SCALEPACK.22  All data were subjected to absorption correction 
using the multi-scan method, SADABS.23  
The Bruker KAPPA APEX II DUO diffractometer used graphite-monochromated Mo-Kα 
radiation (λ = 0.71069 Å). The unit cells of the crystals were determined at low temperature 
(100 ± 2 K) after their removal from mother liquor. The data collections were carried out in 
the above temperature range using Cryostream coolers (Oxford Cryosystems, UK). Data 
reduction was performed using the program SAINT.24 
For both instruments the space group determinations were carried out by examining the 
systematic absences and matching the observed conditions to a known space group.25  These 
assignments were confirmed by running the data through the program XPREP.26  SHELXS-
97,27 then input files were generated with XPREP. 
 
Structure Solution and Refinement   
The existing structure in this thesis was solved using different structure solution programs and 
a variety of methods depending on the size of the structure, quality of the data and nature of 
the problem. SHELXS-9727 was used to solve the structure of the crystal. Structures were 
refined on F2 using full-matrix least-squares in the program SHELXL-97.27 Both SHELXS-
9733 and SHELXL-9727 were accessed via the X-SEED28 interface.  
 
Dissolution test 
Dissolution tests were carried out according to the US Pharmacopeia 2006.29 Tests were 
carried out in the Vankel VK 700 (220 V) dissolution apparatus and with the Vankel VK 650 
A Heater/Circulator Benchsaver® series used  to regulate temperature at 37 ºC. The 
dissolution media was de-aerated by passing helium gas through media for 5-10 minutes or 
boiling the media vigorously for 20 minutes. 
Gelatine capsules were filled with 10 mg of the sample formulation. Samples were grinded 
prior to filling capsules to obtain an even particle size range between 3 to 9 µm. The particle 
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size for the sampl5 ml dissolution samples were withdrawn at 10, 20, 30, 40, 50 and 60 min 
and replaced with an equal volume of fresh medium to maintain a constant total volume. 
The assay was by UV spectrophotometry at an appropriate wavelength for the active 
ingredient 
 
Chapter 1 highlighted the literature review and main objectives of the study with chapter 2 
providing the methodology. Chapter 3 and 4 will discuss the results of the thesis with special 
emphasis on the point that even though the intention of the study was to produce co-crystals 
of sulfasalazine and sulfamethoxazole, results obtained included several supramolecular 
phenomena viz. formation of salts, formation of amorphic compounds and co-crystallization   
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CHAPTER 3 
CRYSTAL ENGINEERING OF 
SULFAMETHOXAZOLE 
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3.1 INTRODUCTION 
 
In this chapter we present the characterization of each compound and the results of the co-
crystal experimentation attempts of sulfamethoxazole (SMZ) with trimethoprim (TMP) and 
the selected co-formers [i.e. saccharin, nicotinamide, salicylic acid, L-tartaric acid, D-tartaric 
acid, L-aspartic acid, benzoic anhydride, oxalic acid (as the dihydrate), benzoic acid, 4-
hydroxybenzoic acid, succinic acid, maleic acid, L-glutamic acid and citric acid (as the 
monohydrate)]. 
The co-formers were selected based on the presence of their carboxylic acid, amino group 
and/or other potentially complementary functionalities and because most appeared on the 
GRAS1 (generally regarded as safe) list. Some of these co-formers are no longer on the GRAS 
list, for example, saccharin and oxalic acid. 
The existence of a carboxylic acid or amino group in the API and the co-formers provide a 
good opportunity to form co-crystals.2,3 
Figure 3.1 illustrates the structures of SMZ, TMP and the 14 co-crystal formers selected for 
this study. Table 3.1 provides the physicochemical data such as melting point, uses and 
solubility of SMZ, TMP and the 14 co-formers selected. 
Sulfamethoxazole has five polymorphic forms, which is a good co-crystallising characteristic. 
If a molecular compound exists in several polymorphic forms it demonstrates structural 
flexibility and is not locked into a single type of crystalline structure or packing mode. Thus, 
the chance of bringing such a molecule into a different packing arrangement into co-existence 
with another molecule is increased.4  
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Sulfamethoxazole                       Trimethoprim                               Succinic acid                                                                                     
                                                             
Salicylic acid                            Benzoic acid                          L- glutamic acid  
                                                      
Nicotinamide       Oxalic acid (as the dihydrate)   D and L Tartaric acid                               
                                        
Maleic acid                      Citric acid (as the monohydrate)          Saccharin   
                                         
L-aspartic acid                             Benzoic anhydride                        4- hydroxybenzoic acid                                                  
Figure 3.1 The structures of SMZ, TMP and selected co-formers 
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Table 3.1 Physicochemical properties of SMZ, TMP and co-crystal formers 
Compound  Melting point  Uses  Molecular 
formula  
Solubility in 
water  at pH 7, 
25 ºC mg/ml 
Sulfamethoxazole 
(SMZ) 
167- 170 °C Antibacterial  C10 H11 N3 
O3 S 
        0.5 
 
Trimethoprim 
(TMP) 
199-203 °C Antibacterial C14 H18 N4 O3          1 
Succinic acid 
(SUA) 
185 °C Flavourant  C4 H6 O4         80 
Maleic acid 
(MA) 
135 °C Compound used for 
making maleate 
salts of bulk-drugs 
and prevents 
rancidity in oils 
C4 H4 O4        780 
Saccharin 
(SC) 
228.8- 229.7  °C Artificial sweetener C7 H5 N O3 S        3.4  
Benzoic 
anhydride 
(BAN) 
39- 40 °C Used in organic 
syntheses, as 
benzoylating agent 
in the manufacture 
of pharmaceuticals, 
dyes, and 
intermediates 
C14 H10 O3        0.01  
Nicotinamide 
(NC)  
128-131 °C Vitamin B3 C6 H6 N2 O   691-1000 
Benzoic acid 
(BA) 
122.41 °C Food preservative C7 H6 O2         2.9 
4-hydroxy 
benzoic acid 
(4-HBA) 
214-217 °C Antioxidant C7 H6 O3           5 
L-aspartic acid 
(L-AA) 
270- 271 °C Amino acid C4 H7 N O4           4 
Oxalic acid (as 
the dihydrate) 
(OA) 
104- 106 °C Cleaning and 
bleaching agent 
C2 H2 O4         143   
D- or L-tartaric 
acid (TA) 
172-174 °C  Antioxidant  C4 H6 O6        1390    
Salicylic acid  
(SCA) 
159 °C Anti-inflammatory  
drug 
C7 H6 O3       0.002 
L- glutamic acid 
(L-GA) 
205 °C Amino acid C5 H9 N O4        8.64 
Citric acid (as the 
monohydrate) 
(CA) 
135-152 °C Preservative, and 
adds acidic taste to 
foods 
C6 H8 O7. 
H2O 
     1630  
63 
 
 
 
 
 
3.2. Characterization of APIs and co-formers 
3.2.1. Characterization of sulfamethoxazole (SMZ) 
SMZ identification 
 
Hot Stage Microscopy (HSM) 
HSM was used to analyse the thermal behaviour of SMZ upon heating at a constant rate of 10 
K/min. A small amount of the powder was immersed in silicone oil to assess the presence of 
water or organic solvent as would be indicated by bubble formation. Photographs were taken 
in the temperature range of 30 ºC to 400 ºC.  
The photographs of SMZ were recorded at (a) the start of analysis at room temperature, (b) 
the first sign of melting, occurring at 170 ºC, (c) completion of the melt at 173 ºC and  (d) the 
onset of decomposition at 255 ºC with a brown discolouration of the powder (Figure 3.2). 
 
                                      
                                        (a) 25 ºC                          (b) 170 ºC  
                                      
                                        (c) 173 ºC                         (d) 255ºC  
 
                           Figure 3.2 HSM for SMZ at different temperatures 
 
Differential Scanning Calorimetry (DSC) 
The DSC trace displayed a melting point for SMZ peaking at 170.7 ºC (Figure 3.3) with a 
single endotherm between 168 ºC and 172 ºC. The DSC data correspond with the HSM 
observations and the degradation of SMZ was observed between 255 ºC and 260 ºC. 
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 Figure 3.3 DSC trace for SMZ 
Infrared spectroscopy (FTIR) 
Fourier transform infrared spectroscopy was used to study the spectral features of SMZ 
presented in table 3.2 and the IR spectrum is seen in figure 3.4.  
 
Figure 3.4 FTIR spectra for SMZ 
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SMZ
3466.85
3377.26
3298.44
3144.28
1617.73
1595.76
1501.70
1469.10
1439.06
1382.04
1362.65
1303.00
1265.87
1188.52
1155.12
1090.57
1041.50
1026.65
1014.08
925.97
883.13
826.93
782.08
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680.51
1914.75
1141.62
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Table 3.2 FTIR absorption bands for SMZ. 
    Compound  Experimental 
frequency bands 
(cm-1) 
Standard  
frequency bands 
(cm-1) 5 
Associated 
functional group(s) 
from IR bands 
SMZ 3466  and 3377 3469 and 3379 NH2 stretch 
 3298 3300 NH stretch 
 1617 1616 Combination NH2 
deformation and 
isoxazole ring stretch 
 1595 and 1501 1595 and 1500 Aromatic C=C 
stretch 
 1303 1313 – 1303 Asymmetric SO2 
stretch 
 1155 – 1141 1155 – 1143 Symmetric SO2 
stretch 
 
Frome table 3.2 it can be seen that the experimental and standard frequency bands are very 
close to each other and the small differences is as a result of the different method used for 
sample preparation. The standard spectrum was obtained by the KBr method and the 
experimental spectrum used the ATR (Attenuated Total Reflectance) method. 
The sulfamethoxazole structure (Figure 3.1) is characterised by a primary aromatic amine (–
NH2) and a secondary aliphatic amine (-NH) for which the difference between the two is 
important and strongly influences the chemistry of the N-H group (primary and secondary). 
The infrared spectrum is obtained as a consequence of the absorption of electromagnetic 
radiation at frequencies that correlate with the vibration of specific sets of chemical bonds 
from within molecules. 
 
3.2.2. Characterization of trimethoprim (TMP) 
TMP identification 
Hot Stage Microscopy (HSM) 
 
Photographs of TMP were recorded at (a) room temperature 25 ºC, (b) initial indication of 
melting at 204 ºC, (c) after the TMP has melted completely at 208 ºC, and (d) the start of 
decomposition at 310 ºC (Figure 3.5). 
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                                           (a) 25 ºC                             (b) 204 ºC 
   
                                             (c) 208 ºC                           (d) 310 ºC 
Figure 3.5 HSM of TMP 
 
Differential Scanning Calorimetry (DSC) 
The DSC trace for TMP (Figure 3.6) indicated a melting point at 202.5 ºC with the endotherm 
appearing between 199 ºC and 203 ºC. The DSC data correlated well with the HSM 
observations. Furthermore, decomposition appeared at 310 ºC. 
 
 
Figure 3.6 DSC trace for TMP 
 
 
 
 
67 
 
 
 
 
 
Infrared spectroscopy (FTIR) 
The infrared spectrum of trimethoprim is presented in figure 3.7, and the assignments of the 
observed fundamental bands have been reported in table 3.3.  
 
Figure 3.7 FTIR spectra of TMP 
Table 3.3 FTIR absorption bands of TMP 
    Compound  Experimental  
frequency bands 
 (cm-1) 
Standard  
frequency  
bands (cm-1) 6 
Associated functional 
group(s) from IR bands 
TMP 3468 3516 Asymmetric NH2 stretching 
 3316 3414 Symmetric NH2 stretching 
 3106 3010 Aromatic CH stretching 
 3015, 2929, 2834 2966, 2940, 2840 Aliphatic CH stretching 
 1506 1506 Aromatic ring 
 1234, 1123 1236, 1129 Aromatic methoxy 
  
The reason for the difference between the standard and experimental frequency is that the 
standard spectrum was obtained by infrared spectroscopy from a solution of TMP in 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
31.0
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TMP
3468.36
3316.57
3106.73
2929.83
2834.24
1632.06
1589.11
1562.83
1506.77
1456.28
1420.60
1334.93
1263.14
1234.73
1188.44
1123.77
1000.00
981.78
967.38
926.37
829.64
796.95
782.09
768.24
740.82
713.06
3015.87
1649.11
1486.56
1355.72
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chloroform (concentration of 14.8 mg/ml, path length 0.1 mm NaCl) and the experimental 
spectrum was recorded using the ATR technique.  
 
3.2.3 Characterization of co-formers 
All the co-formers were characterised using HSM, DSC, TGA, PXRD and FTIR. The 
significant functional groups identified by the FTIR spectra are presented for each co-former 
(Figure 3.1) in table 3.4 whereas the FTIR spectra and the DSC curves will be presented in 
Appendix A (see CD-Rom).   
Table 3.4 FTIR absorption bands for the 14 co-formers  
Compound  Experimental 
frequency bands 
(cm-1) 
Standard frequency 
bands (cm-1)  
Associated 
functional group(s) 
from IR bands 
Salicylic acid (SCA) 
 
 
1609 
1654 
3231 
1615-15807 
16508 
3220 8 
 
Aromatic ring C=C- 
C = O (carboxylic) 
-OH 
 
Nicotinamide (NC) 1614 
1673 
3357 
1600- 1630 9 
1700 9 
3500-330010 
C=C Stretch 
C=O 
N-H Stretch; amide 
Saccharin (SC) 969 
1715 
3400, 3093 
1592 
975 11,12 
172211 
3410, 3100 11 
159511 
S-N-C 
O=C-NH 
CO-NH 
Aromatic –C=C- 
Oxalic acid (as the 
dihydrate) (OA) 
1611 
3415 
1690 – 1760 7,10 
3335-250010 
C=O 
O-H 
Tartaric acid 1723 
3404 
1690 – 1760 7,10 
3335-2500 10 
C=O 
O-H 
Citric acid 
monohydrate (CA) 
1671 
3067-2542 
1690 – 1760 7,10 
3335-2500 10 
C=O 
O-H 
Succinic acid (SUA) 2980 
1680 
3335-2500 10 
1690 – 17607,10 
O-H Carboxylic 
C=O stretch 
Benzoic anhydride 
(BAN) 
1829 
1773 
1800- 183010 
1740- 177510 
C=O 
C=O 
Maleic acid (MA) 1703 
2951-2507 
1725-170010 
3335-250010 
C=O 
O-H 
L-aspartic acid (L-
AA) 
2951 
1684 
3345-33257 
1690 – 1760 7,10 
NH2 
C=O 
L- glutamic acid 
 
3012 
1637 
3345-33257 
1690 – 1760 7,10 
Aliphatic NH2 
C=O 
Benzoic acid 3071-2552 
1679 
3300- 2500 13 
168713 
Bonded-OH stretch 
Carbonyl –C=O 
stretch 
4- hydroxybenzoic 
acid 
 
3377- 3543 
1670 
3300- 2500 13 
168713                
Bonded-OH stretch 
Carbonyl –C=O 
stretch 
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Each co-former is characterized by its specific FTIR spectrum which serves as a reference for 
its identification. The difference between the spectra of the experimental and the standard is 
due to the different preparation techniques used. The standards, such as salicylic acid, 
nicotinamide, saccharin and benzoic acid used the KBr preparation technique but the 
experimental spectra were obtained using the ATR technique. 
Several experiments, using different techniques and several solvents or mixed solvent systems 
(miscible solvents) were performed to find co-crystals of SMZ. A few representative results 
are listed in table 3.5. For a full representation of all the experiments, refer to appendix B (see 
CD-Rom).   
Table 3.5 Representative experiments using different methods to prepare a SMZ co-crystal. 
Drug Co-former Method Solvent Ratio Result 
SMZ NC Dry grinding        - 1:1 SMZ 
 NC Slow 
evaporation 
Methanol  1:3 Mixture of 
SMZ and NC 
 OA Vapour diffusion   Ethanol: 
chloroform 
1:1 No crystal 
 OA Solvent  
assisted grinding 
Acetone 1:1 SMZ form I 
 SCA Dry grinding     - 1:2 SCA  
 SC Slow 
evaporation 
Ethanol  1:1 Mixture of 
SMZ and SC 
 NC Slow 
evaporation 
Acetic acid 1:1 SMZ form I 
 D-TA Slow 
evaporation 
Methanol 1:3 SMZ form I 
 SCA Slow 
evaporation 
Propan-2-ol 1:1 Hydrate form 
of SMZ 
 SUA Slow 
evaporation 
1,4-dioxane 1:1 Decomposition  
 
 BAN Slurry method Methanol  1:1 Co-crystal 
 MA Slow 
evaporation 
Distilled water: 
methanol 
1:1 Hydrate form 
of SMZ 
 4-HBA Slow 
evaporation 
Mixed solvent 
water+ acetone 
1:1 Hydrate form 
of 4-HBA 
 TMP Slow 
evaporation 
Methanol/ 
Ethanol/ 
Propanol 
1:1 SMZ-TMP Co-
crystal 
 TMP Melt - 1:1 Amorphous 
form of the co-
crystal 
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3.3 Preparation of sulfamethoxazole complexes               
3.3.1 Sulfamethoxazole benzoic anhydride co-crystal (SMZ-BAN)               
Preparation of SMZ-BAN co-crystal using the slurry method 
0.16 g of sulfamethoxazole and 0.142 g of benzoic anhydride (1:1 molar ratio) were weighed 
and mixed in a glass vial. The mixture was supersaturated with methanol and stirred with a 
magnetic stirrer on a hot plate at 55 ºC for 15 minutes (Slurry method). The sample was 
filtered with a 0.45 µm filter, transferred to a second vial and closed with perforated 
parafilm®. Thereafter, the sample was placed in the refrigerator at 4 - 6 ºC to allow for 
crystallisation to occur.  
The crystal was prepared by several other methods such as dry grinding and slow evaporation 
using different solvents such as acetone, ethyl acetate and propan-2-ol. 
 
Analysis 
Hot Stage Microscopy (HSM) 
The SMZ-BAN crystal was immersed in silicone oil. The sample was heated at a constant rate 
of 10 K/min and the photographs were taken in the temperature range 30 to 300 ºC. SMZ-
BAN snapshots were noted at (a) the start of analysis at 25 ºC, (b) the beginning of the melt at 
260 ºC and (c) the end of melting followed immediately by decomposition at 280 ºC (Figure 
3.8).  
             
                 (a) 25 ºC                                   (b) 260 ºC                         (c) 280 ºC 
Figure 3.8 HSM of SMZ-BAN. 
 
Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC)  
The TGA indicated no solvent loss; this was also established from the HSM and DSC results. 
The DSC indicated a melting point for SMZ-BAN at 266 ºC (Figure 3.9) with a single 
exotherm between 262 and 280 ºC. Furthermore, the melting point differed significantly from 
those of the parent compounds, SMZ (m.p. 167-170 ºC) and BAN (m.p. 35-40 ºC). 
Decomposition was accompanied by sample melt as shown by the HSM analysis.  HSM 
clearly illustrated the discolouration of the sample as melting finalised.  
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 Figure 3.9 DSC of SMZ-BAN 
 
Infrared spectroscopy (FTIR) 
In the FTIR spectrum of SMZ-BAN compared with SMZ and BAN spectra, the symmetrical 
and antisymmetrical stretching vibration toward a lower and higher wave number is seen in 
table 3.6 and figure 3.10. 
 
Figure 3.10 FTIR spectra for SMZ-BAN, SMZ and BAN 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
% T 
SMZ-BAN
SMZ
BAN
3466.85
3377.26
3298.44
3144.28
1617.73
1595.76
1501.70
1469.10
1439.06
1382.04
1362.65
1303.00
1265.87
1188.52
1155.12
1141.80
1090.57
1041.50
1026.65
1014.08
925.97
883.13
826.93
782.08
713.55
680.51
3063.48 2556.33 1920.31
1773.13
1713.31
1686.02
1598.00
1584.84
1490.88
1450.71
1423.54
1321.34
1283.33
1208.09
1169.57
1073.34
1032.09
1011.54
993.05
939.20
874.56
803.63
779.60
683.17
667.10
3348.20
3274.73
3161.36
1784.85
1660.35
1615.95
1589.53
1511.08
1498.02
1474.11
1402.49
1384.74
1312.69
1258.14
1188.24
1167.08
1143.04
1105.80
1090.45 1076.24
1029.26
1011.51
949.07
927.18
895.83
828.29
808.03
789.88
706.27
687.86
657.12
3067.46
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Table 3.6 Selected infrared data (from FTIR) for the compound SMZ-BAN compared to SMZ 
and BAN 
SMZ standard 
frequency bands  
(cm-1) 
BAN standard 
frequency bands 
(cm-1) 
Co-crystal 
Frequency bands  
(cm-1)  
Interactions and 
comment 
3377 
NH2 
1773 
C=O 
SMZ-BAN 
3348-1784 
C=O•••H-NH 
Decrease in the intensity 
3377 
NH2 
3063.48  
C-H stretch 
in aromatic ring 
SMZ-BAN 
3348-3067 
-H•••NH2 
Decrease in the intensity 
3298 
NH 
1773 
C=O 
SMZ-BAN 
3274-1784 
C=O•••H-N 
Decrease in the intensity 
3298 
NH 
3063.48 
C-H stretch 
in aromatic ring 
SMZ-BAN 
3274-3067 
-H•••NH  
Decrease in the intensity 
 
                                               
            Sulfamethoxazole                                                            Benzoic anhydride  
Figure 3.11 Indication (based on FTIR spectra) of the functional groups which might be 
interacting between the SMZ and BAN molecule to form SMZ-BAN 
 
As indicated by the red arrows seen in figure 3.11 the functional groups which might be 
affected are NH2, NH for SMZ, and C=O, -H for BAN. The possible interactions for the two 
compounds based on the shifts are as follows: C=O•••H-N, C=O•••H-NH, -H•••NH, -
H•••NH2.  
These interactions can be confirmed from figure 3.10 by the decrease in the intensity of the 
BAN carbonyl group band and the shift from 1773 cm-1 to 1784 cm-1 accompanied by an 
intensity decrease indicating the interaction with SMZ’s NH2 which shifts from 3377 cm-1 to 
3348 cm-1 and NH shift from 3298 cm-1 to 3274 cm-1. This shift with an intensity decrease 
indicates that a possible inter-molecular hydrogen bond was made.  
The best fit based on the FTIR data is: C=O•••H-N and/or C=O•••H-NH. 
FTIR can be a very powerful tool in distinguishing co-crystals from salts. If neutral carbonyl 
group has a strong carbonyl (C=O) stretching peak around 1700 cm-1 and a weak C–O stretch 
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around 1200 cm-1,14 and a neutral amino group (–NH2) has a strong stretching peak around 
3466 cm-1 and a weak NH3 stretch around 1665-1585, 1530-1490 cm-1, a co-crystal is 
confirmed.10  
 
Because there is one peak at 1784 cm-1 (highlighted in red) for the carbonyl group and one 
peak at 3348 cm-1 for the amino group, this indicates no protonation nor deprotonation 
occurring which confirms that SMZ-BAN is a co-crystal and not a salt. Henceforth, SMZ-
BAN will now be referred to as a co-crystal. 
 
Powder X-ray diffraction (PXRD) 
PXRD is a useful method for the fast identification of a new crystalline phase. A different 
PXRD pattern from those of the individual components confirms the formation of the new 
phase. The PXRD pattern of the pure compounds and the co-crystal are shown in figure 3.12. 
There are new peaks appearing at 2θ values of 5.4◦, 7.2◦, 7.8◦, 9.8◦, 16.5◦, 19.1◦, 26.2◦, 28.1◦, 
with some peaks disappearing at 2θ value of, 11.1◦, 27.1◦, 27.5◦ which is clearly an indication 
of the newly derivatives form.  
 
 
Figure 3.12 PXRD traces for SMZ-BAN, SMZ and BAN 
 
Figure 3.13, illustrates the PXRD patterns for the products obtained by the different 
preparative methods with different solvents such as propan-2-ol, ethyl acetate, and acetone. 
These patterns closely match the pattern of the SMZ-BAN co-crystal prepared from methanol.   
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Figure 3.13 Comparison of the PXRD patterns of SMZ-BAN obtained in different solvents 
 
Comment  
Purity of the SMZ-BAN co-crystal obtained by the slurry method was evident from the DSC 
trace, which displayed a single exotherm corresponding to the co-crystal melting point at a 
temperature that differed from the melting points of the individual components. This was 
further confirmed by the FTIR results since both parent compounds were clearly evident in 
the SMZ-BAN spectrum.  SMZ-BAN has a melting point higher than the parent compounds 
which might suggest a higher stability than both the untreated SMZ and BAN. The crystal 
was of poor quality; hence no crystal of appropriate size was available for single crystal X-ray 
diffraction analysis. Literature also reports a co-crystal of sulfamethoxazole and trimethoprim 
induced by the slurry technique; however, no single crystal X-ray diffraction data were 
collected either.15 It could be concluded that the slurry technique is a reliable technique to 
induce new co-crystal phases. 
 
3.3.2 Preparation of amorphous sulfamethoxazole - co-former forms 
3.3.2.1 Amorphous Sulfamethoxazole-trimethoprim (SMZ-TMP)             
 
Preparation of amorphous SMZ-TMP  
0.040 g sulfamethoxazole and 0.046 g trimethoprim (1:1 molar ratio) were weighed, mixed 
and ground together manually using a small porcelain mortar and pestle. The grinding was 
carried out for 30 min. A small amount of the ground product was transferred to a DSC pan 
and placed on a hot plate. The temperature was set to 180 ºC so that the sample could liquefy. 
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The sample was then removed and allowed to solidify at room temperature. A glassy 
appearance became visible which is the first indication of an amorphous form. 
Analysis 
Hot Stage Microscopy (HSM) 
Photographs of SMZ-TMP (Figure 3.14) were recorded at (a) start of analysis at 25 ºC of the 
glassy material, (b) opacity of sample at 100 ºC, (c) spontaneous bubbling at 150 ºC, (d) the 
first sign of melting at 180 ºC, (e) the completion of the melt at 188 ºC and (f) decomposition 
of SMZ-TMP at 230 ºC indicated by discolouration at the edges of the photograph. 
 
                
                         (a) 25 ºC                        (b) 100 ºC                            (c) 150 ºC    
                                     
               
                       (d) 180 ºC                          (e) 188 ºC                        (f) 230 ºC 
    
Figure 3.14 HSM photographs of amorphous SMZ-TMP 
 
Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC)   
TGA was used to determine the possible presence of included solvent in the amorphous SMZ-
TMP which indicates a 5.8% (n=1.9) mass loss of water since no solvent was used to prepare 
the product, consistent with the HSM observations seen in figure 3.14 and the TGA trace in 
3.15. Mass loss with respect to water loss occurs in the temperature range of 100 ºC to 150 ºC 
followed by the melt of the sample at 180 ºC. 
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Figure 3.15 TGA of amorphous SMZ-TMP 
 
The DSC indicated a peak melting point of the amorphous SMZ-TMP at 180.6 ºC (Figure 
3.16) with a single endotherm between 177 ºC and 183 ºC and an exotherm between 106 ºC 
and 120 ºC for the presence of the water molecules. Both these events are confirmed by the 
HSM and TGA analysis and the thermal events differ from those for the parent APIs SMZ 
(m.p. 167-170 ºC) and TMP (m.p. 200-203 ºC). The degradation of the amorphous SMZ-TMP 
was observed at about 230 ºC.       
                
 
 
Figure 3.16 DSC trace of amorphous SMZ-TMP  
 
Infrared spectroscopy (FTIR) 
Figure 3.17 shows a decrease in the intensity of peaks of amorphous SMZ-TMP compared to 
the SMZ and TMP spectra. There is a shift in the peaks with some peaks disappearing 
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indicating an amorphous precipitate (table 3.7). The amorphous sample differs in the 
hydrogen-bonding region (2000–4000 cm−1), between 1350 and 1450 cm−1, and in the 
fingerprint region (<1000 cm−1). 
The amorphous sample has an extended hydrogen-bonding system, probably containing a 
considerable number of water molecules bound in various ways, which was confirmed by the 
previous analyses (HSM, DSC and TGA). Intensity inconsistencies generally come from an 
amorphous structure as depicted in this the sample due to the irregular packing arrangement 
of the molecules. 
 
 
Figure 3.17 FTIR spectra of amorphous SMZ-TMP, SMZ and TMP 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
% T 
SMZ-TMP
SMZ
TMP
3466.85
3377.26
3298.44
3144.28
1617.73
1595.76
1501.70
1469.10
1439.06
1382.04
1362.65
1303.00
1265.87
1188.52
1155.12
1141.80
1090.57
1041.50
1026.65
1014.08
925.97
883.13
826.93
782.08
713.55
680.51
3468.36
3316.57
3106.73
2929.83
2834.24
1632.06
1589.11
1562.83
1506.77
1456.28
1420.60
1334.93
1263.14
1234.73
1188.44
1000.00
981.78
967.38
926.37
829.64
796.95
782.09
768.24
740.82
713.06
3351.05
3203.35
2939.13
1658.71
1593.35
1503.20
1454.85
1419.43
1322.76
1234.07
1186.63
1156.04
1119.09
1090.80
1048.82
1002.51
938.76
829.49
752.51
673.17
3464.28 2833.33
1613.43
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Table 3.7 Selected infrared data (from FTIR) for the compound SMZ-TMP compared to SMZ 
and TMP 
SMZ standard 
frequency bands 
(cm-1) 
TMP standard 
frequency bands 
(cm-1) 
Amorphous  
SMZ-TMP 
frequency 
bands (cm-1) 
Interactions and 
comment 
3466 
NH2 Asymmetric 
3468 
NH2 Asymmetric 
3464 
NH2 
-NH-H•••NH2 
Decrease in the intensity. 
3298 
NH stretch 
3468 
NH2 Asymmetric 
3203-3464 
NH- NH2  
-HN-H•••NH 
Decrease in the intensity. 
3377 
NH2 symmetric 
3316 
NH2 symmetric 
3351 
NH2 
-NH-H•••NH2 
Decrease in the intensity. 
3298 
NH stretch 
3316 
NH2 symmetric 
3203-3351 
NH- NH2  
-HN-H•••NH 
Decrease in the intensity. 
3466 
NH2 Asymmetric 
1123 
Aromatic methoxy 
3464-1119 
NH2-OCH3 
-OCH2-H•••NH2 
Decrease in the intensity. 
3298 
NH stretch 
1123 
Aromatic methoxy 
3203-1119 
NH-OCH3 
-OCH2-H•••NH 
Decrease in the intensity. 
3377 
NH2 symmetric 
1123 
Aromatic methoxy 
3351-1119 
NH2-OCH3 
-OCH2-H•••NH2 
Decrease in the intensity. 
 
                                                  
Figure 3.18 Indication from FTIR spectra of the functional groups which might be interacting 
between the SMZ and TMP molecules to form SMZ-TMP 
 
As shown by the blue arrows in figure 3.18, the functional groups that might be affected by 
the decrease in the intensity or shift of the peaks are NH2 and NH for SMZ and NH2 and the 
aromatic methoxy group for TMP. The possible interactions for the two compounds based on 
the shifts are as follows:  (-HN-H•••NH, -NH-H•••NH2, -O -CH2-H•••NH, -O-CH2-H•••NH2).  
The IR spectrum of the SMZ-TMP sample was markedly different from that of the parent 
compounds (SMZ and TMP) as shown in table 3.7 which indicates a new compound had 
formed. When a neutral amino group (–NH2) has a strong stretching peak around 3466 cm-1 
and a weak NH3 stretch around 1665-1585, 1530-1490 cm−1, a co-crystal is confirmed.10 
Furthermore, a marked decrease in intensity of the peaks suggests an amorphous form of the 
co-crystal.  
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Because there a peaks at 3464 cm-1 (–NH2) this indicates no protonating occurring which 
confirms that SMZ-TMP is an amorphous co-crystal. Henceforth, SMZ-TMP will now be 
referred to as an amorphous co-crystal. 
 
Powder X-ray diffraction (PXRD) 
The PXRD patterns of the amorphous SMZ-TMP did not display any sharp peaks that 
characterize a crystal substance. The lack of such peaks (Figure 3.19) indicates an amorphous 
form.16 
 
 
Figure 3.19 PXRD patterns of amorphous SMZ-TMP, SMZ, TMP 
 
Comment  
The analytical results of the experimental system allowed us to describe the structural 
character of the amorphous SMZ-TMP with FTIR and relate the product to the crystalline 
phase reported in literature by Zaini et al15 which was prepared by the slurry method. 
Crystallization of the glassy amorphous form with different solvent systems recrystallized it 
into the crystalline form of a co-crystal with the same melting point of the amorphous SMZ-
TMP at 180 ºC which further confirms that the amorph is a co-crystal form of SMZ-TMP.  
The amorphous SMZ-TMP substance has a glassy property hence the material cannot diffract 
X-rays. 
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3.3.2.2 Amorphous sulfamethoxazole-oxalic acid (as the dihydrate) (SMZ-OA) 
 
Preparation of amorphous SMZ-OA  
0.040 g sulfamethoxazole and 0.0066 g oxalic acid in 1:1 molar ratio was weighed 
individually. Each solid was separately dissolved in minimum volumes of ethanol (1.5 ml) at 
10 ºC below the boiling point of the solvent and magnetically stirred until clear solutions were 
obtained. The solution of greater volume was added to that of smaller volume and the 
resultant solution magnetically stirred, filtered (0.45 μm) and allowed to crystallise at room 
temperature. This preparation employed the slow evaporation method and gave the same 
product with methanol and ethyl acetate in the ratios 1:2 and 1:3 of SMZ:OA.  
Analysis 
Hot Stage Microscopy (HSM) 
 
SMZ-OA photographs were captured at (a) the beginning of the investigation at 25 ºC,                                         
(b) start of the melt at 167 ºC, (c) completion of the melt at 170 ºC and (d) the onset of 
decomposition at 210 ºC by spontaneous bubbling of the sample (Figure 3.20)  .  
 
           
(a) 25 ºC                                    (b) 167 ºC 
           
                                       (c) 170 ºC                                   (d) 210 ºC  
 
Figure 3.20 HSM of amorphous SMZ-OA 
 
Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC)   
TGA was used to determine the possible presence of included solvent in the SMZ-OA 
preparation. The TGA curve of SMZ-OA showed a mass loss of 1.8% (n=0.4) of water per 
SMZ-OA molecule. Several calculations using TGA analysis was applied including both 
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ethanol and water as a presumed solvent given the percentage mass loss. Water was the most 
compatible solvent for the equation, OA dihydrate was used as a co-former which desolvated 
from OA. Water loss is almost negligible and therefore not identified during the HSM 
analysis. 
DSC analysis was performed to characterize the thermal behaviour of SMZ-OA which 
indicated a melting point at 169.5 ºC (Figure 3.21) with a single endotherm in the range 
165.6–180 ºC. The DSC data matched the melting point determined by HSM observations. It 
is noted that the melting point is significantly close to the SMZ melting point (167-170 ºC), 
but different from the melting point of OA (104- 106 ºC). The degradation of SMZ-OA was 
observed at 210 ºC which differs from the SMZ decomposition at 260 ºC.  
Figure 3.21 compared to figure 3.22 presents a comparison of SMZ-OA and the physical 
mixtures of SMZ and OA. The physical mixture of SMZ and OA in figure 3.22 showed three 
endothermic peaks, for oxalic acid dihydrate water evaporation occurs at 60 ºC and melting 
occurs at 132 ºC and for sulfamethoxazole melting occurs at 167 ºC. 
 
Figure 3.21 DSC for amorphous SMZ-OA 
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 Figure 3.22 DSC of physical mixture of SMZ and OA 
 
Further analysis of the sample presents more convincing data towards whether SMZ-OA is 
amorphous or crystalline.  
Infrared spectroscopy (FTIR) 
A comparison between SMZ-OA and the parent compounds is presented in figure 3.23. Peak 
intensities in the spectrum of SMZ-OA are generally lower than the corresponding ones in the 
spectra of the individual components. There is also a shift and some peaks disappear. Table 
3.8 highlights the most significant functional groups that may be interacting with each other 
within the product. 
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Figure 3.23 FTIR spectra of amorphous SMZ-OA, SMZ and OA. 
 
Table 3.8 Selected infrared data (from FTIR) for the compound SMZ-OA compared to SMZ 
and OA 
SMZ standard 
frequency (cm-1) 
OA standard 
frequency (cm-1) 
Amorphous  
SMZ-OA  
Frequency (cm-1)  
Interactions and 
comment 
3377 
Asymmetric NH2 
1672 
C=O 
3308-1719 
NH2-C=O 
C=O•••H-NH 
Decrease in the intensity. 
3144 
symmetric NH2 
1672 
C=O 
3134-1719 
NH2-C=O 
C=O•••H-NH 
Decrease in the intensity. 
3298 
NH 
1672 
C=O 
3308-1719 
NH-C=O 
C=O•••H-N 
Decrease in the intensity. 
3377 
Asymmetric NH2 
3415 
O-H 
3308 
NH2- O-H 
O-H•••NH2 
Decrease in the intensity. 
3144 
symmetric NH2 
3415 
O-H 
3134-3308 
NH2- O-H 
O-H•••NH2 
Decrease in the intensity. 
3298 
NH 
3415 
O-H 
3308 
 NH- O-H 
O-H•••NH 
Decrease in the intensity. 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
% T 
SMZ-OA
SMZ
OA
3466.85
3377.26
3298.44
3144.28
1617.73
1595.76
1501.70
1469.10
1439.06
1382.04
1362.65
1303.00
1265.87
1188.52
1155.12
1141.80
1090.57
1041.50
1026.65
1014.08
925.97
883.13
826.93
782.08
713.55
680.51
3415.25
1437.16 1113.69
719.20
1609.47
2630.95
2476.19
3308.18
2600.14 1719.94
1614.56
1593.44
1495.90
1465.56
1384.83
1374.75
1313.97
1263.54
1231.45
1174.16
1089.27
1020.85
1008.81
921.33
888.10
827.60
712.40
663.00
3134.92
1565.85
2849.20
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Figure 3.24 Indication from FTIR spectra of the functional groups which might be interacting 
between the SMZ and OA molecules to form amorphous SMZ-OA 
 
From figure 3.23 we can see that on product formation most of the peaks decreased in 
intensity and some bands disappeared, such as those at 3466 cm-1 and 3298 cm-1, which can 
often provide more information about the nature of a compound, suggesting an amorphous 
form in this instance.  
Functional groups that might be affected by a decrease in the intensity, shift of the peaks or 
peak disappearance, are pointed out by orange arrows in figure 3.24; these are NH2, NH for 
SMZ and C=O, O-H for OA. 
The possible interactions for the two compounds based on the shifts are as follows: 
(C=O•••H-N, C=O•••H-NH, O-H•••NH, O-H•••NH2) confirmed by table 3.8.  
From FTIR spectroscopy amorphous co-crystals can be identified. A neutral carbonyl group 
(–COOH) has a strong carbonyl (C=O) stretching peak around 1700 cm-1 and a weak C–O 
stretch around 1200 cm−1; however, if deprotonation has occurred, a carboxylate anion (–
COO−) results and this species displays only a single C–O stretch in the fingerprint region of 
1000–1400 cm-1.14 Also, when a neutral amino group (–NH2) has a strong stretching peak 
around 3466 cm-1 and a weak NH3 stretch around 1665-1585, 1530-1490 cm-1, a co-crystal is 
confirmed.10 Furthermore, a marked decrease in intensity of the peaks suggests an amorphous 
form of the co-crystal.  
1719 cm-1 appears for the carbonyl group (C=O) and 3308 cm-1 appears for the amino group 
(NH2) indicating no deprotonation of the carboxylic acid group and no protonation for the 
amino group occurring which confirms that SMZ-OA is an amorphous co-crystal. 
 
Powder X-ray diffraction (PXRD) 
Confirmation that a material is amorphous can be achieved with PXRD. In this case, no 
specific Bragg peaks as a function angle should be seen.17 The diffraction pattern of an 
amorphous form lacks high intense peaks that characterize the substance. Thus SMZ-OA is an 
amorphous substance (Figure 3.25). 
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Figure 3.25 PXRD patterns of amorphous SMZ-OA, SMZ and OA 
 
Comment   
Solid samples were subjected to thermal analysis (DSC and TGA) to determine the thermal 
characteristics of the product and X-ray diffraction (PXRD) was used to establish the physical 
state (i.e. amorphous or crystalline) and these were compared to the physical mixtures of the 
parent compounds. From the results produced above it can be concluded that an amorph 
formed from the reaction in solution between sulfamethoxazole and oxalic acid dihydrate.  
The experiment was repeated many times by using different ratios (1:1, 1:2, 1:3 SMZ:OA) 
and solvent systems which produced the same result, indicating that the reaction lends itself to 
an amorphous form.   
 
3.4 Dissolution 
Dissolution is a dynamic process whereby the amount of drug substance goes into solution per 
unit time under consistent conditions.18 Dissolution testing is a requirement for all solid oral 
dosage forms and is used in all phases of development for product release and stability 
testing.19 The aim of any dissolution test is to measure the rate at which the drug substance is 
releasled from the dosage form and dissolves in a particular dissolution medium.20 
Drug factors that can influence the dissolution rate are the particle size, wettability, solubility 
and the form of the drug (for example, whether a salt or a free acid/base form).21   
Poorly water soluble drugs present a problem in terms of obtaining the satisfactory dissolution 
within the gastrointestinal tract that is necessary for good bioavailability. This is a challenge 
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to ensure that new drugs are not only active pharmacologically but also have sufficient 
solubility. 
 
Dissolution test 
Dissolution tests were carried out according to the procedures described in the United States 
Pharmacopeia.22 The dissolution tests of all forms were carried out using the rotating basket 
method at 37 °C. Powders were placed in capsules after kneading ~5 minutes to obtain a 
uniform and predictable dissolution of the drug. The particle size range of the powders was  
between 3 to 9 µm. Powders were not sieved prior to encapsulation due to limited resources 
of ingredients.  
Sulfamethoxazole capsules were added to 900 ml of de-aerated dilute hydrochloric acid (0.1 
M at pH 0.8) at 37.0 ± 0.5ºC as a dissolution medium. The rotational speed of the baskets was 
set at 100 rpm. Dissolution samples were withdrawn at 10, 20, 30, 40, 50 and 60 min and 
replaced with an equal volume of fresh medium to maintain a constant total volume. 
The assay was achieved by UV-VIS spectrophotometry at an appropriate wavelength for the 
active ingredient. The samples were placed in 2 mm quartz cuvettes and the concentrations 
were suitably adjusted such that all absorbance readings were measurable between zero and 
one absorbance unit. Calibration curves for the various drugs were constructed using readings 
taken at the λmax value of SMZ (265 nm). The absorbance of a test solution was determined 
based on the calibration curves. USP 29 states that for SMZ not less than 80 % dissolution is 
required after 30 minutes and this must be met by each capsule. The dissolution profiles for 
SMZ, SMZ-OA, SMZ-BAN and SMZ-TMP are presented in Table 3.9 and Figure 3.26. The 
concentration of SMZ was determined from the calibration curve y = 36.86x – 0.00233 (R2 = 
0.9999) where y=0. 00233 and x=0.00006. 
 
Table 3.9 Comparative dissolution profiles of SMZ SMZ-OA, SMZ-BAN and SMZ-TMP   
Time 
(minutes) 
SMZ 
(% 
dissolved) 
SMZ-OA 
(% 
dissolved) 
SMZ-BAN 
(% 
dissolved) 
SMZ-TMP 
(% 
dissolved) 
0 0 0 0 0 
10 41.6 23.6 33.8 57.9 
20 45.6 37.1 35.9 75.2 
30 54.9 41.7 38.0 100.0 
40 57.5 47.4 42.1 100.0 
50 56.6 51.5 60.8 100.0 
60 60.6 68.2 64.2 100.0 
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Figure 3.26 Dissolution test for SMZ compared with the new compounds 
 
Figure 3.26 indicates that SMZ-OA and SMZ-BAN did not pass the USP dissolution test. 
However, we see a 100% dissolution profile of SMZ as SMZ-TMP. We find that amorphous 
SMZ-TMP represents the best dissolution profile by reaching 100% SMZ dissolved within 30 
minutes. In fact, there is a steady increase in the amorphous SMZ-TMP profile from time zero 
to 60 minutes. SMZ, SMZ-OA and SMZ-BAN present very close profiles from the onset with 
a ~10 % difference throughout the run and finally resulting in a very similar range of 60% to 
68% SMZ dissolved after 60 minutes.  
The amorphous solid state possesses several advantages in comparison to the crystalline state, 
allowing enhanced forms of drugs to be produced. Many drugs when generated as an 
amorphous form will exhibit better solubility and wettability since the amorphous state is 
thermodynamically the form with the highest solubility. Consequently, amorphous forms will 
exhibit a greater solubility in a solvent than any crystalline form of the same compound. The 
increased solubility of amorphous actives can lead to dramatically increased intrinsic 
dissolution rates when compared to crystalline forms. Also, for a drug to dissolve, its surface 
has to be wetted by the surrounding fluid. Amorphous forms possess a chemically randomised 
surface which expresses equal amounts of hydrophobic and hydrophilic interactions which 
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can lead to improved wettability expressed by a lower contact angle of the drug particle 
surface with a liquid. A lower contact angle represents a higher degree of hydrophilicity, with 
consequently faster surface wetting and faster dissolution. 
 
To illustrate statistically the variation in dissolution profiles we applied the ANOVA 
statistical test. The One-Way analysis of variance (ANOVA test) was used to determine how 
dissolution was affected by two factors simultaneously. The percentage dissolved was the 
dependent variable and time was the repeated factor. Statistically significant differences 
(P<0.0001) in the dissolution rates of SMZ, SMZ-OA, SMZ-BAN and SMZ-TMP were 
observed in the analysis.  
 
Table 3. 10 pKa and melting point values for SMZ, BAN, TMP, OA compared to the melting 
point of the new products. 
 M.p. of API 
(°C) 
pKa of 
API 
M.p. of co-
former (°C) 
pKa of 
co-former 
M.p. of new 
product (°C) 
SMZ-BAN 170 5.7 35-40 4.19 266 
SMZ-TMP 170 5.7 199-203 7.04 180 
SMZ-OA 170 5.7 104-106 1.25 169 
 
It is well known that when the melting point of a compound is lower, then the dissolution 
characteristics are generally higher. However, upon comparing the dissolution profiles of 
SMZ-OA, SMZ-BAN and SMZ-TMP (figure 3.26) to table 3.10, it is clear that this is not the 
case. Explanations for this can be deduced from the respective pKa values of the parent 
compounds.    
SMZ-OA, SMZ-BAN and SMZ-TMP were dissolved in acidic media at pH 0.8. From table 
3.10 we see that SMZ-OA and SMZ-BAN have pKa values < 6 which suggests that the 
compounds will not dissolve spontaneously in the acidic media. However, upon comparison 
of the TMP pKa value to OA and BAN we see that TMP has a pKa > 6 equating to 7.04 
suggesting that TMP synergistically allows SMZ with pKa 5.7 to go into solution faster than 
the other two products. Hence, both OA and BAN retard the dissolution of SMZ in acid 
media.  
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3.5 Challenges faced when forming a sulfamethoxazole co-crystal 
Recrystallization problems 
Sulfamethoxazole has five polymorphs23-25 and a hemihydrate26 form. Upon co-crystallization 
of SMZ with respective co-formers in selected solvent system the hemihydrate form of SMZ 
recrystallized. Furthermore, one of the five identified polymorphs also recrystallized during 
experimentation.   
 
Quality of the crystals 
The quality of the crystals was the most challenging problem in the experiments. A good 
crystal with specific properties and a particular size is required for single crystal X-ray 
diffraction analysis. It was difficult to prepare crystals with these properties, because many of 
the crystals were either fibrous or opaque in nature. Other crystals were far too thin for single 
crystal XRD. 
Good quality crystals are known to grow over long periods. Portalone and Colapietro27 
reported that it took 6 months to prepare a single co-crystal of suitable quality for single X-ray 
diffraction analysis. 
 
Solubility 
Sulfamethoxazole is soluble in specific solvent system as shown in Chapter 1. To prepare co-
crystals of the API and co-former, the two compounds must have the same solubility, or 
similar solubilities, in the same solvent, otherwise the less soluble compound will 
precipitate.28 However, “similar solubility”, alone will not guarantee success. When 
considering the solubility, sometimes we need to use solvents in which the API or the co-
former does not completely dissolve in; however, when mixed with the other solution (API or 
co-former solution) the two solutions become clear. To explain this phenomenon, one of the 
components is possibly acting as a surface-active agent, thereby aiding solubility. 
 
Stability 
The stability of a solid drug material with respect to relative humidity is important to the 
pharmaceutical industry, for example, due to the practical implications of the hydrate form 
upon processing, formulation, storage and packaging.29 This problem always occurs with 
sulfamethoxazole even though the solvent is not water because of the atmosphere. 
Sulfamethoxazole is also sensitive to light. Light-catalysed oxidation gives analogous 
products of sulfamethoxazole.  
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 Preparation methods 
Many co-crystal materials can be prepared from both solution growth and solid-state grinding, 
while some can only be obtained by solid-state grinding.30 
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CHAPTER 4 
CRYSTAL ENGINEERING OF 
SULFASALAZINE 
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4. 1 Introduction 
This chapter will present the experimentation performed with sulfasalazine (SSZ) monoclinic 
and triclinic forms in an attempt to prepare co-crystals with trimethoprim and the 10 co-
formers presented in chapter 3 [nicotinamide, oxalic acid ( as the dihydrate), salicylic acid, 
maleic acid, succinic acid, benzoic acid, D-tartaric acid, saccharin, 4-hydroxybenzoic acid and 
citric acid (as the monohydrate)].  
Sulfasalazine is an anti-inflammatory that belongs to the class of sulfa drugs. It has 
antibacterial properties that are useful in the treatment of ulcerative colitis and Crohn,s 
disease.1a,1b,1c From the literature review and Cambridge Structural Database (CSD)1d it was 
evident that there were no reports regarding co-crystallization between SSZ and the selected 
co-formers for the purpose of exploring useful physical, chemical or medicinal properties of 
potential multi-component products. Figure 4.1 illustrates the chemical structures of the 
sulfasalazine monoclinic (imide tautomer)1e and triclinic (amide tautomer)1f tautomeric forms. 
Tautomers are organic compounds that are interconvertible by a chemical reaction called 
tautomerization. This reaction results in the formal migration of a hydrogen atom or proton, 
accompanied by a switch of a single bond and adjacent double bond. 
 
        
             
                  Figure 4.1 The structures of SSZ triclinic and monoclinic forms 
 
4.2 Characterization of SSZ monoclinic and triclinic forms 
SSZ monoclinic and triclinic identification 
The following identification tests were carried out for SSZ: HSM, DSC, FTIR and PXRD.  
The SSZ (monoclinic) form is readily available at all suppliers of SSZ. 
 
Hot Stage Microscopy (HSM) 
 
SSZ (monoclinic) powder was placed on a slide in a drop of silicone oil for solvent detection 
by bubble formation upon heating. The sample was heated at constant rate of 10 K/min in the 
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temperature range of 30 to 300 ºC with photographs taken at set temperatures (Figure 4.2). 
We note that the sulfasalazine (monoclinic) form’s melting point (270 ºC) is followed 
immediately by decomposition at 273 ºC (Figure 4.2 b, c).  
The two forms (monoclinic and triclinic) melted and decomposed at the same temperature, 
but the triclinic form changed colour from orange to dark red a little earlier at 246 ºC 
compared to the monoclinic form at 257 ºC as shown by HSM in figure 4.3. 
                
      Figure 4.2 HSM for SSZ (monoclinic)                 Figure 4.3 HSM for SSZ (triclinic)            
 
Differential Scanning Calorimetry (DSC) 
The DSC indicates a melting point peak for SSZ (monoclinic) at 277 ºC (Figure 4.4) with a 
single endotherm between 273 ºC and 280 ºC. The degradation of SSZ was observed 
immediately after the melt. Sulfasalazine triclinic had the same melting point as the 
monoclinic form. 
 
Figure 4.4 DSC for SSZ (monoclinic) 
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Infrared spectroscopy (FTIR) 
The infrared absorption spectrum of sulfasalazine (monoclinic) is presented in figure 4.5, and 
the structure interpretation in table 4.1 includes the most significant functional group 
frequencies. SSZ (monoclinic) is characterized by a carboxylic acid group (–COOH), a 
hydroxy group (-OH) and a secondary amine (-NH-) group. The reference spectrum was 
recorded in a potassium bromide pellet which is different from the experimental technique 
used for the present study, namely the ATR method.  
 
 
Figure 4.5 FTIR for SSZ (monoclinic) 
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Table 4.1 FTIR absorption bands for SSZ (monoclinic form) 
    Compound  Experimental 
frequency bands (cm-1) 
Standard frequency 
bands (cm-1) 2 
Characterisation of 
functional groups 
SSZ  2634- 3134 2500- 3400 OH stretch 
 1675 1670- 1680 C=O vibration 
 1586- 1633 1580- 1630 C=C or N=N vibration 
 1356 1360 CO2NH Vibration 
 1279 1280- 1290 SO2 asymmetrical 
 1261 1260-1278 C–O stretching 
vibration or OH 
deformation 
 1172 – 1195 1170- 1195 RSO2 NR 
 1123 1135 SO2  group 
symmetrical 
 
The FTIR experimental data compared to the theoretical data suggests that the SSZ 
monoclinic form is reflective of what literature states2 and more importantly of the certificate 
of analysis. The SO2N in the 1170-1195 cm-1 range is what defines the monoclinic and 
triclinic tautomers for this particular group, hence FTIR will not be used as an analytical 
method to distinguish which form is being used.  
Powder X-ray diffraction (PXRD) 
Powder X-ray diffraction provides structural data to identify and differentiate solid phases. 
PXRD is very powerful and allows rapid assignment of e.g. polymorphic forms.3 Even though 
the triclinic and monoclinic forms of sulfasalazine are not polymorphic forms of each other 
but tautomers of one another, a clear PXRD pattern distinction is made between the two, as 
shown in figure 4.6. 
 
Figure 4.6 PXRD patterns for SSZ tautomeric forms 
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Table 4.2 is a representation summary of the SSZ (monoclinic and triclinic) experiments with 
selected co-formers discussed in chapters 2 and 3, undertaken with the aim of preparing a SSZ 
co-crystal. For a full account of all the SSZ experiments, refer to appendix C (see CD-Rom).   
 
Table 4.2 Representative SSZ (monoclinic) and SSZ (triclinic) experiments 
Drug Co-former Method Solvent Ratio Result 
SSZ 
monoclinic 
      NC Solidification of 
the melt 
     - 1:3 Co-crystal  
       OA Solvent assisted 
grinding 
Methanol 1:2 Mixture of SSZ and 
OA 
      SCA Solvent assisted 
grinding 
Methanol 1:2 Mixture of SSZ and 
SCA 
       MA Dry grinding      - 1:2 Mixture of SSZ and 
MA 
      SUA Dry grinding      - 1:2 SUA 
       BA Solvent assisted 
grinding 
  THF 1:1 Mixture of SSZ and 
BA 
      TMP Slow 
evaporation 
  THF 1:1 Salt 
SSZ  
Triclinic 
     OA Slow 
evaporation  
  THF 1:2 Mixture of SSZ and 
OA 
      SUA Slow 
evaporation  
  THF 1:2 SUA 
      MA Slow 
evaporation  
  THF 1:2 SSZ triclinic 
      TMP Slow 
evaporation  
  THF 1:1 The triclinic form 
give a salt as the 
monoclinic form 
       D-TA Solvent assisted  
grinding   
  Ethanol  1:2 Mixture  
 
4.3 Preparation of sulfasalazine co-crystals and salt   
4.3.1 Sulfasalazine (monoclinic form) and trimethoprim salt (SSZ-TMPs) 
 
The salt form of APIs sulfasalazine and trimethoprim was synthesized by slow evaporation 
and characterized by elemental analysis, HSM, DSC, TGA, powder X-ray diffraction and 
single X-ray diffraction. 
 
Preparation of SSZ-TMPs 
 
0.04 g sulfasalazine and 0.029 g trimethoprim (1:1 molar ratio) were weighed and each solid 
was separately dissolved in minimum volumes of THF (4 ml) at 67 ºC and magnetically 
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stirred for 20 minutes. The contents of the two vials were then mixed and another 2 ml of 
THF added, magnetically stirred for another 20 minutes, filtered through a 0.45 μm filter and 
allowed to crystallise in a desiccator for 20 days, which resulted in large irregularly shaped 
crystals. Evaporation of the solvent at room temperature produced small irregularly shaped 
crystals. 
Analysis 
Hot Stage Microscopy (HSM) 
A single crystal was immersed in silicone oil to assess the presence of included water or 
organic solvent and the sample was heated at a constant rate of 10 K/min. The photographs of 
SSZ-TMPs were taken at (a) the start of analysis at 25 ºC, (b) the fragmentation and 
appearance of bubbles at 180 ºC, (c) the first sign of melting at 185 ºC, (d) the completion of 
the melt at 200 ºC and (e) the onset of decomposition at 290 ºC where the product colour 
changed to a darker orange (Figure 4.7). 
 
      
                            (a) 25 ºC                        (b) 180 ºC                      (c) 185 ºC                                                                        
            
    (d) 200 ºC                             (e) 290 ºC 
Figure 4.7 HSM of SSZ-TMPs 
 
Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC) 
TGA was used to determine the possible presence of included solvent in SSZ-TMPs. There 
are two significant mass losses noted prior to the melt of the sample (figure 4.8). The 
sequential mass losses were 2.8 % and 9.5 %, totalling 12.3 % 
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                                                  Figure 4.8 TGA of SSZ-TMPs 
 
The DSC trace (figure 4.9) exhibited two endothermic peaks with the first peak at 176 ºC 
indicating fragmentation of the crystal and solvent evolution which corresponded well with 
the HSM and TGA data. The second peak indicates a melting point for SSZ-TMPs at 189 ºC 
with a single endothermic peak between 185 and 200 ºC. Furthermore, the melting point 
differed from that of the parent APIs (SSZ and TMP). The product has a lower melting point 
than those of the parent compounds which might suggest a lower stability or weaker 
intermolecular forces acting within, therefore possibly indicating that the salt might have a 
higher dissolution rate compared to the untreated SSZ and TMP. Degradation was observed 
from 290 ºC. 
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 Figure 4.9 DSC trace for SSZ-TMPs 
 
Infrared spectroscopy (FTIR) 
As shown in figure 4.10 the FTIR absorption bands of SSZ-TMPs are compared with the 
spectral data for the individual parent compounds. If the organic carboxylic acid of SSZ were 
to be converted to its deprotonated state, this would result in an ideal bonding equilibrium 
between the C=O-double- and the C-O-single bond due to charge delocalisation. The 
absorption bands of the carboxylate -COO- and of the ammonium -NH3+ groups are shown in 
table 4.3 
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 Figure 4.10 FTIR spectra of SSZ-TMPs, SSZ and TMP 
                          
Figure 4.11 Indication from FTIR spectra of the functional groups which might be interacting 
between the SSZ and TMP molecules to form SSZ-TMPs salt 
 
The red arrows seen in figure 4.11 point to the functional groups which are affected by salt 
formation, namely the C=O and -OH for SSZ and NH2 for TMP. This can be confirmed from 
figure 4.10 where the decrease in the intensity of the TMP amino group peak, shifts from 
3468 cm-1 to 3473 cm-1 and the SSZ carbonyl group peak, shifts from 1675 cm-1 to 1672 cm-1. 
Other peaks affected by the interaction with a decrease in the intensity of the peaks or peak 
shifting toward a lower and higher wave number are also noted in table 4.3. 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
% T 
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SSZ
TMP
3029.67 2822.99
2763.83
1916.02
1675.63
1633.21
1616.36
1587.02
1537.98
1488.92
1463.03
1428.55
1393.15
1356.25
1279.54
1261.88
1195.47
1172.33
1153.02
1124.46
1111.67
1077.39
1042.90
1003.92
964.42
935.37
922.50
843.60
789.61
765.15
728.72
708.04
663.52
3468.36
3316.57
3106.73
2929.83
2834.24
1632.06
1589.11
1562.83
1506.77
1456.28
1420.60
1334.93
1263.14
1234.73
1188.44
1000.00
981.78
967.38
926.37
829.64
796.95
782.09
768.24
740.82
713.06
3473.95
3444.28
2940.70
2835.42
2705.54
1672.08
1634.84
1589.52
1534.55
1504.61
1486.78
1454.86
1422.44
1390.68
1361.68
1325.35
1291.37
1276.24
1241.75
1168.72
1118.49
1082.76
1064.45
1000.75
954.45
843.75
804.70
780.96
721.44
674.42
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Table 4.3 Selected infrared data (from FTIR) for the compound SSZ-TMPs compared to SSZ 
and TMP  
SSZ standard 
frequency bands  
(cm-1) 
TMP standard 
frequency bands 
(cm-1) 
Salt Frequency 
bands (cm-1)  
Interactions and 
comment 
3029 
OH stretch 
3468 Asymmetric 
NH2 stretch 
2940-3473 
OH-NH2 
O•••H-NH,   
Decrease in the intensity 
3029 
OH stretch 
3316 Symmetric 
NH2 stretch 
2940-3444 
OH-NH2 
O•••H-NH,  
Decrease in the intensity 
1675 
C=O vibration 
3468 Asymmetric 
NH2 stretch 
1672-3473 
C=O- NH2 
C=O•••H-NH 
1675 
C=O vibration 
3316 Symmetric 
NH2 stretch 
1672-3444 
C=O- NH2 
C=O•••H-NH 
 
Powder X-ray diffraction (PXRD)  
The PXRD patterns show distinctly different peak positions and intensities for the reactant 
sulfasalazine and trimethoprim. PXRD was a potent method for the characterization of the 
formation of a new crystalline phase. The diffraction pattern of the salt should be clearly 
distinct from that of the superimposition of each of the parent compounds if a true salt has 
been formed between two solid phases. SSZ-TMPs was characterized by peak interferences at 
various diffraction angles at 2 theta 5.3º, 13.8º, 14.3º, 20.2º, 25.3º and 30.1º (Figure 4.12). 
 
Figure 4.12 PXRD for SSZ-TMPs, SSZ and TMP 
Elemental analysis  
Elemental analysis was used to determine the percentage of carbon, hydrogen, sulphur and 
nitrogen present in the sample (Table 4.4). Quantification of the solvent present was 
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determined together with TGA analysis to facilitate elucidation of the single X-ray structure. 
SXRD presented solvent disorder which could now be solved based on these calculations.  
Table 4.4 Elemental analysis of SSZ-TMPs 
SSZ.TMPs FORMULA M.WT %C %H %N %S 
Experimental  
SSZ-TMP 
C32H32N8O8S 688.7 55.9 5.6 14.8 3.7 
Calculated 
SSZ+TMP+THF+0.5H2O 
C36H41N8O9S 769.8 56.8 5.3 14.7 4.2 
 
There is a 1% discrepancy in the %C for the above table which should be considered 
provisional at this point since it is not a reasonable % difference value between the 
experimental and calculated data. The minimum difference allowed is 0.3%. Later in the 
single X-ray analysis the 1% difference in C will be explained with several alternative 
formulae below. 
X-ray crystallographic analysis of SSZ-TMPs  
 
Data-collection 
Diffraction intensities were collected on a Nonius Kappa CCD diffractometer using graphite-
monochromated MoKα radiation at low temperature (-100 ºC). Unit cell determinations were 
performed only at low temperature (-100 ºC). The program XPREP4 was used to determine 
the space group of SSZ-TMPs 
For SSZ-TMPs Laue symmetry -1 was indicated for the collected intensity data, thus 
confirming the triclinic crystal system and thus implying space group P1 or P1. Intensity 
statistics provided by XPREP4 indicated the centro-symmetric space group P1. This choice 
was justified by the successful solution and refinement of the structure in this space group. 
The final R1 [F◦ >4σ(F◦)] value was 0.0444.  
 
Structure Solution and Refinement 
The program SHELXS-975 was used for the structure solution of SSZ-TMPs. Direct methods 
revealed the positions of all the non-hydrogen atoms of the SSZ and TMP moieties in the 
asymmetric unit. All non-hydrogen atoms were refined isotropically on F2 with SHELXL-976 
and subsequently with anisotropic thermal parameters. Atoms of disordered THF and water 
were recognized in subsequent difference Fourier syntheses and their special treatment is 
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described below. Particular attention was given to H-atom placement, given the need to 
distinguish between a co-crystal or a salt. The atomic numbering scheme is shown in figure 
4.13. SSZ has two donor atoms (O28, N45) and seven acceptors (O30, O31, O41, O42, N33, 
N32, N43). TMP has three donors (N1, N7, N8) and four acceptors (O16, O18, O20, N3). All 
of these atoms were critical during location of hydrogen atoms, since if the latter had not been 
unambiguously located, the possibility of salt formation would have been overlooked. All 
hydrogen atoms were located in difference electron density maps, revealing unequivocally 
that the compound is a salt, with SSZ containing a carboxylate group and the TMP molecule 
being protonated at atom N1. The H atoms were subsequently placed in idealised geometric 
positions using a riding model and were refined isotropically with Uiso values in the range 1.2-
1.5 those of their parent atoms. Disorder problems were encountered due to the presence of 
solvent in the crystal, the composition of which had been carefully assigned using TGA and 
elemental analysis for eventual reconciliation with the single crystal X-ray diffraction 
solution. Repeated attempts to refine the included solvent (as THF and water molecules, both 
disordered) were only partially successful and therefore it was decided to employ the 
SQUEEZE7 technique to obtain a satisfactory refinement. Treatment of the disordered solvent 
in the structure using this procedure is explained fully in section: “Treatment of the solvent in 
the X-ray structural refinement of the solvated salt,” below. This ultimately led to very 
satisfactory results. The resulting crystal and refinement data are presented in Table 4.5. 
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 Figure 4.13 The asymmetric unit of SSZ-TMPs salt with principal hydrogen bonds between 
the SSZ and TMP molecules drawn as red dashed lines.  
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Table 4.5 Crystal and refinement data for SSZ-TMPs 
Parameter  
Molecular Formula C32 H32 N8 O8 S  
(C18 H13 N4 O5 S-, C14 H19 N4 O3+) 
Formula Weight/g mol-1 688.73 [Note: Based on SHELXL97 Atomic 
Weights] 
Crystal System Triclinic 
Space group P1 
a (Å) 8.9324(5) 
b (Å) 12.7551(7) 
c (Å) 16.8196(9) 
α (º) 79.505(1) 
β (º) 82.084(1) 
γ (º) 83.831(1) 
Volume (Å3) 1859.62(2)  
Z 2 
Densitycalc / g cm-3 1.230 
µ (MoKα) / mm-1 0.144  
F(000)  720 
Crystal size / mm3 0.09 x 0.21 x 0.24 
Temperature (K) 173(2) 
Range scanned θ / ° 1.6 ≤ θ ≤ 28.5 
Index ranges  h: -11,11; k:-17,17; l:-22,22 
Total no. of reflections collected 75835 
No. of unique reflections 9347 
No. of reflections with I > 2σ(I) 7228 
No. of L.S. parameters 446 
Rint, Rσ 0.050 
S 1.082 
R1 (F◦ >4σ(F◦)) 0.0444 
wR2 (all reflections) 0.1235 
∆ρ excursions / eÅ-3  -0.29, 0.31 
Description of the Structure 
SSZ-TMPs crystallises in the triclinic space group P1 with Z=2 and with one sulfasalazine 
anion and one trimethoprim cation, as well as disordered THF and water, in the asymmetric 
unit. The POV-RAY8 diagram of the low temperature (LT) asymmetric unit of SSZ-TMPs 
(solvent excluded) is presented in figure 4.14. The thermal ellipsoids of the LT structure 
indicate the reduced atomic thermal motion, which led to a high precision of the structural 
determination of the main structure excluding the solvent.  
In figure 4.14 shows asymmetric unit of SSZ-TMPs salt with thermal ellipsoids drawn at the 
50% probability level excluding disordered solvent. 
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Figure 4.14 The asymmetric unit of SSZ-TMPs salt with thermal ellipsoids drawn at the 50% 
probability level 
Geometrical Analysis of SSZ-TMPs 
 
The most significant geometrical parameters to be considered when SSZ and TMP crystallize 
as a salt are presented in Table 4.6. Selected representative bond distances and torsion angles 
of SSZ-TMPs are presented. A full set of the molecular parameters is available in Appendix D 
on a CD-ROM provided. 
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Table 4.6 Selected geometrical parameters for SSZ-TMPs 
Parameter SSZ-TMPs 
Selected bond distances (Å)  
O28  - C27   1.345(2) 
O30  - C29    1.284(2) 
O31  - C29  1.242(2) 
N7 - C2 1.324(1) 
N1 - C2 1.353(2) 
C2 - N3 1.323(1) 
Selected torsion angles (º)  
C4  N3  C2 N7                        -179.5(1) 
C27  C22  C29  O30  6.2(2)     
O31 C29 C22 C23  4.8(2) 
C23 C22 C27 O28 179.5(1) 
H1 N1 C2 N3      179.2(1) 
C2 N1 H1 O31 179.3(1) 
H7A N7 C2 N3   180.0 
C23 C22 C27 C26 -1.0(2) 
C6 N1C2 N3 -0.8 (2) 
N8 C4 N3C2 -178.9(1) 
H28 O28 C27 C22  2 
O30 C29 C22 C23 -175.2(1) 
C27 C22 C29 O31 -173.8(1) 
C23 C22 C29 O30 -175.2(1) 
 
Bonding Motifs in SSZ-TMPs 
In the SSZ-TMPs structure (Figure 4.15) the TMP cation forms two with the SSZ anion, 
giving rise to the ring motif with graph descriptor R2 2(8). In addition, SSZ gives rise to intra-
molecular ring motifs with graph descriptor S(6) for the O-H•••O interaction. 
  
 
Figure 4.15 Bonding motif in SSZ-TMPs 
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Hydrogen Bonding Interactions in SSZ-TMPs  
 
Table 4.7 lists all the hydrogen bonds for SSZ-TMPs as calculated by PLATON.7 It is evident 
from the table and figure 4.15 that the SSZ-TMPs salt resulted through formation of the H-
bonds N7-H7A•••O30 and N1-H1•••O31. Table 4.7 presents the interaction between sulfasalazine 
and trimethoprim, the donor and acceptor atoms and the distances between each interacted 
atom. 
Table 4.7 Hydrogen-bonding geometry (distances in Å, angles in degrees)  
  D---H•••A                D – H H•••A D•••A D-H•••A Symmetry 
codes 
N1---H 1•••O31# 0.88 1.88 2.760 179 x,y,z 
N7---H7A•••O30# 0.88 1.82 2.700        173 x,y,z 
O28---H28•••O30* 0.84 1.72 2.470       147 x,y,z 
N8---H8A •••N3* 0.88 2.07 2.946 176 -1-x,1-y,-z 
N45---H45•••N43* 0.88 1.98 2.850       168 2-x,2-y,1-z 
C26---H26•••O20* 0.95 2.59    3.472 154 1+x,-1+y,z 
C38---H38•••O42*  0.95 2.47 2.867 105 x,y,z 
C49---H49•••O42*       0.95 2.52 3.088 119 x,y,z 
C46---H46•••O41*       0.95      2.47    3.136 127 2-x,2-y,1-z 
N7---H7B•••O18*       0.88              2.33 3.082 143 x,-1+y,z 
  # Indicates intermolecular bonds *Indicates intramolecular bonds  
 
In SSZ-TMPs, SSZ is an API and acts as the hydrogen bond donor to H-bond N-H•••O as 
indicated in figure 4.16. SSZ may act as a weak acid when it is crystallized with APIs that 
contain a sufficiently basic centre.9 In this instance protonation of the TMP by SSZ is easily 
accomplished and a salt formed instead of co-crystals. Proton transfer thus occurred from the 
SSZ molecules [leaving an anion (SSZ)-] to the TMP molecules [forming a cation (TMP)+].  
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 Figure 4.16 Comprehensively the representative part of the fuller picture of the hydrogen 
bonding that generates a typical layer 
 
Crystal Packing of SSZ-TMPs 
Figure 4.17 presents a crystal packing diagram of the SSZ-TMPs salt down the b-axis. This 
shows the SSZ and TMP molecules overlapping in column formation. In the central cavity, a 
channel forms creating adequate space for the inclusion of solvent. This was proved with 
TGA, elemental analysis and a comprehensive discussion of the treatment of the solvent in the 
X-ray structural refinement of the disorder of the included solvent molecules which follows 
the crystal packing diagram. 
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 Figure 4.17 Crystal packing of SSZ-TMPs down b-axis 
  
Treatment of the solvent in the X-ray structural refinement of the solvated salt 
As indicated above, the disordered solvent in the crystal structure of the (TMP)+ (SSZ)- salt 
required special treatment. Difference Fourier syntheses had clearly indicated the presence of 
disordered THF molecules in the crystal. On refining the disordered THF molecule over two 
alternative positions close to a centre of symmetry, additional electron density peaks appeared 
in that region, indicating further disorder, but the peaks were not sufficiently definitive to 
allow simple modelling. Furthermore, in a second isolated region of the unit cell, three 
discrete peaks of relatively low electron density occurred near a second centre of symmetry. 
These were initially interpreted as resembling an acetonitrile molecule disordered over two 
positions. However, subsequent tests of the solvent used for crystallization of the salt showed 
that it was free of acetonitrile, leaving only water molecules as possible candidates for the 
remaining disordered solvent. Exhaustive attempts were made to refine all atoms of the 
solvent molecules with appropriate site-occupancy factors, but the refinements were not stable 
and subsequent difference Fourier syntheses revealed additional disorder which could not be 
modelled. 
At this point, the SQUEEZE strategy in programme PLATON.10 was invoked in order to deal 
with the solvent disorder problem. All atoms previously assigned as potential solvent atoms 
were duly deleted from the model, leaving only the salt components and relatively large 
voids, the latter with peaks of residual electron density up to a maximum value of 2.6 eÅ-3. 
The resulting computations using the SQUEEZE routine led to excellent refinement of the 
TMP+ SSZ- unit and very satisfactory crystallographic agreement factors for the final model 
(R1 = 0.0444 for 7228 data with I > 2σ(I), wR2 = 0.1235, S = 1.082 and final difference 
electron density ∆ρ = 0.31 eÅ-3). It should be emphasised that this special refinement is based 
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on a full set of intensities that have been corrected so as to be ‘solvent-free’. The resulting 
estimated void electron count was 120 per unit cell, and hence 60 electrons for the 
crystallographically unique void corresponding to one salt formula unit. Later inspection of 
the voids containing the respective disordered THF and water molecules revealed that they 
merged, forming two intersecting channels, the major one running parallel to the crystal b-
axis and the minor, constricted channel running parallel to the a-axis.  
Finally, it was necessary to attempt to reconcile the calculated number of electrons in the 
crystal void space (60 electrons per salt formula unit (TMP)+ (SSZ)-) with solvent 
composition (THF/water mixture) within the crystal, using as guides the analytical data, 
namely elemental analysis and thermogravimetric data for the solvated crystals. Since the 
TGA data from multiple measurements varied considerably, data from elemental analyses 
were considered somewhat more reliable. For these, duplicate measurements were averaged 
and the final percentage values of C, H, N and S were used as the primary guide to 
determining the overall composition of the solvated crystal.   
In a situation where there is mixed solvent in the crystal, there are alternative overall formulae 
that could satisfy the analytical data within reasonable bounds. For example, if the formula for 
the solvated salt is proposed as (TMP)+ (SSZ)- ·0.83(THF)·0.66(H2O), with an extended 
formula C35.3 H40.0 N8 O9.5 S (Mr = 760.4 g mol-1), a calculated composition of %C 55.8, %H 
5.3, %N 14.7, %S 4.2 results, in very good agreement with the elemental analysis data, 
namely %C 55.9, %H 5.6, %N 14.8, %S 3.7, except in the case of the sulphur content, which 
is somewhat low.  It should, however, be noted that for the above proposed formula, the 
solvent content per formula unit accounts for filling of the unique void space by only 40 
electrons (as opposed to the predicted 60), which therefore casts doubt on the reliability of the 
formula. The predicted total solvent mass loss from the formula unit is 9.7 %, which is again 
somewhat lower than the estimates from thermogravimetric analysis (2.8, 9.5%).  
An alternative formula is (TMP)+ (SSZ)- 1.25(THF)·(H2O), with an extended formula C37 H44 
N8 O10.5 S (Mr = 796.9 g mol-1), for which the calculated composition is %C 55.8, %H 5.6, 
%N 14.1, %S 4.0, compared to the experimental values of %C 55.9, %H 5.6, %N 14.8, %S 
3.7; in this instance, there is very good agreement except in the case of the nitrogen content, 
where the difference is ~ 0.7%. However, the merits of this formula are (a) very good 
agreement of the elemental analysis data for C, H and S, (b) the solvent content does account 
for 60 electrons per crystallographically unique void space, the value indicated by the 
SQUEEZE refinement, and (c) the percentage solvent loss in TGA is calculated as 12.3%, 
which is within the range of the various values measured.  
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It should be noted that possible variability in the analytical data is expected for a solvated 
compound of this kind in view of (i) the presence of mixed solvent with different tendencies 
to escape from the crystal, and (b) the presence of channels in the crystal that could allow 
spontaneous efflux of solvent in two directions. In these circumstances, it is reasonable that 
some compromise must be reached in defining the solvent content.  
Finally, it should be noted that in the context of the present study, the determination of the 
composition of mixed solvent molecules within the crystal is of relatively minor importance 
given its significant disorder, and furthermore the inability to determine it precisely does not 
detract from the major result, namely establishment of the ionic nature of the compound 
formed between TMP and SSZ and the accurate model obtained for this salt using X-ray 
diffraction. 
 
Calculated PXRD 
The computed and experimental patterns of SSZ-TMPs are presented below (Figure 4.18). In 
each case, the computed pattern is based on the final, refined single crystal X-ray parameters 
for these phases. 
 
Figure 4.18 PXRD comparisons between experimental and calculated salt 
 
In figure 4.18, the two traces above cannot be in good agreement because the experimental 
trace accounts for the presence of the solvent in the crystal, but the calculated one specifically 
does not ( the solvent contribution has been eliminated from the intensity data). 
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SSZ-TMPs desolvated 
Due to solvent risk, such as toxicity problems for pharmaceutical formulation purposes, we 
attempted to remove the solvent from the salt by controlled heating using TGA (Figure 4.19) 
and we successfully managed to achieve this, as confirmed by DSC (Figure 4.20). The 
structure of the salt was not affected by solvent removal and it is still intact established by 
PXRD analysis (Figure 4.21).  
 
 
Figure 4.19 TGA comparison between solvated and desolvated salt 
 
 
Figure 4.20 DSC comparison between solvated and desolvated salt 
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 Figure 4.21 PXRD comparisons between solvated and desolvated salt 
 
Comment  
Salt formation is one of the primary solid-state approaches used to modify the physical 
properties of APIs. From the literature review of sulfa drugs there is a sulfamethoxazole and 
trimethoprim salt prepared by Nakai et al11 which has potential as a candidate for 
pharmaceutical co-crystal development.  
SSZ-TMPs has a melting point lower than those of the parent compounds; this might suggest 
weaker intermolecular forces acting within the salt and therefore possibly a greater dissolution 
rate of the salt compared to the untreated SSZ and TMP. A salt will generally yield a more 
water soluble API due to its ionized state.12 
4.3.2 Sulfasalazine (monoclinic) and trimethoprim co-crystal (SSZ-TMP) 
 
SSZ-TMP was prepared and characterized by HSM, DSC, TGA, FTIR and powder X-ray 
diffraction. 
Preparation of a SSZ-TMP co-crystal  
Solvent-assisted grinding was used to prepare SSZ-TMP. 0.04 g of SSZ and 0.029 g TMP 
(1:1) molar ratio were weighed, mixed and ground together manually using a small porcelain 
mortar and pestle. 1 ml of methanol was added while grinding for 30 minutes.  The product 
was analysed as follows. 
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Analysis 
 
Hot Stage Microscopy (HSM) 
Hot stage microscopy photographs of SSZ-TMP were conducted at (a) room temperature (25 
ºC), at (b) when the sample changes from yellow to orange with slight bubbling indicated by 
the blue arrow (170 ºC), at (c) melting of the sample (215 ºC), at (d) completion of the melt 
(225 ºC) and (e) the onset of decomposition at 280 ºC (Figure 4.22). 
  
                                      
(a) 25 ºC                           (b) 170  ºC                         (c) 215 ºC 
                                           
                                          (d) 225 ºC                          (e) 280 ºC 
                                                 Figure 4.22 HSM of SSZ-TMP 
 
Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC) 
The TGA trace of SSZ-TMP shows a mass loss of 1.4 % (n= 0.3) of methanol. The DSC trace 
of SSZ-TMP shows an endotherm peak between 215 ºC and 230 ºC where the sample 
changed to a dark orange colour with solvent evaporation on the HSM; this was followed 
immediately by the melt peak at 223 ºC (Figure 4.23) which corresponds well with the HSM 
and TGA observations. The degradation of SSZ-TMP was observed at 270 ºC.  
The melting point of SSZ-TMP differs considerably from those of the individual parent 
compounds with SSZ melting at 270 ºC and TMP melting at 200 ºC. 
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 Figure 4.23 DSC trace for SSZ-TMP 
Infrared spectroscopy (FTIR) 
FTIR is an excellent technique to give an insight into the interaction occurring between the 
two APIs (SSZ and TMP). The FTIR spectra presented in figure 4.24 show a decrease in the 
intensity and shift in peak frequencies, which suggest the formation of a new compound.  
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 Figure 4.24 FTIR spectra of SSZ-TMP, SSZ and TMP. 
 
                
Figure 4.25 Indication from FTIR spectra of the functional groups which might be interacting 
between the SSZ and TMP molecules to form SSZ-TMP co-crystal. 
 
The FTIR spectrum shows shifting of the trimethoprim asymmetric NH2 stretch from 3468 to 
the higher frequency at 3515 cm-1,  and the symmetric NH2 stretch from 3317 cm-1 to the 
higher frequency 3359 cm-1, while sulfasalazine –OH shifting from 2938 cm-1 to 2916 cm-1 
and the C=O shifting from 1675 cm-1 to 1667 cm-1. The possible interactions between the two 
compounds are -O-H•••NH2, HO•••H-NH and C=O•••H-NH. The functional groups which 
might be affected are shown in figure 4.25 and other groups affected are also listed in table 
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4.8. Confirmation of salt complex/Complex/Co-crystal is confirmed by presence of the NH2 in 
TMP  at 3515 cm-1 not protonated and C=O in SSZ at 1657 cm-1 (not C-O) with another peak 
in fingerprint area around 1200 cm-1 (1175 cm-1) indicating no deprotonation in the carboxylic 
acid group. Thus, SSZ-TMP will henceforth be referred to as a co-crystal not salt. 
Table 4.8 Selected infrared data (from FTIR) for the compound SSZ-TMP compared to SSZ 
and TMP 
SSZ standard 
frequency (cm-1) 
TMP standard 
frequency (cm-1) 
Co-crystal 
 Frequency (cm-1)  
Interactions and 
comment 
2938 
OH stretch 
3468 Asymmetric 
NH2 stretch 
2916-3515 
OH-NH2 
HO•••H-NH or  
O-H••• NH2 
Decrease in the intensity 
2938 
OH stretch 
3317 Symmetric NH2 
stretch 
2916-3359 
OH-NH2 
HO•••H-NH or  
O-H••• NH2 
Decrease in the intensity 
1675 
C=O vibration 
3468 Asymmetric 
NH2 stretch 
1657-3515 
C=O- NH2 
C=O•••H-NH 
1675 
C=O vibration 
3317 Symmetric NH2 
stretch 
1657-3359 
C=O- NH2 
C=O•••H-NH 
 
Powder X-ray diffraction (PXRD) 
A different PXRD pattern for the co-crystal from those of the individual components was 
distinguished in figure 4.26. The co-crystal exhibited a pattern with different peak positions 
from their active ingredients. Furthermore, the relative intensities of their PXRD peaks were 
modified which might be attributed to the different crystal habits.13 
The PXRD pattern of the SSZ-TMP co-crystal shows some characteristic peaks at 2 θ that 
7.7°, 8.1° , 11.1°, 13.5°, 14.5°  and 20.1°. Also peaks disappeared at 9.8°, 10.1°, 12.1°, 28.1° 
and 30.3° 2 θ. 
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 Figure 4.26 PXRD of SSZ-TMP co-crystal 
Figure 4.27 looks at PXRD patterns which show the difference between the SSZ-TMPs salt 
and SSZ-TMP co-crystal.  
 
Figure 4.27 Different between PXRD of SSZ-TMP co-crystal and SSZ-TMPs salt 
Comment   
The solvent-assisted grinding approach for co-crystallization formation is simple, easily 
performed and an alternative method to the traditional method of solution crystallisation. 
However, the method is not considered favourable for obtaining single crystal due to the fact 
that grinding results in microcrystalline powders, which are unsuitable for single crystal X-ray 
diffraction. In 1995, Caira and co-workers demonstrated the pharmaceutical application of co-
crystallization via solid-state grinding by systematically studying a range of different 
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pharmaceutical co-crystals of sulfa drugs with aromatic carboxylic acids.14 The SSZ-TMP co-
crystal produced in this study has a melting point between the two parent compounds which 
might suggest a better dissolution rate than the untreated SSZ and higher stability compared to 
TMP. 
4.3.3 Sulfasalazine (monoclinic) and nicotinamide co-crystal (SSZ-NC) 
Preparation of SSZ-NC co-crystal 
0.05 g of SSZ and 0.045 g of NC (1:3 molar ratio) were weighed, mixed manually and the 
sample then melted in a pan until liquefied by increasing the temperature slowly to 188 ºC. 
The colour of the sample changed from orange to red. The sample temperature was gradually 
decreased to room temperature until solidification. 
 
Analysis 
 
Hot Stage Microscopy (HSM)  
The sample was immersed in silicone oil and heated at a constant rate of 10 K/min. Pictures 
were recorded at (a) 25 ºC, start of analysis, (b) 165 ºC, when the sample changed to dark 
orange, (c) 188 ºC, sample started to melt, (d) 195 ºC, the end of the melt and (e) 275 ºC, 
decomposition of the sample with colour change to dark brown (Figure 4.28). The SSZ-NC 
melting point and decomposition profile differed from those of the parent compounds, which 
indicated that a new compound had formed; this was confirmed by further analysis. 
 
                           
                     (a) 25 ºC                     (b) 165 ºC                       (c) 188 ºC      
                                      
                                            (d) 195 ºC                  (e) 275 ºC 
                                         Figure 4.28 HSM of SSZ-NC 
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Thermogravimetric Analysis (TGA) Differential Scanning Calorimetry (DSC)  
TGA indicated no mass loss, which confirmed that no solvent was present in the sample.  
With DSC analysis the sample melted at 192 °C with a broad endothermic peak (Figure 4.29) 
between 182 ºC and 200 ºC. Furthermore, the melting point differed significantly from those 
of the parent compounds. The degradation of SSZ-NC was observed from 260 ºC. 
 
Figure 4.29 DSC of SSZ-NC 
Infrared spectroscopy (FTIR) 
The vibrational spectrum of SSZ-NC is considered to be unique and is characteristic of the 
new compound. The comparison of the SSZ-NC spectrum with the parent compounds is 
presented in figure 4.30.  
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 Figure 4.30 FTIR spectrum of SSZ-NC 
 
        l                         
Figure 4.31 Indication from FTIR spectra of the functional groups which might be interacting 
between the SSZ and NC molecules to form SSZ-NC co-crystal 
Figure 4.31 presents the functional groups which are affected by the interaction between the 
sulfasalazine (–OH, C=O) and nicotinamide (N-H, C=O) molecules. 
The possible interactions for the two compounds based on the shifts are as follows: (-O-
H•••O=C, C=O•••H-NH, HO•••H-NH, O-H••• NH2) confirmed by peak shifting and decrease 
in the intensity of some peaks.  
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
% T 
SSZ-NC
SSZ
NC
3029.40
2938.91
2824.45
2763.80
1980.39
1914.34
1675.45
1633.28
1615.77
1586.90
1537.92
1488.95
1462.90
1428.28
1392.86
1355.82
1279.44
1261.57
1195.10
1172.40
1152.73
1123.98
1111.38
1076.47
1043.20
1003.84
964.05
935.49
922.16
843.57
789.19
764.88
728.53
707.89
663.13
3357.30
3149.40
2786.35
1673.74
1614.70
1593.00
1574.86
1485.90
1421.73
1339.82
1231.38
1202.07
1153.89
1124.59
1091.59
1028.58
969.41
936.00
828.17
776.84
700.80
3416.61
3316.88
3160.13
1906.95
1678.94
1628.14
1590.60
1573.56
1530.98
1482.93
1458.34
1420.93
1384.52
1351.42
1283.59
1263.96
1228.02
1199.58
1170.70
1127.29
1100.66
1080.83
1040.78
1025.31
1011.57
964.52
897.21
844.76
805.04
778.75
765.16
693.19
673.98
2773.80
2964.28
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The peak assignment for important band shifting is indicated in table 4.9. The results showed 
that the shifts of some of the peaks could be attributed to the hydrogen bond formation 
between the two parent compounds. No significant change in the rest of the peaks of SSZ was 
noted in the intact structure. 
Table 4.9 Selected infrared data (from FTIR) for the compound SSZ-NC compared to SSZ 
and NC 
SSZ standard 
frequency (cm-1) 
NC standard 
frequency (cm-1) 
Co-crystal 
 Frequency (cm-1)  
Interactions and 
comment 
1675 
C=O 
 
3357 
N-H stretch, amide 
1678-3316 
C=O-NH2 
 
C=O•••H-NH Decrease in 
the intensity 
2938 
OH- stretch 
1673 
C=O 
2964-1678 
OH-C=O 
C=O•••H-O 
2763 
OH- stretch 
1673 
C=O 
2773-1678 
OH-C=O 
C=O•••H-O 
2938 
OH- stretch 
3357 
N-H stretch, amide 
2964-3316 
OH-NH2 
HO•••H-NH or  
O-H••• NH2 
Decrease in the intensity 
2763 
OH- stretch 
3357 
N-H stretch, amide 
2773-3316 
OH- NH2 
HO•••H-NH or  
O-H••• NH2 
Decrease in the intensity 
 
To distinguish whether SSZ-NC is a co-crystal or a salt by FTIR, we make use of the fact that 
a neutral carboxylic acid group (–COOH) has a strong carbonyl (C=O) stretching peak around 
1700 cm-1 and a weak C–O stretch around 1200 cm−1; however, if deprotonation has 
occurred, a carboxylate anion (–COO−) should be present and this would exhibit only a single 
C–O stretch in the fingerprint region of 1000–1400 cm-1.15 
Because there is a peak at 1678 cm-1  (highlighted in red) and a peak in the finger print region 
around 1200 cm-1 (1199 cm-1), this indicates that no deprotonation had occurred for the 
carboxylic acid group, confirming that SSZ-NC  is a co-crystal and not a salt. Henceforth, 
SSZ-NC will be referred to as a co-crystal. 
Powder X-ray diffraction (PXRD) 
The generation of co-crystalline material was confirmed by recording powder X-ray patterns 
of pure sulfasalazine, nicotinamide and the SSZ-NC co-crystal (Figure 4.32). A unique PXRD 
pattern, distinguishable from those of the API and co-former, was noted, indicating formation 
of a new crystal form. This was also strongly supported by the melting points observed for the 
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co-crystals which were completely different from those of their respective host and guest 
crystals, as discussed earlier.8 The PXRD pattern of SSZ-NC co-crystal shows some specific 
peaks at 2θ° 5.1°, 13.1°, 13.5°  and 24.5° and peaks disappeared at 2θ° 36.1°  and 38.1°  
(Figure 4.32). 
 
Figure 4.32 PXRD of SS-NC, SSZ and NC 
Comment  
The SSZ-NC co-crystal melting point is altered, resulting in a melting point between that of 
API and that of co-former. Solidification of the melt to prepare a co-crystal is not well-known 
because it generally results in an amorphous form. This co-crystal did not show amorphous 
properties as confirmed from the PXRD pattern. 
 
Dissolution test 
 
Dissolution tests were carried out according to the procedures described in the United States 
Pharmacopeia,16 The dissolution test of all three forms viz. SSZ-TMPs, SSZ-TMP and SS-NC 
were carried out using the rotating basket method at 37 °C.  
Powders were placed in capsules after kneading ~5 minutes to obtain a uniform and 
predictable dissolution of the drug. The particle size range of the powders were  between 3 to 
9 µm. Powders were not sieved prior to encapsulation due to limited resources of ingredients.  
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Sulfasalazine capsules were added to 900 ml of de-aerated phosphate buffer solution (pH 7.5) 
at 37.0 ± 0.5ºC as a dissolution medium. The rotational speed of the baskets was set at 100 
rpm. Dissolution samples were withdrawn at 10, 20, 30, 40, 50 and 60 min and replaced with 
an equal volume of fresh medium to maintain a constant total volume. 
The assay was achieved by UV-VIS spectrophotometry at an appropriate wavelength for the 
active ingredient. The samples were placed in 2 mm quartz cuvettes and the concentrations 
were suitably adjusted such that all absorbance readings were measurable between zero and 
one absorbance unit. Calibration curves for the various drugs were constructed using readings 
taken at the λmax value of SSZ (358 nm). The absorbance of a test solution was determined 
based on the calibration curves. USP 29 states that for SSZ not less than 85 % dissolution is 
required after 60 minutes and this must be met by each capsule. The dissolution profiles for 
SSZ, SSZ-TMPs, SSZ-TMP and SSZ-NC is presented in Table 4.10 and Figure 4.33. The 
concentration of SSZ was determined from the calibration curve y = 37.28x + 0.4147 (R2 = 
0.8364) where y=0. 4147 and x=0.0.01112.  
Table 4.10 Comparative dissolution profile of SSZ, SSZ-TMPs, SSZ-TMP and SSZ-NC 
Time 
(minutes) 
SSZ 
(% 
dissolved) 
SSZ-TMP 
(% 
dissolved) 
SSZ-NC 
(% 
dissolved) 
SSZ-TMPs 
(% 
dissolved) 
0 0 0 0 0 
10 5.7 18.1 7.6 1.0 
20 5.8 34.9 29.0 1.5 
30 8.6 37.8 30.9 1.7 
40 12.9 71.9 38.8 2.0 
50 13.4 73.9 44.7 3.6 
60 16.3 75.9 50.9 6.9 
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 Figure 4.33 Comparative dissolution profile of SSZ and SSZ derivatized forms 
 
Figure 4.33 indicates that none of the SSZ samples passed the USP dissolution test. However, 
SSZ-TMP had a 75.9 % SSZ dissolved and SSZ-NC had a 50.9 % SSZ dissolved after 60 
minutes. Both these products have been identified as co-crystals. In comparison to the pure 
SSZ with a dissolution profile of 16.3% after 60 minutes, SSZ-TMP and SSZ-NC have 
increased the % SSZ dissolved by 59.6% (3.7 fold increase) and 34.6% (2 fold increase), 
respectively.  
On the other hand, SSZ-TMPs is a salt and salts are known to have a much better dissolution 
profile than its free acids or bases. This however, is not represented in figure 4.33 since SSZ-
TMPs has a very low dissolution profile of 6.9%, much lower than even the pure SSZ.  
The dissolution of the weak acid is enhanced under GIT conditions, the pH of the GIT ranges 
from 1.2 to 8 with the stomach having an acidic pH and the intestines having a basic pH. 
The dissolution media used as per the USP method suggested a buffer solution of pH 7.5 
which simulates the small intestine pH. Salts frequently enhance dissolution by efficiently 
acting as their own buffers to change the pH of the diffusion layer, therefore providing the 
parent compound with increased solubility at the pH of the dissolution medium. Contrary to 
this statement, the salt may also act as its own buffer by retarding the dissolution profile of the 
parent compound. This scenario is possibly seen in figure 4.33 with the salt SSZ-TMPs.  
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To illustrate statistically the variation in dissolution profiles we applied the ANOVA 
statistical test. The One-Way analysis of variance (ANOVA test) was used to determine how 
dissolution was affected by two factors simultaneously. The percentage dissolved was the 
dependent variable and time was the repeated factor. Statistically significant differences 
(P<0.001) in the dissolution rates of SSZ, SSZ-TMPs, SSZ-TMP and SSZ-NC were observed 
in the analysis.  
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Chapter 5 presents the concluding comments of this thesis compared with literature review 
and recommendations for further studies. 
 
5.1 Conclusion 
 
Three facets of supramolecular chemistry were examined in this study, namely salt formation, 
co-crystallization and amorphism. The synthesis and characterisation of two 
‘supramolecularly modified’ forms of the sulfa drugs viz. sulfamethoxazole and sulfasalazine 
was achieved. The classification of co-crystals and salts cited in this thesis chosen to view old 
sulfonamide antibiotics, in the form of novel molecular design using discrete intermolecular 
interactions, such as hydrogen bonding is increasing for pharmaceutical development, 
particularly during the preformulation stages of the drug. 
A variety of crystallization approaches, including solid-state grinding, solvent assisted 
grinding, slow evaporation, slurry method and solidification of melt was used to produce 
these results.  All results were analysed using HSM, DSC, FTIR, TGA and PXRD. Six 
compounds were finally identified as “newly” derivatised compounds of which one was 
elucidated by single crystal X-ray diffraction analysis as well. 
Table 5.1 Comparison between SMZ results 
 M.p. 
of 
API 
(°C) 
M.p. of 
co-
former 
(°C)  
M.p. of 
complex 
(°C) 
Ratio    % 
Solvent 
 
  Interaction 
sites of 
SMZ 
Interaction 
sites of co-
former  
SMZ-BAN 170 35-40 266 1:1     /   NH2, NH  C=O, -H 
SMZ-TMP 170 199-203 180 1:1   4% 
Water 
  NH2, NH  NH2, 
aromatic 
methoxy 
group for 
TMP 
SMZ-OA 170 104-106 169 1:3  2.5% 
Water 
  NH2, NH  C=O, O-H 
 
Table 5.1 compares the SMZ products obtained viz. SMZ-BAN, SMZ-TMP, SMZ-OA. SMZ-
BAN co-crystal was prepared by the slurry method and when compared to literature reports of 
another SMZ co-crystal prepared by the same method, sulfamethoxazole and trimethoprim 
co-crystal1 the melting point for SMZ-BAN was found to be higher than the parent 
compounds (266°C), but the melting point for SMZ-TMP1 co-crystal was between the two 
parent compounds (180°C). Both crystals produced a fibrous-needle shaped habit with poor 
quality (figure 5.1), hence single crystal X-ray diffraction data was not possible even though 
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several attempts were made to prepare a better quality crystal to facilitate single X-ray 
diffraction.   
 
                   
                                     (a)                       (b) 
          Figure 5.1 Morphology of (a) SMZ-TMP co-crystal1, and (b) SMZ-BAN co-crystal. 
  
The SMZ-TMP amorphous co-crystal melting point compared to the SMZ-TMP  co-crystal1 
previously found in literature was found to be exactly the same (m.p.180°C) but differed in 
their crystal habit with the amorphous form resembling a glass-like and the reported form 
being needle-like (figure 5.2 (a) and (b)).  Re-crystallization of the SMZ-TMP amorphous co-
crystal with different solvent systems produced a co-crystal with the same melting point of 
180 °C  and crystal habit as the reported co-crystal (figure 5.2 (c)). 
    
             
                               (a)                 (b)                                 (c) 
Figure 5.2 Morphology of (a) SMZ-TMP co-crystal, (b) SMZ-TMP amorphous co-crystal and 
(c) SMZ-TMP amorphous co-crystal re-crystallized with selected solvent. 
 
Table 5.1 suggests that the SMZ-TMP amorphous form includes water in the product which 
was previously confirmed by thermal analysis. Here, it was observed that the amorphous 
material has the ability to absorb large quantities of water vapour2 and no water molecules 
were present in the reported SMZ-TMP co-crystal.1  
Absorption is a process whereby one molecule passes into the bulk of another material and 
should not be confused with adsorption, which is where something concentrates at the surface 
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of another material. In figure 5.3, it is evident why water could easily access the regions 
within the amorphous form compared to the structured crystal form. The random, 
unstructured region of the amorphous material allows small molecules to penetrate the 
material in an unstructured interwoven manner filling every space possible within the 
material.  
 
 
Figure 5.3 Water vapour absorption in a structured crystal region and an unstructured 
amorphous region 
 
SMZ-OA also crystallised as an amorphous form. Oxalic acid (as the di-hydrate) has good co-
forming properties for crystal engineering because as a carboxylic acid, it is known to form 
co-crystals.3,4,5 Carboxylic acids contain a hydroxyl group (O-H) and a carbonyl group 
(COOH) within its structure6 which offers the carboxylic acid function as a hydrogen bond 
donor and acceptor for designing co-crystals to possibly improve physicochemical properties 
of pharmaceuticals during preformulation studies. The SMZ-OA amorphous form was 
prepared by a co-crystallization technique but resulted in an amorphous form of the co-
crystal. Experiments were attempted with several different methods, different solvent systems  
and different ratios and all gave the same result confirming that oxalic acid converts 
sulfamethoxazole to an amorphous  co-crystal with a melting point range between 165.55 °C 
and 180 °C. 
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Table 5.2 Comparison between SSZ results 
 M.p. 
of 
API 
(°C) 
M.p. 
of co-
former 
(°C)  
M.p. 
of co-
crystal 
(°C) 
Ratio    % 
Solvent 
 
  Interaction 
sites of 
SSZ 
Interaction 
sites of co-
former  
SSZ-TMPs 270 199-
203 
189 1:1 2.8%  
H2O, 
9.5% 
THF 
  C=O, -OH  NH2  
SSZ-TMP 270 199-
203 
223 1:1   2 % 
Methanol 
  C=O, -OH  NH2  
SSZ-NC 270 128-
131 
191 1:2    /   –OH, C=O  N-H, C=O 
 
Table 5.2 list the comparisons between the sulfasalazine (SSZ) products prepared. From the 
literature review and Cambridge Structural Data Base (2014),7 no sulfasalazine complexes 
were reported, however  
The SSZ-TMPs (1:1) salt melting point (189°C) compared to the parent compounds was 
lower than the two APIs which is different from the previous TMP complex with SMZ, where 
the melting point of the amorphous co-crystal was between the two APIs much like the SSZ-
TMP co-crystal melting point also found between the two APIs.  
Other earlier examples of 1:1 salts containing sulphonamides include complexes between the 
antiseptic 9-aminoacridine and sulfamethoxypyridazine,8  9-aminoacridine and 
sulfadimidine,9 (both associates containing an acridinum-sulfanilamidate ion pair), and the 
complex between trimethoprim and sulfametrole.10 Distinction between such salts and co-
crystals depends largely on the accurate determination of the H atom location. This is usually 
achieved by single crystal X-ray analysis. 
 
The theory that the molecular association between a given pair of drug molecules frequently 
belongs to one or the other of these types of salts must be treated with caution especially in 
view of the possibility of tautomerism of such compounds. For example, sulfasalazine 
crystallizes in both the monoclinic and triclinic forms, which by chance are in fact tautomers 
of each other.  
 
SSZ-TMPs, the SSZ molecule occurs in the imide tautomer (monoclinic form). SSZ-TMP 
crystallized as salt when the solvent was THF, and as a co-crystal when the media was 
methanol, which is similar to the interaction between trimethoprim and 
sulfamethoxypyridazine, which was shown to result in a co-crystal when the crystallization 
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medium was methanol but as a hydrated salt when crystallization was from water.11 Solvent 
assistant grinding was used to prepare a (1:1)  hydrogen bonded co-crystal identical to those 
obtained from the reaction between the components in solution,12 but the reason it is not a 
preferred technique for obtaining co-crystal material is because grinding results in 
microcrystalline powders, which are unsuitable for single crystal XRD. 
 
6.2 Recommendations  
 
To improve the crystal quality of all the new forms identified in this study for SXRD, or use 
Rietveld refinement where appropriate to determine the structure of the crystals with poor 
quality. 
 
To further understand why the SSZ and SMZ did not present dissolution profiles as per the 
USP method by repeated dissolution testing and compare pure SSZ and SMZ to the products 
produced. Speculation is made that the capsules used to prepare the formulation for 
dissolution could have been one reason for the discrepancy. Furthermore, UV analysis was 
used to quantify the dissolved drug which is not as accurate as techniques such as HPLC. 
 
To complete antibacterial studies of the products compared to pure SMZ and SSZ. 
 
The pharmaceutical department will continue to make formulation dosage forms of these 
complexes because of synergistic effects of the compounds when combined with selected co-
formers for therapeutic purposes. 
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Appendix A 
 
1. FTIR for salicylic acid (SCA) 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
45.8
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
95.8
cm-1
% T 
SCA
3231.62
2851.58 2591.24
1654.88
1609.43
1579.23
1481.75
1464.77
1441.21
1382.82
1324.05
1291.01
1243.04
1207.72
1153.56
1089.18
1030.21
964.32
887.27
867.19
852.08
783.87
690.51
657.81
3000.00
757.04
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2. FTIR for nicotinamide (NC) 
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29.6
35
40
45
50
55
60
65
70
75
80
85
90
94.8
cm-1
% T 
NC
3357.30
3149.40
2786.35
1673.74
1614.70
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1574.86
1485.90
1421.73
1339.82
1231.38
1202.07
1153.89
1124.59
1091.59
1028.58
969.41
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828.17
776.84
700.80
3055.55
1391.40
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3. FTIR for Saccharin (SC) 
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4. FTIR for Oxalic acid (as the di-hydrate) (OA) 
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5. (L, D) Tartaric acid (D-TA)(L-TA) 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
37.7
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98.7
cm-1
% T 
L and D- TA
3405.10
3358.54
2884.19
2639.27
1723.98
1454.21
1399.67
1326.36
1289.94
1233.07
1219.38
1135.60
983.92
914.40
887.74
866.72
830.32
762.32
682.15
1092.07
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6. Citric acid (as the monohydrate) (CA) 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
38.4
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92.9
cm-1
% T 
CA
2828.86
2542.75
1671.37
1627.56
1577.73
1495.21
1448.85
1418.09
1333.02
1311.47
1283.33
1220.34
1206.16
1176.64
1098.55
1073.81
1026.42
1000.64
977.15
942.89
911.16
874.95
845.90
766.81
708.61
3027.77
3067.46
1890.96
2968.25
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7. Succinic acid (SUA) 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
49.5
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98.6
cm-1
% T 
SUA
2929.76
2625.89
2532.40
1680.31
1409.20
1305.32
1196.18
1175.58
891.13
800.17
905.72
2246.03
1829.51
2730.152980.15
2428.57
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8. Benzoic anhydride (BAN) 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
19.1
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
96.4
cm-1
% T 
BAN
3063.48 2556.33
1920.31
1773.13
1713.31
1686.02
1598.00
1584.84
1490.88
1450.71
1423.54
1321.34
1283.33
1208.09
1169.57
1073.34
1032.09
1011.54
993.05
939.20
874.56
803.63
779.60
683.17
667.10
1982.15 1829.51
3007.93
705.50
701.54
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9. Maleic acid (MA) 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
27.9
30
35
40
45
50
55
60
65
70
75
80
85
90
95
96.9
cm-1
% T 
MA
3057.94
2870.85
2684.90
2605.08
2505.69
2378.10
2162.17
1887.77
1703.85
1632.98
1584.52
1563.50
1458.11
1429.49 1259.78
1218.50
985.31
914.27
785.45
858.14
2039.68
2793.65
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10. L-aspartic acid (L-AA) 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
54.0
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
97.8
cm-1
% T 
L- AA
2951.16
1879.98
1684.66
1641.24
1599.50
1501.76
1419.72
1357.56
1289.75
1149.23
1118.71
1033.61
988.95
935.99
898.28
872.92
777.19
752.57
2507.93
2650.79
2730.15
2861.11
1244.71
2083.33
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11. L- glutamic acid (L-GA) 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
50.6
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
97.5
cm-1
% T 
L-GA
3012.70
2739.84
1637.05
1614.35
1504.42
1419.75
1350.04
1309.72
1255.76
1213.13
1149.84
1125.02
1074.76
945.97
912.15
865.49
804.99
758.50
701.59
670.21
2964.28
2650.79
2484.12 2075.39
1982.15
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12. 4- Hydroxybenzoic acid 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
50.4
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96.2
cm-1
% T 
4-HBA
3377.11 2814.44
2543.56
1670.26
1607.39
1593.62
1509.06
1446.82
1418.16
1364.67
1315.49
1287.90
1240.84
1167.75
1127.87
1100.92
1012.33
924.92
768.10
692.10
1926.65
854.18
2952.38
2654.76
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13. Benzoic acid (BA) 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
20.8
25
30
35
40
45
50
55
60
65
70
75
80
85
90
94.1
cm-1
% T 
BA
3071.58
2827.41
2552.45
1915.69
1679.44
1601.14
1582.83
1496.64
1453.46
1420.25
1323.59
1288.91
1179.67
1127.56
1100.68
1072.69
1026.59
999.99
931.55
804.25
683.49
666.38
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Appendix B 
Includes all experiment attempts of sulfamethoxazole with 14 selected excipient co-formers 
and another active ingredient (TMP). The different solvents used in the experiments included 
methanol, ethanol 96%, propan-2-ol, benzyl alcohol, 1,4 dioxane, diethyl ether, chloroform, 
acetone, ethyl acetate, tetrahydrofuran (THF), butanol, butanone and dimethyl sulfoxide 
(DMSO). The reason for did not include a lot of solvent for the reason of solubility problems. 
1. SMZ-BAN (sulfamethoxazole + benzoic anhydride), 18 experiments. 
SMZ BAN Method Ratio Solvent Storage 
temperature  
Result 
        Dry grinding 1:1 - 25 °C Mixture of 
SMZ and BAN 
        Slow evaporation 1:1 Methanol 25 °C Co-crystal 
  Slow evaporation 1:1 Ethanol 25 °C Co-crystal 
  Slow evaporation 1:1 Ethyl 
acetate 
25 °C Decomposition 
  Slow evaporation 1:1 acetone 25 °C Co-crystal 
  Slow evaporation 1:1 Propan-
2-ol 
25 °C Co-crystal 
  Slow evaporation 1:1 1,4-
Dioxane 
25 °C Decomposition 
  Slow evaporation 1:1 Acetic 
acid 
25 °C Co-crystal 
  Slow evaporation 1:1 Methanol 2-6 °C Mixture of 
SMZ and BAN 
  Slow evaporation 1:1 Ethanol 2-6 °C Co-crystal 
  Slow evaporation 1:1 Ethyl 
acetate 
2-6 °C Decomposition 
  Slow evaporation 1:1 acetone 2-6 °C Co-crystal 
  Slow evaporation 1:1 Propan-
2-ol 
2-6 °C SMZ form I 
  Slow evaporation 1:1 1,4-
Dioxane 
2-6 °C Decomposition 
  Slow evaporation 1:1 Acetic 
acid 
2-6 °C Co-crystal 
  Slow evaporation 1:1 Butanol 2-6 °C No crystal 
  Slow evaporation 1:1 acetone 2-6 °C Co-crystal 
  Slurry method 1:1 Methanol 2-6 °C Co-crystal 
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2. SMZ-D-TA (Sulfamethoxazole + D-tartaric acid), 28 experiments. 
SMZ D-TA Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding 1:1 - 25 °C SMZ form II 
  Dry grinding 1:2 - 25 °C SMZ form II 
  Dry grinding 1:3 - 25 °C Mixture of 
SMZ and D-
l2TA 
  Solvent assisted 
grinding 
1:1 Ethanol 25 °C SMZ form II 
  Solvent assisted 
grinding 
1:2 Ethanol 25 °C Mixture of 
SMZ and D-
TA 
  Solvent assisted 
grinding 
1:1 Methanol 25 °C SMZ form II 
  Slow 
evaporation 
1:1 Methanol 25 °C SMZ form II 
  Slow 
evaporation 
1:2 Methanol 25 °C SMZ form I 
  Slow 
evaporation 
1:1 Butanol 2-6 °C No crystal  
  Slow 
evaporation 
1:1 Acetic 
acid 
25 °C Decomposition  
  Slow 
evaporation 
1:1 Acetic 
acid 
2-6 °C SMZ form I 
  Slow 
evaporation 
1:1 1,4-
dioxane 
2-6 °C SMZ form I 
  Slow 
evaporation 
1:2 1,4-
dioxane 
2-6 °C Mixture of 
SMZ and D-
TA 
  Slow 
evaporation 
1:3 Methanol 25 °C SMZ form I 
  Slow 
evaporation 
1:4 Methanol 25 °C Mixture of 
SMZ and D-
TA 
  Slow 
evaporation 
1:1 Methanol 2-6 °C Hemihydrate 
of SMZ 
  Slow 
evaporation 
1:1 Methanol 35 °C Hemihydrate 
of SMZ 
  Slow 
evaporation 
1:3 Acetone 25 °C Mixture of 
SMZ and D-
TA 
  Slow 
evaporation 
1:3 Methanol 25 °C Mixture of 
SMZ and D-
TA 
  Slow 
evaporation 
1:1.5 Methanol 25 °C Hemihydrate 
of SMZ 
  Slow 
evaporation 
1:2 Ethanol 25 °C Hemihydrate 
of SMZ 
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  Slow 
evaporation 
1:4 Methanol Desiccator  Fine crystal 
  
  Slow 
evaporation 
1:1 1,4- 
Dioxane 
25 °C Decomposition   
  Vapour 
diffusion 
1:1 Methanol 25 °C No crystal 
  Vapour 
diffusion 
1:1 Ethanol 25 °C No crystal 
  Dry grinding + 
recrystallization  
1:1 Methanol  25 °C SMZ form II 
  Dry grinding + 
recrystallization  
1:2 Acetone  25 °C SMZ form II 
  Seeding 1:1 Ethanol  25 °C SMZ form I 
 
3. SMZ-MA (sulfamethoxazole + maleic acid), 28 experiments. 
SMZ MA Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding 1:1 - 25 °C MA 
recrystallized 
  Dry grinding 2:1 - 25 °C Mixture of 
SMZ and MA 
  Solvent assisted 
grinding 
1:1 Ethanol 25 °C MA 
recrystallized 
  Solvent assisted 
grinding 
2:1 Ethanol 25 °C Mixture of 
SMZ and MA 
  Solvent assisted 
grinding 
1:1 Methanol 25 °C Mixture of 
SMZ and MA  
  Flask method 1:1 Ethanol 25 °C No crystal 
  Flask method 1:2 Ethanol 25 °C No crystal 
  Slow 
evaporation 
1:1 Ethanol 25 °C No crystal 
  Slow 
evaporation 
1:1 Butanol 2-6 °C No crystal 
  Slow 
evaporation 
1:1 Acetic acid 25 °C No crystal 
  Slow 
evaporation 
1:1 Methanol  25 °C SMZ form I 
  Slow 
evaporation 
1:2 Methanol  25 °C Mixture of 
SMZ and MA 
  Slow 
evaporation 
1:1 Methanol  2-6 °C SMZ form I 
  Slow 
evaporation 
1:1 Ethyl 
acetate 
25 °C Mixture of 
SMZ and MA 
  Slow 
evaporation 
1:1 Ethyl 
acetate 
2-6 °C No crystal 
  Slow 
evaporation 
1:1 Propan-2-
ol 
25 °C Decomposition 
  Slow 1:1 Propan-2- 2-6 °C No crystal 
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evaporation oll 
  Slow 
evaporation 
1:1 Acetone 25 °C Mixture of 
SMZ and MA 
  Slow 
evaporation 
1:1 Acetone 2-6 °C SMZ form I 
  Slow 
evaporation 
1:1 Distilled 
water+ 
methanol 
25 °C SMZ form I 
  Slow 
evaporation 
1:1 Distilled 
water+ 
methanol 
2-6 °C SMZ form I 
  Slow 
evaporation 
1:1 Ethyl 
acetate 
25 °C  Amorphous 
form of SMZ 
  Slow 
evaporation 
1:1.5 Acetone 2-6 °C No crystals 
  Slow 
evaporation 
1:2 Acetone 2-6 °C No crystals 
  Vapour 
diffusion 
1:2 Ethanol  25 °C No crystal 
  Seeding 1:1 Methanol  25 °C SMZ form I 
  Dry grinding + 
recrystallization  
 Methanol  25 °C SMZ form I 
  Dry grinding + 
recrystallization  
 Acetone  25 °C Mixture of 
SMZ and MA 
 
4. SMZ-NC (sulfamethoxazole + nicotinamide), 30 experiments. 
SMZ NC Method Ratio Solvent Storage 
temperature  
Result 
  Dry 
grinding 
1:1 - 25 °C NC polymorph  
  Dry 
grinding 
2:1 - 25 °C SMZ form I 
  Solvent 
assisted 
grinding 
1:1 Methanol 25 °C NC polymorph  
  Solvent 
assisted 
grinding 
2:1 Methanol 25 °C SMZ form I 
  Solvent 
assisted 
grinding 
1:1 Ethanol 25 °C NC polymorph  
  Slow 
evaporation 
1:1 Methanol 25 °C NC polymorph  
  Slow 
evaporation 
2:1 Methanol 25 °C Mixture of 
SMZ and NC 
  Slow 
evaporation 
1:1 Acetic 
acid 
25 °C NC polymorph  
  Slow 1:1 Methanol 50  °C SMZ form I 
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evaporation 
  Slow 
evaporation 
1:1 DMSO 25 °C No crystal 
  Slow 
evaporation 
1:1 Butanol 2-6 °C Not soluble  
No crystal 
  Slow 
evaporation 
1:2 Methanol 25 °C SMZ form I 
  Slow 
evaporation 
1:3 Methanol 2-6 °C  Mixture of 
SMZ and NC 
  Slow 
evaporation 
1:1 Methanol 2-6 °C  SMZ form I 
  Slow 
evaporation 
1:3 Methanol 45 °C NC polymorph  
  Slow 
evaporation 
1:1.5 Acetone  25 °C NC polymorph  
  Slow 
evaporation 
1:2.5 Acetone 2-6 °C NC polymorph  
  Slow 
evaporation 
1:3.5 Acetone 25 °C NC polymorph 
  Slow 
evaporation 
1:1,5 Methanol 25 °C SMZ form I 
  Slow 
evaporation 
1:1,5 Ethanol  25 °C SMZ form I 
  Slow 
evaporation 
1:1,5 Propanol  25 °C No crystal 
  Slow 
evaporation 
1:1 THF 25 °C SMZ form I 
  Slow 
evaporation 
1:2 THF 25 °C SMZ form I 
  Slow 
evaporation 
1:3 THF 25 °C SMZ form I 
  Slow 
evaporation 
1:4 THF 25 °C Mixture of 
SMZ and NC 
  sublimation 1:1 - 25 °C Decomposition 
 
  Vapour 
diffusion 
1:1 Ethanol 50  °C; No crystal 
  Seeding 1:1 Methanol 25 °C SMZ form I 
  Seeding 1:1 Ethanol 25 °C SMZ form I 
  Seeding 1:1 Acetone  25 °C SMZ form I 
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5. SMZ-SCA (sulfamethoxazole + salicylic acid), 22 experiments. 
SMZ SCA Method Ratio Solvent Storage 
temperature  
Result 
  Dry 
grinding 
1:1 - 25 °C SMZ form I 
  Dry 
grinding 
1:2 - 25 °C Mixture of 
SMZ and 
SCA 
  Solvent 
assisted 
grinding 
1:1 Ethanol 25 °C SMZ form I 
  Solvent 
assisted 
grinding 
1:2 Ethanol 25 °C SMZ form I 
  Slow 
evaporation 
1:1 1,4-Dioxan 25 °C Mixture of 
SMZ and 
SCA 
  Slow 
evaporation 
1:2 Methanol  25 °C SMZ form I 
  Slow 
evaporation 
1:1 Butanol 2-6 °C Mixture  
  Slow 
evaporation 
1:1 Ethanol 25 °C SMZ form II 
  Slow 
evaporation 
1:3 Ethanol 25 °C SMZ form II 
  Slow 
evaporation 
1:1 Ethanol 2-6 °C SMZ form I 
  Slow 
evaporation 
1:1 Acetone  25 °C SMZ form I 
  Slow 
evaporation 
1:1 Ethyl acetate 25 °C SMZ form I 
  Slow 
evaporation 
1:1 Propan-2-ol 25 °C SMZ form I 
  Slow 
evaporation 
1:2 Propan-2-ol 25 °C SMZ 
hemihydrate 
  Slow 
evaporation 
1:2.5 Propan-2-ol 25 °C Mixture of 
SMZ and 
SCA  
  Slow 
evaporation 
1:1 THF 25 °C No crystal 
  Slow 
evaporation 
1:2 THF 25 °C SMZ 
polymorph 
  Slow 
evaporation 
1:3 THF 25 °C No crystal  
  Slow 
evaporation  
1:3 Ethanol  Desiccator  SMZ 
polymorph  
  Slow 
evaporation  
1:4 Ethanol  Desiccator  No crystal 
  Flask 1:1 ethanol - No crystal 
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method 
  Vapour 
diffusion 
1:1 Ethanol 25 °C No crystal 
 
6. SMZ-SC (sulfamethoxazole + saccharine), 15 experiments. 
SMZ SC Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding 1:1 - 25 °C SMZ 
polymorph 
  Dry grinding 1:2 - 25 °C Mixture of 
SMZ and SC 
  Slow 
evaporation 
1:1 Methanol  25 °C SMZ form I 
  Slow 
evaporation 
1:2 Methanol  25 °C Mixture of 
SMZ and SC 
  Solvent assisted 
grinding 
1:1 Ethanol  25 °C SMZ form I 
  Slow 
evaporation 
1:1 Ethanol 25 °C SMZ form II 
  Slow 
evaporation 
1:2 Ethanol 25 °C Mixture 
  Slow 
evaporation 
1:1 Butanol 2-6 °C Mixture  
  Slow 
evaporation 
1:1 Acetic 
acid 
25 °C Decomposition  
  Dry grinding + 
recrystallization  
1:1 Methanol  25 °C SMZ form II 
  Dry grinding + 
recrystallization  
1:1 Acetone  25 °C SMZ form II 
  Seeding 1:1 Ethanol  25 °C Hemihydrate 
of SMZ 
  Seeding 1:1 Methanole  25 °C Saccharin acid  
  Seeding 1:1 Acetone  25 °C Saccharin acid 
  Seeding 1:1 Acetic 
acid  
25 °C Saccharin acid 
 
7. SMZ-SUA (sulfamethoxazole + succinic acid), 20 experiments. 
SMZ SUA Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding 1:1 - 25 °C SMZ form II 
  Dry grinding 1:2  25 °C Mixture of 
SMZ and SUA 
  Solvent assisted 
grinding  
1:1 Ethanol 25 °C Mixture of 
SMZ and SUA 
  Slow 
evaporation 
1:1 Water + 
Methanol 
25 °C SMZ form II 
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  Slow 
evaporation 
1:1 Methanol 25 °C No crystal 
  Slow 
evaporation 
1:1 Acetic 
acid 
25 °C No crystal  
  Slow 
evaporation 
1:1 Methanol 25 °C No crystal  
  Slow 
evaporation 
1:2 Methanol 25 °C SMZ form I 
  Slow 
evaporation 
1:3 Methanol 25 °C Mixture of 
SMZ and SUA 
  Slow 
evaporation 
1:1 Acetone  25 °C SMZ form I 
  Slow 
evaporation 
1:1 Acetone  2-6 °C SMZ form I 
  Slow 
evaporation 
1:1 Butanol 2-6 °C Mixture  
  Slow 
evaporation 
1:1 Ethyl 
acetate 
25 °C No crystal 
  Slow 
evaporation 
1:1 Ethyl 
acetate 
2-6 °C SMZ form I 
  Slow 
evaporation 
1:1 1,4-
dioxane 
25 °C Decomposition 
  Slow 
evaporation 
1:1 1,4-
dioxane 
2-6 °C Decomposition 
  Slow 
evaporation 
1:1 Acetic 
acid 
25 °C Decomposition 
  Slow 
evaporation 
1:1 Acetic 
acid 
2-6 °C Decomposition 
  Dry grinding + 
recrystallization  
1:2 Methanol  25 °C SMZ form I 
  Dry grinding + 
recrystallization  
1:1 Acetone  25 °C SMZ form II 
       
 
8. SMZ-OA (sulfamethoxazole + oxalic acid), 18 experiments. 
SMZ SUA Method Ratio Solvent Storage 
temperature  
Result 
  Dry 
grinding 
1:1 - 25 °C Amorphous 
  Dry 
grinding 
1:2 - 25 °C Amorphous  
  Solvent 
assisted 
grinding 
1:1 Acetone 25 °C Amorphous 
  Solvent 
assisted 
grinding 
1:2 Acetone 25 °C Mixture of 
SMZ and 
OA 
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  Solvent 
assisted 
grinding 
1:1 Methanol  25 °C Amorphous 
  Slow 
evaporation  
1:1 Methanol  25 °C No crystal 
  Slow 
evaporation  
1:1 1,4-dioxane   25 °C No crystal 
  Slow 
evaporation  
1:1 Acetic acid    25 °C No crystal 
  Vapour 
diffusion   
1:1 Ethanol in 
chloroform  
25 °C No crystal 
  Slow 
evaporation  
1:1 Ethyl 
acetate   
25 °C  Amorphous 
  Slow 
evaporation  
1:1 Ethyl 
acetate   
2-6 °C  Amorphous 
  Slow 
evaporation  
1:1 Ethanol  25 °C No crystal 
  Slow 
evaporation  
1:1 Ethanol  2-6 °C  Amorphous 
  Slow 
evaporation  
1:2 Methanol  25 °C  Amorphous 
  Slow 
evaporation  
1:2 Methanol  2-6 °C No crystal 
  Slow 
evaporation  
1:3 Ethanol  2-6 °C No crystal 
  Slow 
evaporation  
1:3 Ethanol  2-6 °C No  
Crystal 
  Slow 
evaporation  
1:1 Acetone  2-6 °C  No crystal 
  Slow 
evaporation  
1:1 Methanol  Desiccator  Mixture of 
SMZ and 
OA  
 
9.  SMZ-4-HBA (sulfamethoxazole + 4-Hydroxy benzoic acid), 20 experiments.  
SMZ 4-
HBA 
Method Ratio Solvent Storage 
temperature  
Result 
  Dry 
grinding 
1:1                                         - 25 °C SMZ form I 
  Dry 
grinding 
1:2                                        - 25 °C Mixture of 
SMZ and 4-
HBA 
  Solvent 
assisted 
grinding 
1:1 Ethanol 25 °C SMZ form I 
  Slow 
evaporation 
1:1 Acetone  25 °C 4-HBA 
hydrate form 
  Slow 
evaporation 
1:1 Acetone  2-6 °C 4-HBA 
hydrate form 
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  Slow 
evaporation 
1:1.5 Acetone 25 °C Mixture of 
SMZ and 4-
HBA 
  Slow 
evaporation 
1:1.5 Acetone 2-6 °C Mixture of 
SMZ and 4-
HBA 
  Slow 
evaporation 
1:2 Acetone 25 °C Mixture of 
SMZ and 4-
HBA 
  Slow 
evaporation 
1:1 Methanol  25 °C 4-HBA 
hydrate form 
  Slow 
evaporation 
1:1 Ethanol  25 °C 4-HBA 
hydrate form 
  Slow 
evaporation 
1:1 Ethanol  2-6 °C 4-HBA 
hydrate form 
  Slow 
evaporation 
1:1 Ethyl 
acetate  
25 °C 4-HBA 
hydrate form 
  Slow 
evaporation 
1:1.5 Ethyl 
acetate  
25 °C Mixture of 
SMZ and 4-
HBA 
  Slow 
evaporation 
1:2 Ethyl 
acetate  
25 °C SMZ hydrate 
form 
  Slow 
evaporation 
1:1 Propan-2-ol 25 °C 4-HBA 
hydrate form 
  Slow 
evaporation 
1:2 Ethyl 
acetate 
25 °C SMZ form I 
  Slow 
evaporation 
2:3 Ethyl 
acetate  
25 °C SMZ hydrate 
form 
  Slow 
evaporation 
1:2 Methanol 25 °C Mixture of 
SMZ and 4-
HBA 
  Slow 
evaporation 
1:1 Acetone  + 
water  
25 °C  SMZ form II 
  Slow 
evaporation 
 
1:1.5 
 
Ethyl 
acetate  
45 °C SMZ hydrate 
form 
 
10. SMZ-BA (sulfamethoxazole + benzoic acid), 14 experiments. 
SMZ BA Method Ratio Solvent Storage 
temperature  
Result 
  Dry 
grinding 
1:1                                     - 25 °C Mixture of 
SMZ and BA 
  Slow 
evaporation 
1:1 Methanol  25 °C Mixture of 
SMZ and BA 
  Slow 
evaporation 
1:1 Methanol  2-6 °C Mixture of 
SMZ 
hemihydrate 
and BA 
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  Slow 
evaporation 
1:1 Ethanol  25 °C No crystal 
  Slow 
evaporation 
1:1 Ethanol  2-6 °C Mixture of 
SMZ and BA 
  Slow 
evaporation 
1:1 Acetone  25 °C Mixture of 
SMZ 
hemihydrate 
and BA 
  Slow 
evaporation 
1:1 Acetone  2-6 °C No crystal 
  Slow 
evaporation 
1:1 Propanol  25 °C No crystal 
  Slow 
evaporation 
1:1 Propanol  2-6 °C  No crystal 
  Dry 
grinding 
1:1 Ethyl acetate  25 °C Mixture of 
SMZ and BA 
  Slow 
evaporation 
1:1 Ethyl acetate 2-6 °C Mixture of 
SMZ and BA 
  Dry 
grinding 
1:1 / 25 °C SMZ form I 
  Seeding  1:1 Methanol  25 °C  SMZ form I 
  Slow 
evaporation 
1:2 1,4 dioxane  25 °C Mixture of 
SMZ and BA 
 
11. SMZ-L-TA (sulfamethoxazole + L-tartaric acid), 13 experiments. 
SMZ L-TA Method Ratio Solvent Storage 
temperature  
Result 
  Dry 
grinding 
1:1  - 25 °C SMZ form I 
  Dry 
grinding 
1:3  - 25 °C Mixture of 
SMZ and L-
TA 
  Slow 
evaporation 
1:1 Ethanol  25 °C  SMZ form I 
  Slow 
evaporation 
1:1 Methanol 2-6 °C Hemihydrate 
of SMZ 
  Slow 
evaporation 
1:1 Methanol 35 °C Hemihydrate 
of SMZ 
  Slow 
evaporation 
1:1.5 Methanol 25 °C Hemihydrate 
of SMZ 
  Slow 
evaporation 
1:3 Methanol 25 °C Mixture of 
SMZ and L-
TA 
  Slow 
evaporation 
1:1 Ethanol 25 °C Hemihydrate 
of SMZ 
  Slow 
evaporation 
1:2 Ethanol 25 °C Hemihydrate 
of SMZ 
  Slow 1:3 Acetone 25 °C Mixture of 
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evaporation SMZ and L-
TA 
  Slow 
evaporation 
1:1  Acetic acid  2-6 °C Decomposition  
  Slurry  1:1 Chloroform  25 °C  SMZ form I 
  Slurry  1:1 Chloroform  2-6 °C SMZ form I 
 
12. SMZ-CA ( sulfamethoxazole + citric acid monohydrate), 10 experiments. 
SMZ CA Method Ratio Solvent Storage 
temperature  
Result 
  Dry 
grinding  
1:1  25 °C Mixture of 
SMZ and CA 
  Solvent 
assisted 
grinding 
1:1 Ethanol  25 °C Mixture of 
SMZ and CA 
  Flask 
method  
1;1 Ethanol  Flask  No crystal 
  Slow 
evaporation  
1:1 Ethanol  25 °C Mixture of 
SMZ and CA 
  Slow 
evaporation  
1:1 Methanol  25 °C SMZ 
hemihydrate  
  Slow 
evaporation  
1:2 Methanol  25 °C No crystal 
  Slow 
evaporation  
1:1 Propanol  25 °C Mixture of 
SMZ and CA 
  Slow 
evaporation  
1:1 Ethyl 
acetate  
25 °C SMZ form I 
  Slow 
evaporation  
1:1 Acetone  25 °C SMZ 
hemihydrate  
  Slow 
evaporation  
1:1 1,4-dioxane  25 °C Decomposition  
 
13. SMZ-L-GA (Sulfamethoxazole +L-glutamic acid), 8 experiments. 
SMZ L-GA Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding 1:1 - 25 °C SMZ form 
I 
  Slow 
evaporation  
1:1 Methanol  25 °C SMZ form 
I 
  Slow 
evaporation  
1:1 Ethanol  25 °C SMZ form 
I 
  Slow 
evaporation  
1:1 Acetone  25 °C SMZ form 
I 
  Slow 
evaporation  
1:1 Ethyl acetate  25 °C SMZ form 
I 
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  Slow 
evaporation  
1:1 Propanol  25 °C SMZ form 
I 
  Slow 
evaporation  
1:1.5 Ethyl acetate  25 °C SMZ form 
I 
  Slow 
evaporation  
1:2 Acetone  25 °C SMZ form 
I 
 
14. SMZ-L-AA (Sulfamethoxazole +L-aspartic acid ), 6 experiments. 
SMZ L-AA Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding 1:1 / 25 °C SMZ form 
I 
  Slow 
evaporation  
1:1 Methanol  25 °C SMZ form 
I 
  Slow 
evaporation  
1:1 Ethanol  25 °C SMZ form 
I 
  Slow 
evaporation  
1:1 Ethyl acetate  25 °C SMZ form 
I 
  Slow 
evaporation  
1:1 Acetone  25 °C SMZ form 
I 
  Slow 
evaporation  
1:1 Propanol  25 °C SMZ form 
I 
  
15. SMZ-TMP (Sulfamethoxazole + trimethoprime), 28 experiments. 
SMZ TMP Method Ratio Solvent Storage 
temperature  
Result 
  Slow 
evaporation 
1:1 1,4-Dioxane 25 °C TMP 
  Slow 
evaporation 
1:1 Propan-2-ol 25 °C Fine co-crystal 
Poor quality 
  Slow 
evaporation 
1:1 Ethyl 
acetate 
25 °C No crystal 
  Slow 
evaporation 
1:1 Butan-1-ol 25 °C No crystal 
  Slow 
evaporation 
1:1 Ethanol 25 °C Fine co-crystal 
Poor quality  
  Slow 
evaporation 
1:1 Methanol 25 °C Fine co-crystal 
Poor quality 
  Slow 
evaporation 
1:1 Acetone 25 °C Fine co-crystal 
Poor quality 
  Slow 
evaporation 
2:1 1,4-Dioxane 25 °C TMP 
  Slow 
evaporation 
2:1 Propan-2-ol 25 °C Fine co-crystal 
Poor quality 
  Slow 
evaporation 
2:1 Ethanol 25 °C Fine co-crystal 
Poor quality 
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  Slow 
evaporation 
1:2 Ethanol 25 °C Fine co-crystal 
Poor quality 
  Slow 
evaporation 
1:2 Methanol 25 °C Fine co-crystal 
Poor quality 
  Slow 
evaporation 
1:2 Propan-2-ol 25 °C Fine co-crystal 
Poor quality 
  Slow 
evaporation 
1:1 Acetic acid 
glacial 
25 °C Fine co-crystal 
Poor quality 
  Slow 
evaporation 
1:1 Methanol 2-6 °C Fine co-crystal 
Poor quality   
  Slow 
evaporation 
1:2 Ethanol 2-6 °C Fine co-crystal 
Poor quality  
  Slow 
evaporation 
2:1 1,4-Dioxane 2-6 °C TMP 
  Slow 
evaporation 
1:1 DMSO 25 °C Decomposition 
  Slow 
evaporation 
1:1 Acetic acid 2-6 °C Decomposition 
  Slow 
evaporation 
1:1 Chloroform 
+ methanol 
2-6 °C No crystal 
  Slow 
evaporation 
1:1 Chloroform 
+ propan-2-
ol 
2-6 °C No crystal 
  Slow 
evaporation 
1:1 Chloroform 
+ ethanol  
2-6 °C Fine co-crystal 
Poor quality  
  Slow 
evaporation 
1:1 Methanol Desiccator  Fine co-crystal 
Poor quality 
   Melt   1:1          - 180 °C Amorphous 
  Vapour 
diffusion 
1:1 Propan-2-ol 25 °C No crystal 
  Dry grinding 1:1 - 25 °C Co-crystal 
Powder 
  Co-
precipitation 
1:1 Methanol  2-6 °C Fine co-crystal 
Poor quality 
  sublimation 1:1 - 25 °C No crystal 
(decomposition) 
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Appendix C 
  
Includes all experiment attempts of Sulfasalazine with 10 selected excipient co-formers and 
another active ingredient (TMP) 
Sulfasalazine (SSZ) monoclinic with different co-former  
 
1. SSZ-NC (sulfasalazine + nicotinamide), 9 experiments.  
SSZ NC Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding  1:1  25 °C SSZ 
  Solvent 
assisted 
grinding 
1:2 Methanol  25 °C Mixture of 
SSZ and NC 
  Vapour 
diffusion  
1:2 THF  25 °C No crystal 
  Vapour 
diffusion  
1:3 THF  25 °C No crystal 
  Melt  1:3 / 25 °C Co-crystal  
  Slow 
evaporation  
1:2 THF 25 °C Mixture of 
SSZ and NC 
  Slow 
evaporation  
1:1 Methanol 25 °C SSZ 
monoclinic  
  Slow 
evaporation  
1:2 Methanol 25 °C SSZ 
monoclinic 
  Slow 
evaporation  
1:3 Methanol 25 °C Mixture of 
SSZ and NC 
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2. SSZ-OA (sulfasalazine +  oxalic acid), 6 experiments. 
SSZ OA Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding  1:1  25 °C SSZ 
monoclinic 
  Solvent 
assisted 
grinding for 
15 minute  
1:2 Methanol  25 °C Mixture of 
SSZ and 
OA 
  Solvent 
assisted 
grinding for 
30 minute  
1:2 Methanol  25 °C Mixture of 
SSZ and 
OA 
  Slow 
evaporation  
1:1 THF 25 °C No crystal  
  Slow 
evaporation  
1:2 THF  25 °C Mixture of 
SSZ and 
OA  
  Slow 
evaporation  
1:2 Methanol 25 °C Mixture of 
SSZ and 
OA 
 
3. SSZ-SCA (sulfasalazine + salicylic acid), 13 experiments. 
SSZ SCA Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding  1:1 - 25 °C SSZ 
monoclinic 
  Solvent 
assisted 
grinding for 
15 minute 
1:2 Methanol  
Drops  
25 °C Mixture of 
SSZ and 
SCA 
  Solvent 
assisted 
grinding for 
15 minute  
1:2 Methanol 
1ML  
25 °C Mixture of 
SSZ and 
SCA 
  Solvent 
assisted 
grinding for 
30 minute  
1:2 Methanol  25 °C Mixture of 
SSZ and 
SCA 
  Slow 
evaporation  
1:2 THF 25 °C SSZ 
monoclinic 
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  Slow 
evaporative  
1:3 THF  25 °C Mixture of 
SSZ and 
SCA 
  Vapour 
diffusion  
1:3 THF  25 °C No crystal 
  Slow 
evaporation  
1:3 THF  25 °C SSZ 
monoclinic 
  Slow 
evaporation  
1:1 Methanol 25 °C SSZ 
monoclinic 
  Slow 
evaporation  
1:2 Methanol 25 °C SSZ 
monoclinic 
  Slow 
evaporation  
1:3 Methanol 25 °C Mixture of 
SSZ and 
SCA 
  Slow 
evaporation 
1:4 THF 25 °C Mixture of 
SSZ and 
SCA 
  Vapour 
diffusion  
1:4 THF 25 °C No crystal 
 
4. SSZ-MA (sulfasalazine +  maleic acid), 10 experiments. 
SSZ MA Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding  1:1 - 25 °C Mixture of SSZ 
and MA  
  Dry grinding  1:2 - 25 °C Mixture of SSZ 
and MA 
  Solvent 
assisted 
grinding 
1:1 Methanol  25 °C Mixture of SSZ 
and MA  
  Seeding  1:2 THF 25 °C No crystal 
  Slow 
evaporation  
1:2 THF  25 °C Decomposition  
  Vapour 
diffusion  
1:2 THF  25 °C No crystal 
  Vapour 
diffusion  
1:3 THF  25 °C No crystal 
  Slow 
evaporation  
1:1 Ethanol 25 °C SSZ monoclinic  
  Slow 
evaporation  
1:2 Ethanol 25 °C No crystal 
  Slow 
evaporation  
1:2 Methanol 25 °C Mixture of SSZ 
and MA 
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5. SSZ-SUA (sulfasalazine + succinic acid), 6 experiments. 
SSZ SUA Method Ratio Solvent Storage 
temperature  
Result 
 SUA Dry grinding 
for 15 
minute  
1:2 - 25 °C SUA 
recrystallize 
 SUA Slow 
evaporation  
1:1 Methanol  25 °C SSZ 
monoclinic 
 SUA Slow 
evaporation  
1:1 Methanol  2-6 SSZ 
monoclinic 
 SUA Slow 
evaporation  
1:3 Methanol  25 °C Mixture of 
SSZ and 
SUA 
 SUA Slow 
evaporation  
1:1 Acetonitrile 25 °C No crystal  
 SUA Slow 
evaporation  
1:1 THF  25 °C SSZ 
monoclinic 
 
6. SSZ- D-TA (sulfasalazine + D-tartaric acid), 8 experiments. 
SSZ D-TA Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding 1:1 / 25 °C Mixture of 
SSZ and D-
TA 
  Slow 
evaporation  
1:1 THF  25 °C SSZ 
monoclinic 
  Slow 
evaporation  
1:2 THF  25 °C Not clear 
crystal  
  Solvent 
assisted 
grinding 
1:2 Ethanol  25 °C Mixture of 
SSZ and D-
TA  
  Solvent 
assisted 
grinding 
1:1 Methanol  25 °C Mixture of 
SSZ and D-
TA  
  Slow 
evaporation  
1:1 Methanol  25 °C Mixture of 
SSZ and D-
TA 
  Slow 
evaporation  
1:2 Methanol  25 °C SSZ 
monoclinic 
  Slow 
evaporation  
1:3 Methanol  25 °C Mixture of 
SSZ and D-
TA 
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7. SSZ- BA (sulfasalazine + benzoic acid), 4 experiments. 
SSZ BA Method Ratio Solvent Storage 
temperature  
Result 
  Solvent 
assisted 
grinding  
1:1 THF 25 °C Mixture of 
SSZ and 
BA 
  Seeding 1:1 THF 25 °C SSZ 
monoclinic  
  Slow 
evaporation  
1:1 THF  25 °C SSZ 
monoclinic  
  Slow 
evaporation  
1:2 THF  25 °C Mixture of 
SSZ and 
BA 
 
8. SSZ- SC (sulfasalazine + saccharine), 4 experiments. 
SSZ SC Method Ratio Solvent Storage 
temperature  
Result 
  Dry grinding  1:1 - 25 °C Mixture of 
SSZ and SC 
  Slow 
evaporation   
1:1 THF 25 °C 
  
Mixture of 
SSZ and SC 
  Slow 
evaporation   
1:1 Methanol 25 °C SSZ 
monoclinic 
  Slow 
evaporation   
1:2 Ethanol  25 °C SSZ 
monoclinic 
 
9. SSZ- 4-HBA (sulfasalazine + 4-hydroxy benzoic acid), 3 experiments. 
SSZ 4-
HBA 
Method Ratio Solvent Storage 
temperature  
Result 
  Slow 
evaporation   
1:1 THF 25 °C SSZ 
monoclinic 
  Slow 
evaporation  
1:2 THF 25 °C Mixture of 
SSZ and 4-
HBA 
  Dry grinding  1:2 - 25 °C Mixture of 
SSZ and 4-
HBA 
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10. SSZ- CA (sulfasalazine + Citric acid (as the monohydrate) ), 3 experiments. 
SSZ CA Method Ratio Solvent Storage 
temperature  
Result 
 CA Slow 
evaporation   
1:1 THF 25 °C SSZ 
monoclinic 
 CA Slow 
evaporation  
1:2 THF 25 °C SSZ 
monoclinic 
 CA Dry grinding  1:1 / 25 °C Mixture of 
SSZ and CA  
 
11. SSZ- TMP (sulfasalazine + trimethoprim), 3 experiments. 
SSZ TMP Method Ratio Solvent Storage 
temperature  
Result 
  Slow 
evaporation  
1:1 THF  25 °C SSZ-TMP 
salt 
  Dry 
grinding  
1:1 - 25 °C Amorphous  
  Solvent 
assisted 
grinding 
1:1 Methanol  25 °C Co-crystal 
 
 
Sulfasalazine (SSZ) triclinic with different co-former, 6 experiments. 
SSZ Co-
former  
Method Ratio Solvent Storage 
temperature  
Result 
 OA Slow 
evaporation  
1:2 THF Desiccator  Mixture of 
SSZ and 
OA 
 SUA Slow 
evaporation  
1:2 THF Desiccator  SUA 
 MA Slow 
evaporation  
1:2 THF 25 °C  SSZ 
triclinic 
 TMP Slow 
evaporation  
1:1 THF Desiccator  Salt as 
monoclinic 
form 
 TMP  Dry 
grinding  
1:1 / 25 °C  Amorphous  
 D-TA Solvent 
assisted 
grinding   
1:2 Ethanol  25 °C  Mixture  
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 Appendix D 
rsh5sr.lis
 
rsh5sr(1).res
 
rsh5sr.XL  
 
 
 
 
